(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
28 January 2010 (28.01.2010)

PCT

(10) International Publication Number
WO 2010/010188 A1

(51) International Patent Classification:
C07D 471/04 (2006.01) *A61P 19/02* (2006.01)
A61K 31/437 (2006.01)

(21) International Application Number:
PCT/EP2009/059600

(22) International Filing Date:
24 July 2009 (24.07.2009)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/135,936 25 July 2008 (25.07.2008) US

(71) Applicant *(for all designated States except US)*: **GALAPAGOS NV** [BE/BE]; Industriepark Mechelen Noord, Generaal De Wittelaan L11/A3, B-2800 Mechelen (BE).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **MENET, Christel Jeanne Marie** [FR/BE]; Galapagos NV, Generaal De Wittelaan L11/A3, B-2800 Mechelen (BE). **BLANC, Javier** [ES/BE]; Galapagos NV, Generaal De Wittelaan L11/A3, B-2800 Mechelen (BE). **JOUANNIGOT, Nolwenn** [FR/FR]; 50 Route de Pringy, F-74940 Annecy le Vieux (FR). **HODGES, Alastair James** [GB/GB]; BioFocus DPI, Chesterford Research Park, Saffron Walden Essex CB10 1XL (GB). **VAN ROMPAEY, Luc Juliaan Corina** [BE/BE]; Galapagos NV, Generaal De Wittelaan L11/A3, B-2800 Mechelen (BE). **FLETCHER, Stephen Robert** [GB/FR]; Galapagos SASU, 102 Avenue Gaston Roussel, B-93230 Romainville (BE).

(74) Agent: **NICHOL, Maria**; Galapagos NV, Chesterford Research Park, Saffron Walden Essex CB10 1XL (GB).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report (Art. 21(3))*

— *with amended claims (Art. 19(1))*

(54) Title: NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES.



(I)

(57) Abstract: Novel [1,2,4]triazolo[1,5-a]pyridine compounds are disclosed that have a formula represented by the Formula I. The compounds may be prepared as a pharmaceutical composition, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non- limiting example, diseases involving cartilage degradation, bone and/or joint degradation, for example osteoarthritis; and/or conditions involving inflammation or immune responses, such as Crohn's disease, rheumatoid arthritis, psoriasis, allergic airways disease (e.g. asthma, rhinitis), juvenile idiopathic arthritis, colitis, inflammatory bowel diseases, endotoxin-driven disease states (e.g. complications after bypass surgery or chronic endotoxin states contributing to e.g. chronic cardiac failure), diseases involving impairment of cartilage turnover (e.g. diseases involving the anabolic stimulation of chondrocytes), congenital cartilage malformations, diseases associated with hypersecretion of IL6 and transplantation rejection (e.g. organ transplant rejection) and proliferative diseases.

WO 2010/010188 A1

NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES

FIELD OF THE INVENTION

[0001] The present invention relates to compounds that are inhibitors of JAK, a family of tyrosine kinases that are involved in the modulation of the degradation of cartilage, joint degeneration and diseases involving such degradation and/or inflammation. The present invention also provides methods for the production of these compounds, pharmaceutical compositions comprising these compounds, methods for the prevention and/or treatment of diseases involving cartilage degradation, bone and/or joint degradation, conditions involving inflammation or immune responses, endotoxin-driven disease states, cancer, and organ transplant rejection; and/ or methods for the prevention and/or treatment of diseases involving cartilage degradation, joint degradation and/or inflammation by administering a compound of the invention.

[0002] Janus kinases (JAKs) are cytoplasmic tyrosine kinases that transduce cytokine signaling from membrane receptors to STAT transcription factors. Four JAK family members are described, JAK1, JAK2, JAK3 and TYK2. Upon binding of the cytokine to its receptor, JAK family members auto- and/or transphosphorylate each other, followed by phosphorylation of STATs that then migrate to the nucleus to modulate transcription. JAK-STAT intracellular signal transduction serves the interferons, most interleukins, as well as a variety of cytokines and endocrine factors such as EPO, TPO, GH, OSM, LIF, CNTF, GM-CSF, PRL Vainchenker W. *et al.* (2008).

[0003] The combination of genetic models and small molecule JAK inhibitor research revealed the therapeutic potential of several JAKs. JAK3 is validated by mouse and human genetics as an immune-suppression target (O'Shea J. *et al.* (2004)). JAK3 inhibitors were successfully taken into clinical development, initially for organ transplant rejection but later also in other immuno-inflammatory indications such as rheumathoid arthritis (RA), psoriasis and Crohn's disease (http://clinicaltrials.gov/).

[0004] TYK2 is a potential target for immuno-inflammatory diseases, being validated by human genetics and mouse knock-out studies (Levy D. and Loomis C. (2007)).

[0005] JAK1 is a novel target in the immuno-inflammatory disease area. JAK1 heterodimerizes with the other JAKs to transduce cytokine-driven pro-inflammatory signaling. Therefore, inhibition of JAK1 and/or other JAKs is expected to be of therapeutic benefit for a range of inflammatory conditions as well as for other diseases driven by JAK-mediated signal transduction.

BACKGROUND OF THE INVENTION

[0006] Cartilage is an avascular tissue of which chondrocytes are the main cellular component. The chondrocytes in normal articular cartilage occupy approximately 5% of the tissue volume, while the extra-

cellular matrix makes up the remaining 95% of the tissue. The chondrocytes secrete the components of the matrix, mainly proteoglycans and collagens, which in turn supply the chondrocytes with an environment suitable for their survival under mechanical stress. In cartilage, collagen type II, together with the protein collagen type IX, is arranged in solid fibril-like structures which provide cartilage with great mechanical strength. The proteoglycans can absorb water and are responsible for the resilient and shock absorbing properties of the cartilage.

[0007] One of the functional roles of cartilage in the joint is to allow bones to articulate on each other smoothly. Loss of articular cartilage, therefore, causes the bones to rub against each other leading to pain and loss of mobility. The degradation of cartilage can have various causes. In inflammatory arthritides, as rheumatoid arthritis for example, cartilage degradation is caused by the secretion of proteases (e.g. collagenases) by inflamed tissues (the inflamed synovium for example). Cartilage degradation can also be the result of an injury of the cartilage, due to an accident or surgery, or exaggerated loading or 'wear and tear'. The ability of cartilage tissue to regenerate after such insults is limited. Chondrocytes in injured cartilage often display reduced cartilage synthesizing (anabolic) activity and / or increased cartilage degrading (catabolic) activity.

[0008] The degeneration of cartilage is the hallmark of various diseases, among which rheumatoid arthritis and osteoarthritis are the most prominent. Rheumatoid arthritis (RA) is a chronic joint degenerative disease, characterized by inflammation and destruction of the joint structures. When the disease is unchecked, it leads to substantial disability and pain due to loss of joint functionality and even premature death. The aim of an RA therapy, therefore, is not only to slow down the disease but to attain remission in order to stop the joint destruction. Besides the severity of the disease outcome, the high prevalence of RA (~ 0.8% of the adults are affected worldwide) means a high socio-economic impact. (For reviews on RA, we refer to Smolen and Steiner (2003); Lee and Weinblatt (2001); Choy and Panayi (2001); O'Dell (2004) and Firestein (2003)).

[0009] Osteoarthritis (also referred to as OA, or wear-and-tear arthritis) is the most common form of arthritis and is characterized by loss of articular cartilage, often associated with hypertrophy of the bone and pain. The disease mainly affects hands and weight-bearing joints such as knees, hips and spines. This process thins the cartilage. When the surface area has disappeared due to the thinning, a grade I osteoarthritis is reached; when the tangential surface area has disappeared, grade II osteoarthritis is reached. There are further levels of degeneration and destruction, which affect the deep and the calcified cartilage layers that border with the subchondral bone. For an extensive review on osteoarthritis, we refer to Wieland *et al.*, 2005.

[0010] The clinical manifestations of the development of the osteoarthritis condition are: increased volume of the joint, pain, crepitation and functional disability that lead to pain and reduced mobility of the joints. When disease further develops, pain at rest emerges. If the condition persists without correction and/or therapy, the joint is destroyed leading to disability. Replacement surgery with total prosthesis is then required.

[0011] Therapeutic methods for the correction of the articular cartilage lesions that appear during the osteoarthritic disease have been developed, but so far none of them have been able to mediate the regeneration of articular cartilage *in situ* and *in vivo*.

[0012] Osteoarthritis is difficult to treat. At present, no cure is available and treatment focuses on relieving pain and preventing the affected joint from becoming deformed. Common treatments include the use of non-steroidal anti-inflammatory drugs (NSAIDs). Although dietary supplements such as chondroitin and glucosamine sulphate have been advocated as safe and effective options for the treatment of osteoarthritis, a recent clinical trial revealed that both treatments did not reduce pain associated to osteoarthritis. (Clegg *et al.*, 2006). Taken together, no disease modifying osteoarthritic drugs are available.

[0013] In severe cases, joint replacement may be necessary. This is especially true for hips and knees. If a joint is extremely painful and cannot be replaced, it may be fused. This procedure stops the pain, but results in the permanent loss of joint function, making walking and bending difficult.

[0014] Another possible treatment is the transplantation of cultured autologous chondrocytes. Here, chondral cellular material is taken from the patient, sent to a laboratory where it is expanded. The material is then implanted in the damaged tissues to cover the tissue's defects.

[0015] Another treatment includes the intra-articular instillation of Hylan G-F 20 (e.g. Synvisc®, Hyalgan®, Artz®), a substance that improves temporarily the rheology of the synovial fluid, producing an almost immediate sensation of free movement and a marked reduction of pain.

[0016] Other reported methods include application of tendinous, periosteal, fascial, muscular or perichondral grafts; implantation of fibrin or cultured chondrocytes; implantation of synthetic matrices, such as collagen, carbon fiber; administration of electromagnetic fields. All of these have reported minimal and incomplete effects, resulting in a poor quality tissue that can neither support the weighted load nor allow the restoration of an articular function with normal movement.

[0017] Stimulation of the anabolic processes, blocking catabolic processes, or a combination of these two, may result in stabilization of the cartilage, and perhaps even reversion of the damage, and therefore prevent further progression of the disease. Various triggers may stimulate anabolic stimulation of chondrocytes. Insulin-like growth factor-I (IGF-I) is the predominant anabolic growth factor in synovial fluid and stimulates the synthesis of both proteoglycans and collagen. It has also been shown that members of the bone morphogenetic protein (BMP) family, notably BMP2, BMP4, BMP6, and BMP7, and members of the human transforming growth factor-ß (TGF-ß) family can induce chondrocyte anabolic stimulation (Chubinskaya and Kuettner, 2003). A compound has recently been identified that induces anabolic stimulation of chondrocytes (US 6,500,854; EP 1 391 211). However, most of these compounds show severe side effects and, consequently, there is a strong need for compounds that stimulate chondrocyte differentiation without these side effects.

[0018] Vandeghinste *et al.* (WO 2005/124342) discovered JAK1 as a target whose inhibition might have therapeutic relevance for several diseases including OA. JAK1 belongs to the Janus kinase (JAK) family

of cytoplasmic tyrosine kinases, involved in cytokine receptor-mediated intracellular signal transduction. The JAK family consists of 4 members: JAK1, JAK2, JAK3 and TYK2. JAKs are recruited to cytokine receptors, upon binding of the cytokine, followed by heterodimerization of the cytokine receptor and a shared receptor subunit (common gamma-c chain, gp130). JAKs are then activated by auto- and/or transphosphorylation by another JAK, resulting in phosphorylation of the receptors and recruitment and phosphorylation of members of the signal transducer and activator of transcription (STATs). Phosphorylated STATs dimerize and translocate to the nucleus where they bind to enhancer regions of cytokine-responsive genes. Knockout of the JAK1 gene in mice demonstrated that JAK1 plays essential and nonredundant roles during development: JAK1-/- mice died within 24h after birth and lymphocyte development was severely impaired. Moreover, JAK1 -/- cells were not, or less, reactive to cytokines that use class II cytokine receptors, cytokine receptors that use the gamma-c subunit for signaling and the family of cytokine receptors that use the gp130 subunit for signaling (Rodig *et al.*, 1998).

[0019] Various groups have implicated JAK-STAT signaling in chondrocyte biology. Li *et al.* (2001) showed that Oncostatin M induces MMP and TIMP3 gene expression in primary chondrocytes by activation of JAK/STAT and MAPK signaling pathways. Osaki *et al.* (2003) showed that interferon-gamma mediated inhibition of collagen II in chondrocytes involves JAK-STAT signaling. IL1-beta induces cartilage catabolism by reducing the expression of matrix components, and by inducing the expression of collagenases and inducible nitric oxide synthase (NOS2), which mediates the production of nitric oxide (NO). Otero *et al.*, (2005) showed that leptin and IL1-beta synergistically induced NO production or expression of NOS2 mRNA in chondrocytes, and that that was blocked by a JAK inhibitor. Legendre *et al.* (2003) showed that IL6/IL6Receptor induced downregulation of cartilage-specific matrix genes collagen II, aggrecan core and link protein in bovine articular chondrocytes, and that this was mediated by JAK/STAT signaling. Therefore, these observations suggest a role for JAK kinase activity in cartilage homeostasis and therapeutic opportunities for JAK kinase inhibitors.

[0020] JAK family members have been implicated in additional conditions including myeloproliferative disorders (O'Sullivan *et al*, 2007, Mol Immunol. 44(10):2497-506), where mutations in JAK2 have been identified. This indicates that inhibitors of JAK in particular JAK2 may also be of use in the treatment of myeloproliferative disorders. Additionally, the JAK family, in particular JAK1, JAK2 and JAK3, has been linked to cancers, in particular leukaemias *e.g.* acute myeloid leukaemia (O'Sullivan *et al*, 2007, Mol Immunol. 44(10):2497-506; Xiang *et al.*, 2008, "Identification of somatic *JAK1* mutations in patients with acute myeloid leukemia" Blood First Edition Paper, prepublished online December 26, 2007; DOI 10.1182/blood-2007-05-090308) and acute lymphoblastic leukemia (Mullighan *et al*, 2009) or solid tumours *e.g.* uterine leiomyosarcoma (Constantinescu *et al.*, 2007, Trends in Biochemical Sciences 33(3): 122-131), prostate cancer (Tam *et al.*, 2007, British Journal of Cancer, 97, 378 – 383) These results indicate that inhibitors of JAK, in particular of JAK1 and/or JAK2, may also have utility in the treatment of cancers (leukaemias and solid tumours e.g. uterine leiomyosarcoma, prostate cancer).

[0021] In addition, Castleman's disease, multiple myeloma, mesangial proliferative glomerulonephritis, psoriasis, and Kaposi's sarcoma are likely due to hypersecretion of the cytokine IL-6, whose biological effects are mediated by intracellular JAK-STAT signaling (Tetsuji Naka, Norihiro Nishimoto and Tadamitsu Kishimoto, Arthritis Res 2002, 4 (suppl 3):S233-S242). This result shows that inhibitor of JAK, may also find utility in the treatment of said diseases.

[0022] A link with autoimmune diseases has been established for JAK3 and Tyk2. Mutations in JAK3 but also in the upstream signaling components gamma-c receptor chain and IL7 receptor account in aggregate for ~70% of cases of human severe combined immunodeficiency ('OShea *et al.*, 2004). Note that JAK1 cooperates with JAK3 in transducing signals from the gamma-c receptor chain. Tyk2 polymorphisms are seen in systemic lupus erythematosus (SLE) (O'Sullivan *et al*, 2007, Mol Immunol. 44(10):2497-506). Hence, targeting the JAK family may provide a therapeutic opportunity in the immuno-inflammation area.

[0023] The current therapies are not satisfactory and therefore there remains a need to identify further compounds that may be of use in the treatment of diseases involving cartilage degradation, bone and/or joint degradation, for example osteoarthritis; and/or conditions involving inflammation or immune responses, such as Crohn's disease, rheumatoid arthritis, psoriasis, allergic airways disease (e.g. asthma, rhinitis), juvenile idiopathic arthritis, colitis, inflammatory bowel diseases, endotoxin-driven disease states (e.g. complications after bypass surgery or chronic endotoxin states contributing to e.g. chronic cardiac failure), diseases involving impairment of cartilage turnover (e.g. diseases involving the anabolic stimulation of chondrocytes), congenital cartilage malformations, diseases associated with hypersecretion of IL6 and transplantation rejection (e.g. organ transplant rejection). Inhibitors of JAK can also find application in the treatment of proliferative diseases. In particular the inhibitors of JAK find application in the treatment of cancers , especially leukaemias and solid tumours (e.g. uterine leiomyosarcoma, prostate cancer). The present invention therefore provides compounds, methods for their manufacture and a pharmaceutical comprising a compound of the invention together with a suitable pharmaceutical carrier. The present invention also provides for the use of a compound of the invention in the preparation of a medicament for the treatment of degenerative joint diseases.

SUMMARY OF THE INVENTION

[0024] The present invention is based on the discovery that inhibitors of JAK are useful for the treatment of diseases involving cartilage degradation, bone and/or joint degradation, for example osteoarthritis; and/or conditions involving inflammation or immune responses, such as Crohn's disease, rheumatoid arthritis, psoriasis, allergic airways disease (e.g. asthma, rhinitis), juvenile idiopathic arthritis, colitis, inflammatory bowel diseases, endotoxin-driven disease states (e.g. complications after bypass surgery or chronic endotoxin states contributing to e.g. chronic cardiac failure), diseases involving impairment of cartilage turnover (e.g. diseases involving the anabolic stimulation of chondrocytes), congenital cartilage malformations, diseases associated with hypersecretion of IL6 and transplantation rejection (e.g. organ transplant rejection). Inhibitors

of JAK can also find application in the treatment of proliferative diseases. In particular the inhibitors of JAK find application in the treatment of cancers, especially leukaemias and solid tumours (e.g. uterine leiomyosarcoma, prostate cancer). The present invention also provides methods for the production of these compounds, pharmaceutical compositions comprising these compounds and methods for treating diseases involving cartilage degradation, joint degradation and/or inflammation by administering a compound of the invention.

[0025] Accordingly, in a first aspect of the invention, substituted bicycloheteroaryl compounds are disclosed having according to Formula (I):



I

wherein

each Cy1 and Cy2 is independently selected from aryl and heteroaryl;

L1 is selected from a single bond, -O-, -C(O)-, -$S(O)_2$-, -$N(R^{4a})$-, -$CON(R^{4a})$-, -$SO_2N(R^{4a})$-, -$N(R^{4a})CO$-, or -$N(R^{4a})SO_2$-;

each R^1 is independently selected from C_1-C_6 alkyl, substituted C_1-C_6 alkyl, acyl, substituted acyl, substituted or unsubstituted acylamino, substituted or unsubstituted amido, substituted or unsubstituted C_1-C_6 alkoxy, substituted or unsubstituted amino, substituted sulfinyl, substituted sulfonyl, substituted or unsubstituted aminosulfonyl, sulfonic acid, sulfonic acid ester, carboxy, cyano, substituted or unsubstituted C_3-C_7 cycloalkyl, substituted or unsubstituted 4-7 membered heterocycloalkyl, halo, and hydroxyl;

each R^{3a} is independently selected from C_1-C_6 alkyl, substituted C_1-C_6 alkyl, acyl, substituted acyl, substituted or unsubstituted acylamino, substituted or unsubstituted amido, substituted or unsubstituted C_1-C_6 alkoxy, alkoxycarbonyl, substituted alkoxycarbonyl, arylalkyloxy, substituted arylalkyloxy, substituted or unsubstituted amino, aryl, substituted aryl, arylalkyl, substituted sulfanyl, substituted sulfinyl, substituted sulfonyl, substituted or unsubstituted aminosulfonyl, substituted or unsubstituted arylsulfonyl, sulfonic acid, sulfonic acid ester, azido, carboxy, cyano, substituted or unsubstituted C_3-C_7 cycloalkyl, substituted or unsubstituted C_4-C_7 heterocycloalkyl, halo, -O-heteroaryl, substituted or unsubstituted heteroaryl, hydroxy, nitro, and thiol;

each R^{2b}, R^{2c}, and R^{2d} is independently selected from H, C_1-C_6 alkyl, substituted C_1-C_6 alkyl, acyl, substituted acyl, substituted or unsubstituted acylamino, substituted or unsubstituted C_1-C_6 alkoxy,

substituted or unsubstituted –O-aryl, alkoxycarbonyl, substituted alkoxycarbonyl, arylalkyloxy, substituted arylalkyloxy, substituted or unsubstituted amino, aryl, substituted aryl, arylalkyl, substituted sulfanyl, substituted sulfinyl, substituted sulfonyl, substituted or unsubstituted aminosulfonyl, substituted or unsubstituted arylsulfonyl, sulfonic acid, sulfonic acid ester, azido, carboxy, substituted or unsubstituted amido, cyano, substituted or unsubstituted C_3-C_7 cycloalkyl, substituted or unsubstituted 4-7 membered heterocycloalkyl, halo, -O-heteroaryl, substituted or unsubstituted heteroaryl, hydroxy, nitro, and thiol;

each R^{2a} and R^{4a} is independently selected from H, C_1-C_6 alkyl, substituted C_1-C_6 alkyl, C_3-C_7 cycloalkyl, or substituted C_3-C_7cycloalkyl;

m1 is 0, 1, or 2; m2 is 0, 1, 2, 3 or 4; and n1 is 0, 1, 2, 3, or 4;

provided that

when L1 is -N(R^{4a})-, -CON(R^{4a})-, or -SO_2N(R^{4a})-, and R^{2c} is other than H, alkyl, cycloalkyl, aryl or heteroaryl, then n1 is 1, 2, 3, or 4;

or pharmaceutically acceptable salts or solvates thereof or the solvates of the pharmaceutically acceptable salts.

[0026] In a further aspect of the invention, substituted bicycloheteroaryl compounds are disclosed which are able to inhibit the activity of JAK *in vivo* according to Formula (I).

[0027] In a further aspect, the present invention provides pharmaceutical compositions comprising a compound of the invention, and a pharmaceutical carrier, excipient or diluent. In this aspect of the invention, the pharmaceutical composition can comprise one or more of the compounds described herein. Moreover, the compounds of the present invention useful in the pharmaceutical compositions and treatment methods disclosed herein, are all pharmaceutically acceptable as prepared and used.

[0028] In a further aspect of the invention, this invention provides a method of treating a mammal susceptible to or afflicted with a condition from among those listed herein, and particularly, such condition as may be associated with aberrant JAK activity, for example diseases involving cartilage degradation, bone and/or joint degradation, for example osteoarthritis; and/or conditions involving inflammation or immune responses, such as Crohn's disease, rheumatoid arthritis, psoriasis, allergic airways disease (e.g. asthma, rhinitis), juvenile idiopathic arthritis, colitis, inflammatory bowel diseases, endotoxin-driven disease states (e.g. complications after bypass surgery or chronic endotoxin states contributing to e.g. chronic cardiac failure), diseases involving impairment of cartilage turnover (e.g. diseases involving the anabolic stimulation of chondrocytes), congenital cartilage malformations, diseases associated with hypersecretion of IL6 and transplantation rejection (e.g. organ transplant rejection), which method comprises administering a therapeutically effective amount of a compound of the invention or a pharmceutical compostion as herein described. Inhibitors of JAK can also find application in the treatment of proliferative diseases, which method comprises administering a therapeutically effective amount of a compound of the invention or a pharmceutical

compostion as herein described. In particular the inhibitors of JAK find application in the treatment of cancers, especially leukaemias and solid tumours (e.g. uterine leiomyosarcoma, prostate cancer). In a particular embodiment the present invention provides a method for treating conditions selected from inflammation, such as rheumatoid arthritis, juvenile idiopathic arthritis, psoriasis, allergic airways disease (e.g. asthma, rhinitis), inflammatory bowel diseases (e.g. Crohn's disease, colitis), endotoxin-driven disease states (e.g. complications after bypass surgery or chronic endotoxin states contributing to e.g. chronic cardiac failure), and organ transplant rejection; and cartilage, bone and/or joint degradation or degeneration, such as osteoarthritis, which method comprises administering an effective amount of one or more of the pharmaceutical compositions or compounds herein described.

[0029] In a further aspect, the present invention provides a method of treating a mammal susceptible to or afflicted with proliferative disorders in particular cancer, (e.g. solid tumours), leukaemias, multiple myeloma or psoriasis.

[0030] In a further aspect, the present invention provides a compound of the invention for use in the treatment or prevention of a condition selected from those listed herein, particularly such conditions as may be associated with aberrant JAK activity such as diseases involving cartilage degradation, bone and/or joint degradation, for example osteoarthritis; and/or conditions involving inflammation or immune responses, such as Crohn's disease, rheumatoid arthritis, psoriasis, allergic airways disease (e.g. asthma, rhinitis), juvenile idiopathic arthritis, colitis, inflammatory bowel diseases, endotoxin-driven disease states (e.g. complications after bypass surgery or chronic endotoxin states contributing to e.g. chronic cardiac failure), diseases involving impairment of cartilage turnover (e.g diseases involving the anabolic stimulation of chondrocytes), congenital cartilage malformations, diseases associated with hypersecretion of IL6 and transplantation rejection (e.g. organ transplant rejection). Inhibitors of JAK can also find application in the treatment of proliferative diseases. In particular the inhibitors of JAK find application in the treatment of cancers, especially leukaemias and solid tumours (e.g. uterine leiomyosarcoma, prostate cancer). In a specific embodiment, the condition is selected from inflammation, such as rheumatoid arthritis, juvenile idiopathic arthritis, psoriasis, allergic airways disease (e.g. asthma, rhinitis), inflammatory bowel diseases (e.g. Crohn's disease, colitis), endotoxin-driven disease states (e.g. complications after bypass surgery or chronic endotoxin states contributing to e.g. chronic cardiac failure), and organ transplant rejection; and cartilage, bone and/or joint degradation or degeneration, such as osteoarthritis.

[0031] In a further aspect, the present invention provides a compound of the invention for use in the treatment or prevention of proliferative disorders, in particular cancer, (e.g. solid tumours), leukaemias, multiple myeloma or psoriasis.

[0032] In yet another method of treatment aspect, this invention provides a method for treating a mammal susceptible to or afflicted with a condition that is causally related to abnormal JAK activity as

described herein, and comprises administering an effective condition-treating or condition-preventing amount of one or more of the pharmaceutical compositions or compounds herein described.

[0033] In a further aspect, the present invention provides a compound of the invention for use in the treatment or prevention of a condition that is causally related to abnormal JAK activity.

[0034] In additional aspects, this invention provides methods for synthesizing the compounds of the invention, with representative synthetic protocols and pathways disclosed later on herein.

[0035] Accordingly, it is a principal object of this invention to provide a novel series of compounds, which can modify the activity of JAK and thus prevent or treat any maladies that may be causally related thereto.

[0036] It is further an object of this invention to provide a series of compounds that can treat or alleviate maladies or symptoms of same, such as cartilage and/or bone degradation and related inflammation, and joint diseases, that may be causally related to the activity of JAK.

[0037] A still further object of this invention is to provide pharmaceutical compositions that may be used in the treatment or prevention of a variety of disease states, including the diseases associated with JAK activity such as diseases involving cartilage degradation, bone and/or joint degradation, for example osteoarthritis; and/or conditions involving inflammation or immune responses, such as Crohn's disease, rheumatoid arthritis, psoriasis, allergic airways disease (e.g. asthma, rhinitis), juvenile idiopathic arthritis, colitis, inflammatory bowel diseases, endotoxin-driven disease states (e.g. complications after bypass surgery or chronic endotoxin states contributing to e.g. chronic cardiac failure), diseases involving impairment of cartilage turnover (e.g. diseases involving the anabolic stimulation of chondrocytes), congenital cartilage malformations, diseases associated with hypersecretion of IL6 and transplantation rejection (e.g. organ transplant rejection). Inhibitors of JAK can also find application in the treatment of proliferative diseases. In particular the inhibitors of JAK find application in the treatment of cancers , especially leukaemias and solid tumours (e.g. uterine leiomyosarcoma, prostate cancer). In a specific embodiment the condition is selected from inflammation, such as Crohn's disease, rheumatoid arthritis, psoriasis, allergic airways disease (e.g. asthma, rhinitis), juvenile idiopathic arthritis, colitis, inflammatory bowel diseases, endotoxin-driven disease states (e.g. complications after bypass surgery or chronic endotoxin states contributing to e.g. chronic cardiac failure), and organ transplant rejection; and cartilage, bone and/or joint degradation or degeneration, such as osteoarthritis or cancers (e.g. solid tumours or leukaemias).

[0038] Other objects and advantages will become apparent to those skilled in the art from a consideration of the ensuing detailed description.

DETAILED DESCRIPTION OF THE INVENTION

Definitions

[0039] The following terms are intended to have the meanings presented therewith below and are useful in understanding the description and intended scope of the present invention.

[0040] When describing the invention, which may include compounds, pharmaceutical compositions containing such compounds and methods of using such compounds and compositions, the following terms, if present, have the following meanings unless otherwise indicated. It should also be understood that when described herein any of the moieties defined forth below may be substituted with a variety of substituents, and that the respective definitions are intended to include such substituted moieties within their scope as set out below. Unless otherwise stated, the term "substituted" is to be defined as set out below. It should be further understood that the terms "groups" and "radicals" can be considered interchangeable when used herein.

[0041] The articles "a" and "an" may be used herein to refer to one or to more than one (i.e. at least one) of the grammatical objects of the article. By way of example "an analogue" means one analogue or more than one analogue.

[0042] 'Acyl' or 'Alkanoyl' refers to a radical $-C(O)R^{20}$, where R^{20} is hydrogen, C_1-C_8 alkyl, C_3-C_{10} cycloalkyl, C_3-C_{10} cycloalkylmethyl, 4-10 membered heterocycloalkyl, aryl, arylalkyl, 5-10 membered heteroaryl or heteroarylalkyl as defined herein. Representative examples include, but are not limited to, formyl, acetyl, cyclohexylcarbonyl, cyclohexylmethylcarbonyl, benzoyl and benzylcarbonyl. Exemplary 'acyl' groups are $-C(O)H$, $-C(O)$-C_1-C_8 alkyl, $-C(O)$-$(CH_2)_t$(C_6-C_{10} aryl), $-C(O)$-$(CH_2)_t$(5-10 membered heteroaryl), $-C(O)$-$(CH_2)_t$(C_3-C_{10} cycloalkyl), and $-C(O)$-$(CH_2)_t$(4-10 membered heterocycloalkyl), wherein t is an integer from 0 to 4.

[0043] 'Substituted Acyl' or 'Substituted Alkanoyl' refers to a radical $-C(O)R^{21}$, wherein R^{21} is independently

- C_1-C_8 alkyl, substituted with halo or hydroxy; or
- C_3-C_{10} cycloalkyl, 4-10 membered heterocycloalkyl, C_6-C_{10} aryl, arylalkyl, 5-10 membered heteroaryl or heteroarylalkyl, each of which is substituted with unsubstituted C_1-C_4 alkyl, halo, unsubstituted C_1-C_4 alkoxy, unsubstituted C_1-C_4 haloalkyl, unsubstituted C_1-C_4 hydroxyalkyl, or unsubstituted C_1-C_4 haloalkoxy or hydroxy.

[0044] 'Acylamino' refers to a radical $-NR^{22}C(O)R^{23}$, where R^{22} is hydrogen, C_1-C_8 alkyl, C_3-C_{10} cycloalkyl, 4-10 membered heterocycloalkyl, C_6-C_{10} aryl, arylalkyl, 5-10 memberd heteroaryl or heteroarylalkyl and R^{23} is hydrogen, C_1-C_8 alkyl, C_3-C_{10} cycloalkyl, 4-10 membered heterocycloalkyl, C_6-C_{10} aryl, arylalkyl, 5-10 membered heteroaryl or heteroarylalkyl, as defined herein. Exemplary 'acylamino' include, but are not limited to, formylamino, acetylamino, cyclohexylcarbonylamino, cyclohexylmethyl-carbonylamino, benzoylamino and benzylcarbonylamino. Exemplary 'acylamino' groups are $-NR^{21'}C(O)$-C_1-C_8 alkyl, $-NR^{21'}C(O)$-$(CH_2)_t$(C_6-C_{10} aryl), $-NR^{21'}C(O)$-$(CH_2)_t$(5-10 membered heteroaryl), $-NR^{21'}C(O)$-$(CH_2)_t$(C_3-C_{10} cycloalkyl), and $-NR^{21'}C(O)$-$(CH_2)_t$(4-10 membered heterocycloalkyl), wherein t is an integer from 0 to 4, each $R^{21'}$ independently represents H or C_1-C_8 alkyl.

[0045] 'Substituted Acylamino' refers to a radical $-NR^{24}C(O)R^{25}$, wherein:

R^{24} is independently

- H, C_1-C_8 alkyl, substituted with halo or hydroxy; or
- C_3-C_{10} cycloalkyl, 4-10 membered heterocycloalkyl, C_6-C_{10} aryl, arylalkyl, 5-10 membered heteroaryl or heteroarylalkyl, each of which is substituted with unsubstituted C_1-C_4 alkyl, halo, unsubstituted C_1-C_4 alkoxy, unsubstituted C_1-C_4 haloalkyl, unsubstituted C_1-C_4 hydroxyalkyl, or unsubstituted C_1-C_4 haloalkoxy or hydroxy; and

R^{25} is independently

- H, C_1-C_8 alkyl, substituted with halo or hydroxy; or
- C_3-C_{10} cycloalkyl, 4-10 membered heterocycloalkyl, C_6-C_{10} aryl, arylalkyl, 5-10 membered heteroaryl or heteroarylalkyl, each of which is substituted with unsubstituted C_1-C_4 alkyl, halo, unsubstituted C_1-C_4 alkoxy, unsubstituted C_1-C_4 haloalkyl, unsubstituted C_1-C_4 hydroxyalkyl, or unsubstituted C_1-C_4 haloalkoxy or hydroxyl;

provided at least one of R^{24} and R^{25} is other than H.

[0046] 'Alkoxy' refers to the group $-OR^{26}$ where R^{26} is C_1-C_8 alkyl. Particular alkoxy groups are methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, tert-butoxy, sec-butoxy, n-pentoxy, n-hexoxy, and 1,2-dimethylbutoxy. Particular alkoxy groups are lower alkoxy, i.e. with between 1 and 6 carbon atoms. Further particular alkoxy groups have between 1 and 4 carbon atoms.

[0047] 'Substituted alkoxy' refers to an alkoxy group substituted with one or more of those groups recited in the definition of "substituted" herein, and particularly refers to an alkoxy group having 1 or more substituents, for instance from 1 to 5 substituents, and particularly from 1 to 3 substituents, in particular 1 substituent, selected from the group consisting of amino, substituted amino, C_6-C_{10} aryl, -O-aryl, carboxyl, cyano, C_3-C_{10} cycloalkyl, 4-10 membered heterocycloalkyl, halogen, 5-10 membered heteroaryl, hydroxyl, nitro, thioalkoxy, thio-O-aryl, thiol, alkyl-S(O)-, aryl–S(O)-, alkyl–$S(O)_2$- and aryl-$S(O)_2$-. Exemplary 'substituted alkoxy' groups are $-O-(CH_2)_t(C_6$-C_{10} aryl), $-O-(CH_2)_t$(5-10 membered heteroaryl), $-O-(CH_2)_t(C_3$-C_{10} cycloalkyl), and $-O-(CH_2)_t$(4-10 membered heterocycloalkyl), wherein t is an integer from 0 to 4 and any aryl, heteroaryl, cycloalkyl or heterocycloalkyl groups present, may themselves be substituted by unsubstituted C_1-C_4 alkyl, halo, unsubstituted C_1-C_4 alkoxy, unsubstituted C_1-C_4 haloalkyl, unsubstituted C_1-C_4 hydroxyalkyl, or unsubstituted C_1-C_4 haloalkoxy or hydroxy. Particular exemplary 'substituted alkoxy' groups are OCF_3, OCH_2CF_3, OCH_2Ph, OCH_2-cyclopropyl, OCH_2CH_2OH, $OCH_2CH_2NMe_2$.

[0048] 'Alkoxycarbonyl' refers to a radical $-C(O)-OR^{27}$ where R^{27} represents an C_1-C_8 alkyl, C_3-C_{10} cycloalkyl, C_3-C_{10} cycloalkylalkyl, 4-10 membered heterocycloalkylalkyl, aralkyl, or 5-10 membered heteroarylalkyl as defined herein. Exemplary "alkoxycarbonyl" groups are $C(O)O$-C_1-C_8 alkyl, $-C(O)O-(CH_2)_t(C_6$-C_{10} aryl), $-C(O)O-(CH_2)_t$(5-10 membered heteroaryl), $-C(O)O-(CH_2)_t(C_3$-C_{10} cycloalkyl), and $-C(O)O-(CH_2)_t$(4-10 membered heterocycloalkyl), wherein t is an integer from 1 to 4.

[0049] 'Substituted Alkoxycarbonyl' refers to a radical -C(O)-OR^{28} where R^{28} represents:

- C_1-C_8 alkyl, C_3-C_{10} cycloalkyl, C_3-C_{10} cycloalkylalkyl, or 4-10 membered heterocycloalkylalkyl, each of which is substituted with halo, substituted or unsubstituted amino, or hydroxy; or
- C_6-C_{10} aralkyl, or 5-10 membered heteroarylalkyl, each of which is substituted with unsubstituted C_1-C_4 alkyl, halo, unsubstituted C_1-C_4 alkoxy, unsubstituted C_1-C_4 haloalkyl, unsubstituted C_1-C_4 hydroxyalkyl, or unsubstituted C_1-C_4 haloalkoxy or hydroxyl.

[0050] 'Alkyl' means straight or branched aliphatic hydrocarbon having 1 to 20 carbon atoms. Particular alkyl has 1 to 12 carbon atoms. More particular is lower alkyl which has 1 to 6 carbon atoms. A further particular group has 1 to 4 carbon atoms. Exemplary straight chained groups include methyl, ethyl n-propyl, and n-butyl. Branched means that one or more lower alkyl groups such as methyl, ethyl, propyl or butyl is attached to a linear alkyl chain, exemplary branched chain groups include isopropyl, iso-butyl, t-butyl and isoamyl.

[0051] 'Substituted alkyl' refers to an alkyl group as defined above substituted with one or more of those groups recited in the definition of "substituted" herein, and particularly refers to an alkyl group having 1 or more substituents, for instance from 1 to 5 substituents, and particularly from 1 to 3 substituents, in particular 1 substituent, selected from the group consisting of acyl, acylamino, acyloxy (-O-acyl or –$OC(O)R^{20}$), alkoxy, alkoxycarbonyl, alkoxycarbonylamino (-NR''-alkoxycarbonyl or -NH-C(O)-OR^{27}), amino, substituted amino, aminocarbonyl (carbamoyl or amido or –C(O)-NR''_2), aminocarbonylamino (-NR''-C(O)-NR''_2), aminocarbonyloxy (-O-C(O)-NR''_2), aminosulfonyl, sulfonylamino, aryl, -O-aryl, azido, carboxyl, cyano, cycloalkyl, halogen, hydroxy, heteroaryl, nitro, thiol, -S-alkyl, –S-aryl, -S(O)-alkyl,–S(O)-aryl, –$S(O)_2$-alkyl, and -$S(O)_2$-aryl. In a particular embodiment 'substituted alkyl' refers to a C_1-C_8 alkyl group substituted with halo, cyano, nitro, trifluoromethyl, trifluoromethoxy, azido, -$NR'''SO_2R''$, -$SO_2NR''R'''$, -C(O)R'', -C(O)OR'', -OC(O)R'', -$NR'''C(O)R''$, -C(O)$NR''R'''$, -$NR''R'''$, or -$(CR'''R'''')_mOR'''$; wherein each R'' is independently selected from H, C_1-C_8 alkyl, -$(CH_2)_t$(C_6-C_{10} aryl), -$(CH_2)_t$(5-10 membered heteroaryl), -$(CH_2)_t$(C_3-C_{10} cycloalkyl), and -$(CH_2)_t$(4-10 membered heterocycloalkyl), wherein t is an integer from 0 to 4 and any aryl, heteroaryl, cycloalkyl or heterocycloalkyl groups present, may themselves be substituted by unsubstituted C_1-C_4 alkyl, halo, unsubstituted C_1-C_4 alkoxy, unsubstituted C_1-C_4 haloalkyl, unsubstituted C_1-C_4 hydroxyalkyl, or unsubstituted C_1-C_4 haloalkoxy or hydroxy. Each of R''' and R'''' independently represents H or C_1-C_8 alkyl.

[0052] 'Amino' refers to the radical -NH_2.

[0053] 'Substituted amino' refers to an amino group substituted with one or more of those groups recited in the definition of 'substituted' herein, and particularly refers to the group -$N(R^{33})_2$ where each R^{33} is independently selected from:

- hydrogen, C_1-C_8 alkyl, C_6-C_{10} aryl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, or C_3-C_{10} cycloalkyl; or

- C_1-C_8 alkyl, substituted with halo or hydroxy; or
- -$(CH_2)_t$(C_6-C_{10} aryl), -$(CH_2)_t$(5-10 membered heteroaryl), -$(CH_2)_t$(C_3-C_{10} cycloalkyl) or -$(CH_2)_t$(4-10 membered heterocycloalkyl) wherein t is an integer between 0 and 8, each of which is substituted by unsubstituted C_1-C_4 alkyl, halo, unsubstituted C_1-C_4 alkoxy, unsubstituted C_1-C_4 haloalkyl, unsubstituted C_1-C_4 hydroxyalkyl, or unsubstituted C_1-C_4 haloalkoxy or hydroxy; or
- both R^{33} groups are joined to form an alkylene group.

When both R^{33} groups are hydrogen, -$N(R^{33})_2$ is an amino group. Exemplary 'substituted amino' groups are –$NR^{33'}$-C_1-C_8 alkyl, –$NR^{33'}$-$(CH_2)_t$(C_6-C_{10} aryl), –$NR^{33'}$-$(CH_2)_t$(5-10 membered heteroaryl), –$NR^{33'}$-$(CH_2)_t$(C_3-C_{10} cycloalkyl), and –$NR^{33'}$-$(CH_2)_t$(4-10 membered heterocycloalkyl), wherein t is an integer from 0 to 4, each $R^{33'}$ independently represents H or C_1-C_8 alkyl; and any alkyl groups present, may themselves be substituted by halo, substituted or unsubstituted amino, or hydroxy; and any aryl, heteroaryl, cycloalkyl or heterocycloalkyl groups present, may themselves be substituted by unsubstituted C_1-C_4 alkyl, halo, unsubstituted C_1-C_4 alkoxy, unsubstituted C_1-C_4 haloalkyl, unsubstituted C_1-C_4 hydroxyalkyl, or unsubstituted C_1-C_4 haloalkoxy or hydroxy.

[0054] "Aminosulfonyl" or "Sulfonamide" refers to the radical –$S(O_2)NH_2$.

[0055] "Substituted aminosulfonyl" or "substituted sulfonamide" refers to a radical such as –$S(O_2)N(R^{48})_2$ wherein each R^{48} is independently selected from:

- H, C_1-C_8 alkyl, C_3-C_{10} cycloalkyl, 4-10 membered heterocycloalkyl, C_6-C_{10} aryl, aralkyl, 5-10 membered heteroaryl, and heteroaralkyl; or
- C_1-C_8 alkyl substituted with halo or hydroxy; or
- C_3-C_{10} cycloalkyl, 4-10 membered heterocycloalkyl, C_6-C_{10} aryl, aralkyl, 5-10 membered heteroaryl, or heteroaralkyl, substituted by unsubstituted C_1-C_4 alkyl, halo, unsubstituted C_1-C_4 alkoxy, unsubstituted C_1-C_4 haloalkyl, unsubstituted C_1-C_4 hydroxyalkyl, or unsubstituted C_1-C_4 haloalkoxy or hydroxy;

provided that at least one R^{48} is other than H.

[0056] Exemplary 'substituted aminosulfonyl' or 'substituted sulfonamide' groups are –$S(O_2)N(R^{48'})$-C_1-C_8 alkyl, –$S(O_2)N(R^{48'})$-$(CH_2)_t$(C_6-C_{10} aryl), –$S(O_2)N(R^{48'})$-$(CH_2)_t$(5-10 membered heteroaryl), –$S(O_2)N(R^{48'})$-$(CH_2)_t$(C_3-C_{10} cycloalkyl), and –$S(O_2)N(R^{48'})$-$(CH_2)_t$(4-10 membered heterocycloalkyl), wherein t is an integer from 0 to 4; each $R^{48'}$ independently represents H or C_1-C_8 alkyl; and any aryl, heteroaryl, cycloalkyl or heterocycloalkyl groups present, may themselves be substituted by unsubstituted C_1-C_4 alkyl, halo, unsubstituted C_1-C_4 alkoxy, unsubstituted C_1-C_4 haloalkyl, unsubstituted C_1-C_4 hydroxyalkyl, or unsubstituted C_1-C_4 haloalkoxy or hydroxy.

[0057] 'Aralkyl' or 'arylalkyl' refers to an alkyl group, as defined above, substituted with one or more aryl groups, as defined above. Particular aralkyl or arylalkyl groups are alkyl groups substituted with one aryl group.

[0058] 'Substituted Aralkyl' or 'substituted arylalkyl' refers to an alkyl group, as defined above, substituted with one or more aryl groups; and at least one of any aryl group present, may themselves be substituted by unsubstituted C_1-C_4 alkyl, halo, cyano, unsubstituted C_1-C_4 alkoxy, unsubstituted C_1-C_4 haloalkyl, unsubstituted C_1-C_4 hydroxyalkyl, or unsubstituted C_1-C_4 haloalkoxy or hydroxy.

[0059] 'Aryl' refers to a monovalent aromatic hydrocarbon group derived by the removal of one hydrogen atom from a single carbon atom of a parent aromatic ring system. In particular aryl refers to an aromatic ring structure, mono-cyclic or poly-cyclic that includes from 5 to 12 ring members, more usually 6 to 10. Where the aryl group is a monocyclic ring system it preferentially contains 6 carbon atoms. Typical aryl groups include, but are not limited to, groups derived from aceanthrylene, acenaphthylene, acephenanthrylene, anthracene, azulene, benzene, chrysene, coronene, fluoranthene, fluorene, hexacene, hexaphene, hexalene, as-indacene, s-indacene, indane, indene, naphthalene, octacene, octaphene, octalene, ovalene, penta-2,4-diene, pentacene, pentalene, pentaphene, perylene, phenalene, phenanthrene, picene, pleiadene, pyrene, pyranthrene, rubicene, triphenylene and trinaphthalene. Particularly aryl groups include phenyl, naphthyl, indenyl, and tetrahydronaphthyl.

[0060] 'Substituted Aryl' refers to an aryl group substituted with one or more of those groups recited in the definition of 'substituted' herein, and particularly refers to an aryl group that may optionally be substituted with 1 or more substituents, for instance from 1 to 5 substituents, particularly 1 to 3 substituents, in particular 1 substituent. Particularly, 'Substituted Aryl' refers to an aryl group substituted with one or more of groups selected from halo, C_1-C_8 alkyl, C_1-C_8 haloalkyl, C_1-C_8 haloalkoxy, cyano, hydroxy, C_1-C_8 alkoxy, and amino.

[0061] Examples of representative substituted aryls include the following



,


and


.

[0062] In these formulae one of R^{49} and R^{50} may be hydrogen and at least one of R^{49} and R^{50} is each independently selected from C_1-C_8 alkyl, 4-10 membered heterocycloalkyl, alkanoyl, C_1-C_8 alkoxy, hetero-O-aryl, alkylamino, arylamino, heteroarylamino, $NR^{51}COR^{52}$, $NR^{51}SOR^{52}$ $NR^{51}SO_2R^{52}$, COOalkyl, COOaryl, $CONR^{51}R^{52}$, $CONR^{51}OR^{52}$, $NR^{51}R^{52}$, $SO_2NR^{51}R^{52}$, S-alkyl, SOalkyl, SO_2alkyl, Saryl, SOaryl, SO_2aryl; or R^{49} and R^{50} may be joined to form a cyclic ring (saturated or unsaturated) from 5 to 8 atoms, optionally containing one or more heteroatoms selected from the group N, O or S. R^{51}, and R^{52} are independently hydrogen, C_1-C_8

alkyl, C_1-C_4 haloalkyl, C_3-C_{10} cycloalkyl, 4-10 membered heterocycloalkyl, C_6-C_{10} aryl, substituted aryl, 5-10 membered heteroaryl.

[0063] 'Arylalkyloxy' refers to an -O-alkylaryl radical where alkylaryl is as defined herein.

[0064] 'Substituted Arylalkyloxy' refers to an -O-alkylaryl radical where alkylaryl is as defined herein; and any aryl groups present, may themselves be substituted by unsubstituted C_1-C_4 alkyl, halo, cyano, unsubstituted C_1-C_4 alkoxy, unsubstituted C_1-$_4$ haloalkyl, unsubstituted C_1-C_4 hydroxyalkyl, or unsubstituted C_1-C_4 haloalkoxy or hydroxy.

[0065] 'Azido' refers to the radical -N_3.

[0066] 'Carbamoyl or amido' refers to the radical -$C(O)NH_2$.

[0067] 'Substituted Carbamoyl or substituted amido' refers to the radical -$C(O)N(R^{53})_2$ wherein each R^{53} is independently

- H, C_1-C_8 alkyl, C_3-C_{10} cycloalkyl, 4-10 membered heterocycloalkyl, C_6-C_{10} aryl, aralkyl, 5-10 membered heteroaryl, and heteroaralkyl; or
- C_1-C_8 alkyl substituted with halo or hydroxy; or
- C_3-C_{10} cycloalkyl, 4-10 membered heterocycloalkyl, C_6-C_{10} aryl, aralkyl, 5-10 membered heteroaryl, or heteroaralkyl, each of which is substituted by unsubstituted C_1-C_4 alkyl, halo, unsubstituted C_1-C_4 alkoxy, unsubstituted C_1-C_4 haloalkyl, unsubstituted C_1-C_4 hydroxyalkyl, or unsubstituted C_1-C_4 haloalkoxy or hydroxy;

provided that at least one R^{53} is other than H.

Exemplary 'Substituted Amido / Carbamoyl' groups are –$C(O)$ $NR^{53'}$-C_1-C_8 alkyl, –$C(O)NR^{53'}$-$(CH_2)_t$(C_6-C_{10} aryl), –$C(O)N^{53'}$-$(CH_2)_t$(5-10 membered heteroaryl), –$C(O)NR^{53'}$-$(CH_2)_t$(C_3-C_{10} cycloalkyl), and –$C(O)NR^{53'}$-$(CH_2)_t$(4-10 membered heterocycloalkyl), wherein t is an integer from 0 to 4, each $R^{53'}$ independently represents H or C_1-C_8 alkyl and any aryl, heteroaryl, cycloalkyl or heterocycloalkyl groups present, may themselves be substituted by unsubstituted C_1-C_4 alkyl, halo, unsubstituted C_1-C_4 alkoxy, unsubstituted C_1-C_4 haloalkyl, unsubstituted C_1-C_4 hydroxyalkyl, or unsubstituted C_1-C_4 haloalkoxy or hydroxy.

[0068] 'Carboxy' refers to the radical -$C(O)OH$.

[0069] 'Cycloalkyl' refers to cyclic non-aromatic hydrocarbyl groups having from 3 to 10 carbon atoms. Such cycloalkyl groups include, by way of example, single ring structures such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl.

[0070] 'Substituted cycloalkyl' refers to a cycloalkyl group as defined above substituted with one or more of those groups recited in the definition of 'substituted' herein, and particularly refers to a cycloalkyl group having 1 or more substituents, for instance from 1 to 5 substituents, and particularly from 1 to 3 substituents, in particular 1 substituent.

[0071] 'Cyano' refers to the radical -CN.

[0072] 'Halo' or 'halogen' refers to fluoro (F), chloro (Cl), bromo (Br) and iodo (I). Particular halo groups are either fluoro or chloro.

[0073] 'Hetero' when used to describe a compound or a group present on a compound means that one or more carbon atoms in the compound or group have been replaced by a nitrogen, oxygen, or sulfur heteroatom. Hetero may be applied to any of the hydrocarbyl groups described above such as alkyl, e.g. heteroalkyl, cycloalkyl, e.g. heterocycloalkyl, aryl, e.g. heteroaryl, cycloalkenyl, e.g. cycloheteroalkenyl, and the like having from 1 to 5, and particularly from 1 to 3 heteroatoms.

[0074] 'Heteroaryl' means an aromatic ring structure, mono-cyclic or polycyclic, that includes one or more heteroatoms and 5 to 12 ring members, more usually 5 to 10 ring members. The heteroaryl group can be, for example, a five membered or six membered monocyclic ring or a bicyclic structure formed from fused five and six membered rings or two fused six membered rings or, by way of a further example, two fused five membered rings. Each ring may contain up to four heteroatoms typically selected from nitrogen, sulphur and oxygen. Typically the heteroaryl ring will contain up to 4 heteroatoms, more typically up to 3 heteroatoms, more usually up to 2, for example a single heteroatom. In one embodiment, the heteroaryl ring contains at least one ring nitrogen atom. The nitrogen atoms in the heteroaryl rings can be basic, as in the case of an imidazole or pyridine, or essentially non-basic as in the case of an indole or pyrrole nitrogen. In general the number of basic nitrogen atoms present in the heteroaryl group, including any amino group substituents of the ring, will be less than five. Examples of five membered monocyclic heteroaryl groups include but are not limited to pyrrole, furan, thiophene, imidazole, furazan, oxazole, oxadiazole, oxatriazole, isoxazole, thiazole, isothiazole, pyrazole, triazole and tetrazole groups. Examples of six membered monocyclic heteroaryl groups include but are not limited to pyridine, pyrazine, pyridazine, pyrimidine and triazine. Particular examples of bicyclic heteroaryl groups containing a five membered ring fused to another five membered ring include but are not limited to imidazothiazole and imidazoimidazole. Particular examples of bicyclic heteroaryl groups containing a six membered ring fused to a five membered ring include but are not limited to benzfuran, benzthiophene, benzimidazole, benzoxazole, isobenzoxazole, benzisoxazole, benzthiazole, benzisothiazole, isobenzofuran, indole, isoindole, isoindolone, indolizine, indoline, isoindoline, purine (e.g., adenine, guanine), indazole, pyrazolopyrimidine, triazolopyrimidine, benzodioxole and pyrazolopyridine groups. Particular examples of bicyclic heteroaryl groups containing two fused six membered rings include but are not limited to quinoline, isoquinoline, chroman, thiochroman, chromene, isochromene, chroman, isochroman, benzodioxan, quinolizine, benzoxazine, benzodiazine, pyridopyridine, quinoxaline, quinazoline, cinnoline, phthalazine, naphthyridine and pteridine groups. Particular heteroaryl groups are those derived from thiophene, pyrrole, benzothiophene, benzofuran, indole, pyridine, quinoline, imidazole, oxazole and pyrazine.

[0075] Examples of representative aryl having hetero atoms containing substitution include the following:



wherein each W is selected from $C(R^{54})_2$, NR^{54}, O and S; and each Y is selected from carbonyl, NR^{54}, O and S; and R^{54} is independently hydrogen, C_1-C_8 alkyl, C_3-C_{10} cycloalkyl, 4-10 membered heterocycloalkyl, C_6-C_{10} aryl, and 5-10 membered heteroaryl.

[0076] Examples of representative heteroaryls include the following:



wherein each Y is selected from carbonyl, N, NR^{55}, O and S; and R^{55} is independently hydrogen, C_1-C_8 alkyl, C_3-C_{10} cycloalkyl, 4-10 membered heterocycloalkyl, C_6-C_{10} aryl, and 5-10 membered heteroaryl.

[0077] As used herein, the term 'heterocycloalkyl' refers to a 4-10 membered, stable heterocyclic non-aromatic ring and/or including rings containing one or more heteroatoms independently selected from N, O and S, fused thereto. A fused heterocyclic ring system may include carbocyclic rings and need only include one heterocyclic ring. Examples of heterocyclic rings include, but are not limited to, morpholine, piperidine (e.g. 1-piperidinyl, 2-piperidinyl, 3-piperidinyl and 4-piperidinyl), pyrrolidine (e.g. 1-pyrrolidinyl, 2-pyrrolidinyl and 3-pyrrolidinyl), pyrrolidone, pyran (2H-pyran or 4H-pyran), dihydrothiophene, dihydropyran, dihydrofuran, dihydrothiazole, tetrahydrofuran, tetrahydrothiophene, dioxane, tetrahydropyran (e.g. 4-tetrahydro pyranyl), imidazoline, imidazolidinone, oxazoline, thiazoline, 2-pyrazoline, pyrazolidine, piperazine, and N-alkyl piperazines such as N-methyl piperazine. Further examples include thiomorpholine and its S-oxide and S,S-dioxide (particularly thiomorpholine). Still further examples include azetidine, piperidone, piperazone, and N-alkyl piperidines such as N-methyl piperidine. Particular examples of heterocycloalkyl groups are shown in the following illustrative examples:



wherein each W is selected from CR^{56}, $C(R^{56})_2$, NR^{56}, O and S; and each Y is selected from NR^{56}, O and S; and R^{56} is independently hydrogen, C_1-C_8 alkyl, C_3-C_{10} cycloalkyl, 4-10 membered heterocycloalkyl, C_6-C_{10} aryl, 5-10 membered heteroaryl, These heterocycloalkyl rings may be optionally substituted with one or more groups selected from the group consisting of acyl, acylamino, acyloxy (-O-acyl or $-OC(O)R^{20}$), alkoxy, alkoxycarbonyl, alkoxycarbonylamino (-NR"-alkoxycarbonyl or -NH-C(O)-OR^{27}), amino, substituted amino, aminocarbonyl (amido or $-C(O)-NR"_2$), aminocarbonylamino (-NR"-C(O)-$NR"_2$), aminocarbonyloxy (-O-C(O)-$NR"_2$), aminosulfonyl, sulfonylamino, aryl, -O-aryl, azido, carboxyl, cyano, cycloalkyl, halogen, hydroxy, nitro, thiol, -S-alkyl, –S-aryl, -S(O)-alkyl,–S(O)-aryl, $-S(O)_2$-alkyl, and -$S(O)_2$-aryl. Substituting groups include carbonyl or thiocarbonyl which provide, for example, lactam and urea derivatives.

[0078] 'Hydroxy' refers to the radical -OH.

[0079] 'Nitro' refers to the radical $-NO_2$.

[0080] 'Substituted' refers to a group in which one or more hydrogen atoms are each independently replaced with the same or different substituent(s). Typical substituents may be selected from the group consisting of:

halogen, $-R^{57}$, $-O^-$, =O, $-OR^{57}$, $-SR^{57}$, $-S^-$, =S, $-NR^{57}R^{58}$, $=NR^{57}$, $-CCl_3$, $-CF_3$, -CN, -OCN, -SCN, -NO, $-NO_2$, $=N_2$, $-N_3$, $-S(O)_2O^-$, $-S(O)_2OH$, $-S(O)_2R^{57}$, $-OS(O_2)O^-$, $-OS(O)_2R^{57}$, $-P(O)(O^-)_2$, $-P(O)(OR^{57})(O^-)$, $-OP(O)(OR^{57})(OR^{58})$, $-C(O)R^{57}$, $-C(S)R^{57}$, $-C(O)OR^{57}$, $-C(O)NR^{57}R^{58}$, $-C(O)O^-$, $-C(S)OR^{57}$, $-NR^{59}C(O)NR^{57}R^{58}$, $-NR^{59}C(S)NR^{57}R^{58}$, $-NR^{60}C(NR^{59})NR^{57}R^{58}$ and $-C(NR^{59})NR^{57}R^{58}$;

wherein each R^{57}, R^{58}, R^{59} and R^{60} are independently:

- hydrogen, C_1-C_8 alkyl, C_6-C_{10} aryl, arylalkyl, C_3-C_{10} cycloalkyl, 4-10 membered heterocycloalkyl, 5-10 membered heteroaryl, heteroarylalkyl; or
- C_1-C_8 alkyl substituted with halo or hydroxy; or
- C_6-C_{10} aryl, 5-10 membered heteroaryl, C_6-C_{10} cycloalkyl or 4-10 membered heterocycloalkyl substituted by unsubstituted C_1-C_4 alkyl, halo, unsubstituted C_1-C_4 alkoxy, unsubstituted C_1-C_4 haloalkyl, unsubstituted C_1-C_4 hydroxyalkyl, or unsubstituted C_1-C_4 haloalkoxy or hydroxy.

In a particular embodiment, substituted groups are substituted with one or more substituents, particularly with 1 to 3 substituents, in particular with one substituent group.

In a further particular embodiment the substituent group or groups are selected from: halo, cyano, nitro, trifluoromethyl, trifluoromethoxy, azido, $-NR'''SO_2R''$, $-SO_2NR''R'''$, $-C(O)R''$, $-C(O)OR''$, $-OC(O)R''$, $-NR'''C(O)R''$, $-C(O)NR''R'''$, $-NR''R'''$, $-(CR'''R''')_mOR'''$, wherein, each R'' is independently selected from H, C_1-C_8 alkyl, $-(CH_2)_t(C_6$-C_{10} aryl), $-(CH_2)_t$(5-10 membered heteroaryl), $-(CH_2)_t(C_3$-C_{10} cycloalkyl), and $-(CH_2)_t$(4-10 membered heterocycloalkyl), wherein t is an integer from 0 to 4; and

- any alkyl groups present, may themselves be substituted by halo or hydroxy; and
- any aryl, heteroaryl, cycloalkyl or heterocycloalkyl groups present, may themselves be substituted by unsubstituted C_1-C_4 alkyl, halo, unsubstituted C_1-C_4 alkoxy, unsubstituted C_1-C_4 haloalkyl, unsubstituted C_1-C_4 hydroxyalkyl, or unsubstituted C_1-C_4 haloalkoxy or hydroxy. Each R'' independently represents H or C_1-C_6alkyl.

[0081] 'Substituted sulfanyl' refers to the group $-SR^{61}$, wherein R^{61} is selected from:

- C_1-C_8 alkyl, C_3-C_{10} cycloalkyl, 4-10 membered heterocycloalkyl, C_6-C_{10} aryl, aralkyl, 5-10 membered heteroaryl, and heteroaralkyl; or
- C_1-C_8 alkyl substituted with halo, substituted or unsubstituted amino, or hydroxy; or
- C_3-C_{10} cycloalkyl, 4-10 membered heterocycloalkyl, C_6-C_{10} aryl, aralkyl, 5-10 membered heteroaryl, or heteroaralkyl, each of which is substituted by unsubstituted C_1-C_4 alkyl, halo, unsubstituted C_1-C_4 alkoxy, unsubstituted C_1-C_4 haloalkyl, unsubstituted C_1-C_4 hydroxyalkyl, or unsubstituted C_1-C_4 haloalkoxy or hydroxy.

[0082] Exemplary 'substituted sulfanyl' groups are $-S$-(C_1-C_8 alkyl) and $-S$-(C_3-C_{10} cycloalkyl), $-S$-$(CH_2)_t(C_6$-C_{10} aryl), $-S$-$(CH_2)_t$(5-10 membered heteroaryl), $-S$-$(CH_2)_t(C_3$-C_{10} cycloalkyl), and $-S$-$(CH_2)_t$(4-10 membered heterocycloalkyl), wherein t is an integer from 0 to 4 and any aryl, heteroaryl, cycloalkyl or heterocycloalkyl groups present, may themselves be substituted by unsubstituted C_1-C_4 alkyl, halo, unsubstituted C_1-C_4 alkoxy, unsubstituted C_1-C_4 haloalkyl, unsubstituted C_1-C_4 hydroxyalkyl, or unsubstituted C_1-C_4 haloalkoxy or hydroxy.

[0083] 'Substituted sulfinyl' refers to the group $-S(O)R^{68}$, wherein R^{68} is selected from:

- C_1-C_8 alkyl, C_3-C_{10} cycloalkyl, 4-10 membered heterocycloalkyl, C_6-C_{10} aryl, aralkyl, 5-10 membered heteroaryl, and heteroaralkyl; or
- C_1-C_8 alkyl substituted with halo, substituted or unsubstituted amino, or hydroxy; or
- C_3-C_{10} cycloalkyl, 4-10 membered heterocycloalkyl, C_6-C_{10} aryl, aralkyl, 5-10 membered heteroaryl, or heteroaralkyl, substituted by unsubstituted C_1-C_4 alkyl, halo, unsubstituted C_1-C_4 alkoxy, unsubstituted C_1-C_4 haloalkyl, unsubstituted C_1-C_4 hydroxyalkyl, or unsubstituted C_1-C_4 haloalkoxy or hydroxy.

[0084] Exemplary 'substituted sulfinyl' groups are $-S(O)-(C_1-C_8$ alkyl) and $-S(O)-(C_3-C_{10}$ cycloalkyl), $-S(O)-(CH_2)_t(C_6-C_{10}$ aryl), $-S(O)-(CH_2)_t$(5-10 membered heteroaryl), $-S(O)-(CH_2)_t(C_3-C_{10}$ cycloalkyl), and $-S(O)-(CH_2)_t$(4-10 membered heterocycloalkyl), wherein t is an integer from 0 to 4 and any aryl, heteroaryl, cycloalkyl or heterocycloalkyl groups present, may themselves be substituted by unsubstituted C_1-C_4 alkyl, halo, unsubstituted C_1-C_4 alkoxy, unsubstituted C_1-C_4 haloalkyl, unsubstituted C_1-C_4 hydroxyalkyl, or unsubstituted C_1-C_4 haloalkoxy or hydroxy.

[0085] 'Substituted sulfonyl' refers to the group $-S(O)_2R^{75}$, wherein R^{75} is selected from:

- C_1-C_8 alkyl, C_3-C_{10} cycloalkyl, 4-10 membered heterocycloalkyl, C_6-C_{10} aryl, aralkyl, 5-10 membered heteroaryl, and heteroaralkyl; or
- C_1-C_8 alkyl substituted with halo, substituted or unsubstituted amino, or hydroxy; or
- C_3-C_{10} cycloalkyl, 4-10 membered heterocycloalkyl, C_6-C_{10} aryl, aralkyl, 5-10 membered heteroaryl, or heteroaralkyl, each of which is substituted by unsubstituted C_1-C_4 alkyl, halo, unsubstituted C_1-C_4 alkoxy, unsubstituted C_1-C_4 haloalkyl, unsubstituted C_1-C_4 hydroxyalkyl, or unsubstituted C_1-C_4 haloalkoxy or hydroxy.

[0086] Exemplary 'substituted sulfonyl' groups are $-S(O)_2-(C_1-C_8$ alkyl) and $-S(O)_2-(C_3-C_{10}$ cycloalkyl), $-S(O)_2-(CH_2)_t(C_6-C_{10}$ aryl), $-S(O)_2-(CH_2)_t$(5-10 membered heteroaryl), $-S(O)_2-(CH_2)_t(C_3-C_{10}$ cycloalkyl), and $-S(O)_2-(CH_2)_t$(4-10 membered heterocycloalkyl), wherein t is an integer from 0 to 4 and any aryl, heteroaryl, cycloalkyl or heterocycloalkyl groups present, may themselves be substituted by unsubstituted C_1-C_4 alkyl, halo, unsubstituted C_1-C_4 alkoxy, unsubstituted C_1-C_4 haloalkyl, unsubstituted C_1-C_4 hydroxyalkyl, or unsubstituted C_1-C_4 haloalkoxy or hydroxy.

[0087] 'Sulfo' or 'sulfonic acid' refers to a radical such as $-SO_3H$.

[0088] 'Substituted sulfo' or 'sulfonic acid ester' refers to the group $-S(O)_2OR^{82}$, wherein R^{82} is selected from:

- C_1-C_8 alkyl, C_3-C_{10} cycloalkyl, 4-10 membered heterocycloalkyl, C_6-C_{10} aryl, aralkyl, 5-10 membered heteroaryl, and heteroaralkyl; or
- C_1-C_8 alkyl substituted with halo, substituted or unsubstituted amino, or hydroxy; or
- C_3-C_{10} cycloalkyl, 4-10 membered heterocycloalkyl, C_6-C_{10} aryl, aralkyl, 5-10 membered heteroaryl, or heteroaralkyl, each of which is substituted by unsubstituted C_1-C_4 alkyl, halo, unsubstituted C_1-C_4 alkoxy, unsubstituted C_1-C_4 haloalkyl, unsubstituted C_1-C_4 hydroxyalkyl, or unsubstituted C_1-C_4 haloalkoxy or hydroxy.

[0089] Exemplary 'Substituted sulfo' or 'sulfonic acid ester' groups are $-S(O)_2-O-(C_1-C_8$ alkyl) and $-S(O)_2-O-(C_3-C_{10}$ cycloalkyl), $-S(O)_2-O-(CH_2)_t(C_6-C_{10}$ aryl), $-S(O)_2-O-(CH_2)_t$(5-10 membered heteroaryl), $-S(O)_2-O-(CH_2)_t(C_3-C_{10}$ cycloalkyl), and $-S(O)_2-O-(CH_2)_t$(4-10 membered heterocycloalkyl), wherein t is an integer from 0 to 4 and any aryl, heteroaryl, cycloalkyl or heterocycloalkyl groups present, may themselves be

substituted by unsubstituted C_1-C_4 alkyl, halo, unsubstituted C_1-C_4 alkoxy, unsubstituted C_1-C_4 haloalkyl, unsubstituted C_1-C_4 hydroxyalkyl, or unsubstituted C_1-C_4 haloalkoxy or hydroxy.

[0090] 'Thiol' refers to the group -SH.

[0091] One having ordinary skill in the art of organic synthesis will recognize that the maximum number of heteroatoms in a stable, chemically feasible heterocyclic ring, whether it is aromatic or non aromatic, is determined by the size of the ring, the degree of unsaturation and the valence of the heteroatoms. In general, a heterocyclic ring may have one to four heteroatoms so long as the heteroaromatic ring is chemically feasible and stable.

[0092] 'Pharmaceutically acceptable' means approved or approvable by a regulatory agency of the Federal or a state government or the corresponding agency in countries other than the United States, or that is listed in the U.S. Pharmacopoeia or other generally recognized pharmacopoeia for use in animals, and more particularly, in humans.

[0093] 'Pharmaceutically acceptable salt' refers to a salt of a compound of the invention that is pharmaceutically acceptable and that possesses the desired pharmacological activity of the parent compound. In particular, such salts are non-toxic may be inorganic or organic acid addition salts and base addition salts. Specifically, such salts include: (1) acid addition salts, formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like; or formed with organic acids such as acetic acid, propionic acid, hexanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, 3-(4-hydroxybenzoyl) benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, 1,2-ethane-disulfonic acid, 2-hydroxyethanesulfonic acid, benzenesulfonic acid, 4-chlorobenzenesulfonic acid, 2-naphthalenesulfonic acid, 4-toluenesulfonic acid, camphorsulfonic acid, 4-methylbicyclo[2.2.2]-oct-2-ene-1-carboxylic acid, glucoheptonic acid, 3-phenylpropionic acid, trimethylacetic acid, tertiary butylacetic acid, lauryl sulfuric acid, gluconic acid, glutamic acid, hydroxynaphthoic acid, salicylic acid, stearic acid, muconic acid, and the like; or (2) salts formed when an acidic proton present in the parent compound either is replaced by a metal ion, e.g., an alkali metal ion, an alkaline earth ion, or an aluminum ion; or coordinates with an organic base such as ethanolamine, diethanolamine, triethanolamine, N-methylglucamine and the like. Salts further include, by way of example only, sodium, potassium, calcium, magnesium, ammonium, tetraalkylammonium, and the like; and when the compound contains a basic functionality, salts of non toxic organic or inorganic acids, such as hydrochloride, hydrobromide, tartrate, mesylate, acetate, maleate, oxalate and the like. The term "pharmaceutically acceptable cation" refers to an acceptable cationic counter-ion of an acidic functional group. Such cations are exemplified by sodium, potassium, calcium, magnesium, ammonium, tetraalkylammonium cations, and the like.

[0094] 'Pharmaceutically acceptable vehicle' refers to a diluent, adjuvant, excipient or carrier with which a compound of the invention is administered.

[0095] 'Prodrugs' refers to compounds, including derivatives of the compounds of the invention,which have cleavable groups and become by solvolysis or under physiological conditions the compounds of the invention which are pharmaceutically active in vivo. Such examples include, but are not limited to, choline ester derivatives and the like, N-alkylmorpholine esters and the like.

[0096] 'Solvate' refers to forms of the compound that are associated with a solvent, usually by a solvolysis reaction. This physical association includes hydrogen bonding. Conventional solvents include water, ethanol, acetic acid and the like. The compounds of the invention may be prepared e.g. in crystalline form and may be solvated or hydrated. Suitable solvates include pharmaceutically acceptable solvates, such as hydrates, and further include both stoichiometric solvates and non-stoichiometric solvates. In certain instances the solvate will be capable of isolation, for example when one or more solvent molecules are incorporated in the crystal lattice of the crystalline solid. 'Solvate' encompasses both solution-phase and isolable solvates. Representative solvates include hydrates, ethanolates and methanolates.

[0097] 'Subject' includes humans. The terms 'human', 'patient' and 'subject' are used interchangeably herein.

[0098] 'Therapeutically effective amount' means the amount of a compound that, when administered to a subject for treating a disease, is sufficient to effect such treatment for the disease. The "therapeutically effective amount" can vary depending on the compound, the disease and its severity, and the age, weight, etc., of the subject to be treated.

[0099] 'Preventing' or 'prevention' refers to a reduction in risk of acquiring or developing a disease or disorder (i.e., causing at least one of the clinical symptoms of the disease not to develop in a subject that may be exposed to a disease-causing agent, or predisposed to the disease in advance of disease onset.

[00100] The term 'prophylaxis' is related to 'prevention', and refers to a measure or procedure the purpose of which is to prevent, rather than to treat or cure a disease. Non-limiting examples of prophylactic measures may include the administration of vaccines; the administration of low molecular weight heparin to hospital patients at risk for thrombosis due, for example, to immobilization; and the administration of an anti-malarial agent such as chloroquine, in advance of a visit to a geographical region where malaria is endemic or the risk of contracting malaria is high.

[00101] 'Treating' or 'treatment' of any disease or disorder refers, in one embodiment, to ameliorating the disease or disorder (i.e., arresting the disease or reducing the manifestation, extent or severity of at least one of the clinical symptoms thereof). In another embodiment 'treating' or 'treatment' refers to ameliorating at least one physical parameter, which may not be discernible by the subject. In yet another embodiment, 'treating' or 'treatment' refers to modulating the disease or disorder, either physically, (e.g., stabilization of a discernible symptom), physiologically, (e.g., stabilization of a physical parameter), or both. In a further embodiment, "treating" or "treatment" relates to slowing the progression of the disease.

[00102] As used herein the term 'condition(s) involving inflammation' refers to the group of conditions including, rheumatoid arthritis, osteoarthritis, juvenile idiopathic arthritis, psoriasis, allergic airway disease (e.g. asthma, rhinitis), inflammatory bowel diseases (e.g. Crohn's disease, colitis), endotoxin-driven disease states (e.g. complications after bypass surgery or chronic endotoxin states contributing to e.g. chronic cardiac failure), and related diseases involving cartilage, such as that of the joints. Partcicularly the term refers to rheumatoid arthritis, osteoarthritis, allergic airway disease (e.g. asthma) and inflammatory bowel diseases.

[00103] As used herein the term 'condition(s) involving an immune response' or 'autoimmune diseases' are used interchangeably and refer to refers to the group of diseases including obstructive airways disease, including conditions such as COPD, asthma (e.g intrinsic asthma, extrinsic asthma, dust asthma, infantily asthma) particularly chronic or inveterate asthma (for example late asthma and airway hyperreponsiveness), bronchitis, including bronchial asthma, systemic lupus erythematosus (SLE), multiple sclerosis, type I diabetes mellitus and complications associated therewith, atopic eczema (atopic dermatitis), contact dermatitis and further eczematous dermatitis, inflammatory bowel disease (e.g. Crohn's disease and ulcerative colitis), atherosclerosis and amyotrophic lateral sclerosis. Particularly the term refers to COPD, asthma, systemic lupus erythematosis, type I diabetes mellitus and inflammatory bowel disease.

[00104] As used herein the term 'transplantation rejection' refers to the acute or chronic rejection of cells, tissue or solid organ allo- or xenografts of e.g. pancreatic islets, stem cells, bone marrow, skin, muscle, corneal tissue, neuronal tissue, heart, lung, combined heart-lung, kidney, liver, bowel, pancreas, trachea or oesophagus, or graft-versus-host diseases.

[00105] As used herein the term 'proliferative disease(s)' refers to conditions such as cancer (e.g. uterine leiomyosarcoma or prostate cancer), myeloproliferative disorders (e.g. polycythemia vera, essential thrombocytosis and myelofibrosis), leukemia (e.g. acute myeloid leukaemia and acute lymphoblastic leukemia), multiple myeloma, psoriasis, restenosis, sclerodermitis or fibrosis. In particular the term refers to cancer, leukemia, multiple myeloma and psoriasis.

[00106] As used herein, the term 'cancer' refers to a malignant or benign growth of cells in skin or in body organs, for example but without limitation, breast, prostate, lung, kidney, pancreas, stomach or bowel. A cancer tends to infiltrate into adjacent tissue and spread (metastasise) to distant organs, for example to bone, liver, lung or the brain. As used herein the term cancer includes both metastatic rumour cell types, such as but not limited to, melanoma, lymphoma, leukaemia, fibrosarcoma, rhabdomyosarcoma, and mastocytoma and types of tissue carcinoma, such as but not limited to, colorectal cancer, prostate cancer, small cell lung cancer and non-small cell lung cancer, breast cancer, pancreatic cancer, bladder cancer, renal cancer, gastric cancer, glioblastoma, primary liver cancer, ovarian cancer, prostate cancer and uterine leiomyosarcoma.

[00107] As used herein the term 'leukaemia' refers to neoplastic diseases of the blood and blood forming organs. Such diseases can cause bone marrow and immune system dysfunction, which renders the

host highly susceptible to infection and bleeding. In particular the term leukemia refers to acute myeloid leukaemia (AML) and acute lymphoblastic leukemia (ALL).

[00108] As used herein the term 'diseases involving impairment of cartilage turnover' and specifically 'diseases involving the anabolic stimulation of chondrocytes' includes conditions such as osteoarthritis, psoriatic arthritis, juvenile rheumatoid arthritis, gouty arthritis, septic or infectious arthritis, reactive arthritis, reflex sympathetic dystrophy, algodystrophy, Tietze syndrome or costal chondritis, fibromyalgia, osteochondritis, neurogenic or neuropathic arthritis, arthropathy, endemic forms of arthritis like osteoarthritis deformans endemica, Mseleni disease and Handigodu disease; degeneration resulting from fibromyalgia, systemic lupus erythematosus, scleroderma and ankylosing spondylitis.

[00109] As used herein the term 'congenital cartilage malformation(s)' includes conditions such as hereditary chondrolysis, chondrodysplasias and pseudochondrodysplasias, in particular, but without limitation, microtia, anotia, metaphyseal chondrodysplasia, and related disorders.

[00110] As used herein the term 'disease(s) associated with hypersecretion of IL6' includes conditions such as Castleman's disease, multiple myeloma, psoriasis, Kaposi's sarcoma and/or mesangial proliferative glomerulonephritis.

[00111] 'Compound(s) of the invention', and equivalent expressions, are meant to embrace compounds of the Formula(e) as hereinbefore described, which expression includes the pharmaceutically acceptable salts, and the solvates, e.g., hydrates, and the solvates of the pharmaceutically acceptable salts where the context so permits. Similarly, reference to intermediates, whether or not they themselves are claimed, is meant to embrace their salts, and solvates, where the context so permits.

[00112] When ranges are referred to herein, for example but without limitation, C_1-C_8 alkyl, the citation of a range should be considered a representation of each member of said range.

[00113] Other derivatives of the compounds of the invention have activity in both their acid and acid derivative forms, but in the acid sensitive form often offers advantages of solubility, tissue compatibility, or delayed release in the mammalian organism (see, Bundgard, H., Design of Prodrugs, pp. 7-9, 21-24, Elsevier, Amsterdam 1985). Prodrugs include acid derivatives well know to practitioners of the art, such as, for example, esters prepared by reaction of the parent acid with a suitable alcohol, or amides prepared by reaction of the parent acid compound with a substituted or unsubstituted amine, or acid anhydrides, or mixed anhydrides. Simple aliphatic or aromatic esters, amides and anhydrides derived from acidic groups pendant on the compounds of this invention are particularly useful prodrugs. In some cases it is desirable to prepare double ester type prodrugs such as (acyloxy)alkyl esters or ((alkoxycarbonyl)oxy)alkylesters. Particular such prodrugs are the C_1 to C_8 alkyl, C_2-C_8 alkenyl, aryl, C_7-C_{12} substituted aryl, and C_7-C_{12} arylalkyl esters of the compounds of the invention.

[00114] As used herein, the term 'isotopic variant' refers to a compound that contains unnatural proportions of isotopes at one or more of the atoms that constitute such compound. For example, an 'isotopic

variant' of a compound can contain one or more non-radioactive isotopes, such as for example, deuterium (^{2}H or D), carbon-13 (^{13}C), nitrogen-15 (^{15}N), or the like. It will be understood that, in a compound where such isotopic substitution is made, the following atoms, where present, may vary, so that for example, any hydrogen may be ^{2}H/D, any carbon may be ^{13}C, or any nitrogen may be ^{15}N, and that the presence and placement of such atoms may be determined within the skill of the art. Likewise, the invention may include the preparation of isotopic variants with radioisotopes, in the instance for example, where the resulting compounds may be used for drug and/or substrate tissue distribution studies. The radioactive isotopes tritium, i.e. ^{3}H, and carbon-14, i.e. ^{14}C, are particularly useful for this purpose in view of their ease of incorporation and ready means of detection. Further, compounds may be prepared that are substituted with positron emitting isotopes, such as ^{11}C, ^{18}F, ^{15}O and ^{13}N, and would be useful in Positron Emission Topography (PET) studies for examining substrate receptor occupancy.

[00115] All isotopic variants of the compounds provided herein, radioactive or not, are intended to be encompassed within the scope of the invention.

[00116] It is also to be understood that compounds that have the same molecular formula but differ in the nature or sequence of bonding of their atoms or the arrangement of their atoms in space are termed 'isomers'. Isomers that differ in the arrangement of their atoms in space are termed 'stereoisomers'.

[00117] Stereoisomers that are not mirror images of one another are termed 'diastereomers' and those that are non-superimposable mirror images of each other are termed 'enantiomers'. When a compound has an asymmetric center, for example, it is bonded to four different groups, a pair of enantiomers is possible. An enantiomer can be characterized by the absolute configuration of its asymmetric center and is described by the R- and S-sequencing rules of Cahn and Prelog, or by the manner in which the molecule rotates the plane of polarized light and designated as dextrorotatory or levorotatory (i.e., as (+) or (-)-isomers respectively). A chiral compound can exist as either individual enantiomer or as a mixture thereof. A mixture containing equal proportions of the enantiomers is called a 'racemic mixture'.

[00118] 'Tautomers' refer to compounds that are interchangeable forms of a particular compound structure, and that vary in the displacement of hydrogen atoms and electrons. Thus, two structures may be in equilibrium through the movement of π electrons and an atom (usually H). For example, enols and ketones are tautomers because they are rapidly interconverted by treatment with either acid or base. Another example of tautomerism is the aci- and nitro- forms of phenylnitromethane, that are likewise formed by treatment with acid or base.

[00119] Tautomeric forms may be relevant to the attainment of the optimal chemical reactivity and biological activity of a compound of interest.

[00120] The compounds of this invention may possess one or more asymmetric centers; such compounds can therefore be produced as individual (R)- or (S)- stereoisomers or as mixtures thereof.

[00121] Unless indicated otherwise, the description or naming of a particular compound in the specification and claims is intended to include both individual enantiomers and mixtures, racemic or otherwise, thereof. The methods for the determination of stereochemistry and the separation of stereoisomers are well-known in the art.

THE COMPOUNDS

[00122] The present invention is based on the discovery that inhibitors of JAK are useful for the treatment of diseases involving cartilage degradation, bone and/or joint degradation, for example osteoarthritis; and/or conditions involving inflammation or immune responses, such as Crohn's disease, rheumatoid arthritis, psoriasis, allergic airways disease (e.g. asthma, rhinitis), juvenile idiopathic arthritis, colitis, inflammatory bowel diseases, endotoxin-driven disease states (e.g. complications after bypass surgery or chronic endotoxin states contributing to e.g. chronic cardiac failure), diseases involving impairment of cartilage turnover (e.g. diseases involving the anabolic stimulation of chondrocytes), congenital cartilage malformations, diseases associated with hypersecretion of IL6 and transplantation rejection (e.g. organ transplant rejection). Inhibitors of JAK can also find application in the treatment of proliferative diseases. In particular the inhibitors of JAK find application in the treatment of cancers , especially leukaemias and solid tumours (e.g. uterine leiomyosarcoma, prostate cancer). In particular diseases involving cartilage degradation, bone and/or joint degradation and/or inflammation, for example osteoarthritis. The present invention also provides methods for the production of these compounds, pharmaceutical compositions comprising these compounds and methods for treating diseases involving cartilage degradation, bone and/or joint degradation and/or inflammation by administering a compound of the invention. The present compounds may be inhibitors of one or more members of the JAK family; specifically they may inhibit the activity of one or more of JAK1, JAK2, JAK3 and/or TYK2.

[00123] Accordingly, in a first aspect of the invention, substituted bicycloheteroaryl compounds are disclosed according to Formula (I):



I

wherein

each Cy1 and Cy2 is independently selected from aryl and heteroaryl;

L1 is selected from a single bond, -O-, -C(O)-, -$S(O)_2$-, -$N(R^{4a})$-, -$CON(R^{4a})$-, -$SO_2N(R^{4a})$-, -$N(R^{4a})CO$-, or -$N(R^{4a})SO_2$-;

each R^1 is independently selected from C_1-C_6 alkyl, substituted C_1-C_6 alkyl, acyl, substituted acyl, substituted or unsubstituted acylamino, substituted or unsubstituted amido, substituted or unsubstituted C_1-C_6 alkoxy, substituted or unsubstituted amino, substituted sulfinyl, substituted sulfonyl, substituted or unsubstituted aminosulfonyl, sulfonic acid, sulfonic acid ester, carboxy, cyano, substituted or unsubstituted C_3-C_7 cycloalkyl, substituted or unsubstituted 4-7 membered heterocycloalkyl, halo, and hydroxyl;

each R^{3a} is independently selected from C_1-C_6 alkyl, substituted C_1-C_6 alkyl, acyl, substituted acyl, substituted or unsubstituted acylamino, substituted or unsubstituted amido, substituted or unsubstituted C_1-C_6 alkoxy, alkoxycarbonyl, substituted alkoxycarbonyl, arylalkyloxy, substituted arylalkyloxy, substituted or unsubstituted amino, aryl, substituted aryl, arylalkyl, substituted sulfanyl, substituted sulfinyl, substituted sulfonyl, substituted or unsubstituted aminosulfonyl, substituted or unsubstituted arylsulfonyl, sulfonic acid, sulfonic acid ester, azido, carboxy, cyano, substituted or unsubstituted C_3-C_7 cycloalkyl, substituted or unsubstituted C_4-C_7 heterocycloalkyl, halo, -O-heteroaryl, substituted or unsubstituted heteroaryl, hydroxy, nitro, and thiol;

each R^{2b}, R^{2c}, and R^{2d} is independently selected from H, C_1-C_6 alkyl, substituted C_1-C_6 alkyl, acyl, substituted acyl, substituted or unsubstituted acylamino, substituted or unsubstituted C_1-C_6 alkoxy, substituted or unsubstituted –O-aryl, alkoxycarbonyl, substituted alkoxycarbonyl, arylalkyloxy, substituted arylalkyloxy, substituted or unsubstituted amino, aryl, substituted aryl, arylalkyl, substituted sulfanyl, substituted sulfinyl, substituted sulfonyl, substituted or unsubstituted aminosulfonyl, substituted or unsubstituted arylsulfonyl, sulfonic acid, sulfonic acid ester, azido, carboxy, substituted or unsubstituted amido, cyano, substituted or unsubstituted C_3-C_7 cycloalkyl, substituted or unsubstituted 4-7 membered heterocycloalkyl, halo, -O-heteroaryl, substituted or unsubstituted heteroaryl, hydroxy, nitro, and thiol;

each R^{2a} and R^{4a} is independently selected from H, C_1-C_6 alkyl, substituted C_1-C_6 alkyl, C_3-C_7 cycloalkyl, or substituted C_3-C_7cycloalkyl;

m1 is 0, 1, or 2; m2 is 0, 1, 2, 3 or 4; and n1 is 0, 1, 2, 3, or 4;

provided that

when L1 is -N(R^{4a})-, -CON(R^{4a})-, or -SO_2N(R^{4a})-, and R^{2c} is other than H, alkyl, cycloalkyl, aryl or heteroaryl, then n1 is 1, 2, 3, or 4;

or pharmaceutically acceptable salts or solvates thereof, or the solvates of the pharmaceutically acceptable salts.

[00124] In one embodiment, the compound is according to Formula I, wherein

each Cy1 and Cy2 is independently selected from aryl and heteroaryl;

L1 is selected from a single bond, -O-, -C(O)-, -$S(O)_2$-, -N(R^{4a})-, -CON(R^{4a})-, -SO_2N(R^{4a})-, -N(R^{4a})CO-, or - N(R^{4a})SO_2-;

each R^1 is independently selected from unsubstituted C_1-C_6 alkyl, unsubstituted acyl, unsubstituted acylamino, unsubstituted amido, unsubstituted C_1-C_6 alkoxy, unsubstituted amino, unsubstituted amino, unsubstituted aminosulfonyl, sulfonic acid, sulfonic acid ester, carboxy, cyano, unsubstituted C_3-C_7 cycloalkyl, unsubstituted 4-7 membered heterocycloalkyl, halo, and hydroxyl;

each R^{3a} is independently selected from C_1-C_6 alkyl (optionally substituted with halo, cyano, hydroxy, unsubstituted C_1-C_6 alkoxy, amino (optionally substituted with –C_1-C_4 alkyl optionally substituted with hydroxy)), unsubstituted acyl, unsubstituted acylamino, amido (optionnally substituted with unsubstituted C_1-C_4 alkyl), C_1-C_6 alkoxy (optionally substituted with halo, cyano), unsubstituted C_1-C_4 alkoxycarbonyl, unsubstituted arylalkyloxy, amino (optionally substituted with C_1-C_4 alkyl), unsubstituted aryl, unsubstituted arylalkyl, unsubstituted sulfonyl, aminosulfonyl (optionally substituted with C_1-C_4 alkyl), unsubstituted arylsulfonyl, sulfonic acid, sulfonic acid ester, azido, carboxy, cyano, unsubstituted C_3-C_7 cycloalkyl, unsubstituted C_4-C_7 heterocycloalkyl, halo, unsubstituted -O-heteroaryl, unsubstituted heteroaryl, hydroxy, nitro, and thiol;

each R^{2b}, R^{2c}, and R^{2d} is independently selected from H, C_1-C_6 alkyl (optionnally substituted with hydroxy, unsubstituted C_1-C_6 alkoxy, unsubstituted aminoacyl, amino (optionally substituted with $C_{1\text{-}4}$ alkyl), unsubstituted amido, 4-7-membered heterocycloalkyl (optionally substituted with $C_{1\text{-}4}$ alkyl), unsubstituted aryl, heteroaryl (optionally substituted with $C_{1\text{-}4}$ alkyl)), unsubstituted acyl, unsubstituted acylamino, unsubstituted C_1-C_6 alkoxy, unsubstituted –O-aryl, unsubstituted C_1-C_6 alkoxycarbonyl, unsubstituted arylalkyloxy, amino (optionnally substituted with unsubstituted C_1-C_6 alkyl), aryl (optionnally substituted with amido (optionally substituted with unsubstituted C_1-C_6 alkyl), C_1-C_6 alkyl (optionally substituted with hydroxy, 5-7 membered heterocycloalkyl), 5-7 membered heterocycloalkyl, amino (optionally substituted with unsubstituted acyl, sulfonyl),), unsubstituted arylalkyl, unsubstituted aminosulfonyl, unsubstituted arylsulfonyl, sulfonic acid, sulfonic acid ester, azido, carboxy, cyano, halo, hydroxy, nitro, thiol, amido (optionnally substituted with unsubstituted C_1-C_6 alkyl), unsubstituted C_3-C_7 cycloalkyl, 4-7 membered heterocycloalkyl (optionnally substituted with C_1-C_6 alkyl (optionnally substituted with acyl, hydroxy), unsubstituted acyl, aryl (optionally substituted with halo)), unsubstituted -O-heteroaryl, heteroaryl (optionnally substituted with unsubstituted C_1-C_6 alkyl, unsubstituted C_1-C_6 alkoxy, unsubstituted C_3-C_7 cycloalkyl, aryl (optionally substituted with amido, 5-7 membered heterocycle (optionally substituted with unsubstituted C_1-C_6 alkyl), C_1-C_6 alkyl (optionally substituted with hydroxy, unsubstituted 5-7 membered heterocycle), amino (optionally substituted with unsubstituted acyl, sulfonyl), heteroaryl (optionally substituted with 5-7 membered heterocycloalkyl (optionally substituted C_1-C_6 alkyl)));

each R^{2a} and R^{4a} is independently selected from H, unsubstituted C_1-C_6 alkyl, unsubstituted C_3-C_7 cycloalkyl;

m1 is 0, 1, or 2; m2 is 0, 1, 2, 3 or 4; and n1 is 0, 1, 2, 3, or 4;

provided that

when L1 is -N(R^{4a})-, -CON(R^{4a})-, or -SO_2N(R^{4a})-, and R^{2c} is other than H, alkyl, cycloalkyl, aryl or heteroaryl, then n1 is 1, 2, 3, or 4;

or a pharmaceutically acceptable salt or solvate thereof or a solvate of a pharmaceutically acceptable salt.

[00125] In a particular embodiment, with respect to the compounds according to Formula I, each R^1 is independently selected from C_1-C_6 alkyl, substituted C_1-C_6 alkyl, and halo.

[00126] In a particular embodiment, with respect to the compounds according to Formula I, each R^1 is independently selected from Me, CF_3, Cl and F.

[00127] In a further embodiment, m1 is 0.

[00128] In a particular embodiment, with respect to the compounds according to Formula I, R^{2a} is independently selected from H, C_1-C_6 alkyl, and substituted C_1-C_6 alkyl.

[00129] In a particular embodiment, with respect to the compounds according to Formula I, R^{2a} is H.

[00130] In a particular embodiment, with respect to the compounds according to Formula I, the compound is according to Formula II:



II

wherein Cy2, L1, R^{2b}, R^{2c}, R^{2d}, R^{3a}, m2 and n1 are as defined with respect to Formula I.

[00131] In another particular embodiment, with respect to the compounds according to Formula I, the compound is according to Formula III:



III

wherein Cy2, L1, R^{2b}, R^{2c}, R^{2d}, R^{3a}, m2 and n1 are as defined with respect to Formula I.

[00132] In a particular embodiment, with respect to the compounds according to Formula II or III, each of R^{2b}, and R^{2d} is independently H, C_1-C_6 alkyl, substituted C_1-C_6 alkyl, or halo.

[00133] In a particular embodiment, with respect to the compounds according to Formula II or III, each of R^{2b}, and R^{2d} is independently H, Me, F or Cl.

[00134] In a particular embodiment, with respect to the compounds according to Formula I, II or III, L1 is a single bond, n1 is 0, and R^{2c} is H, Cl, F, Me, Et, OMe, OEt, O-i-Pr, CF_3, $CONH_2$, $CONMe_2$, CONHMe, CN, NHCOMe, COOH, OH or COOEt.

[00135] In a particular embodiment, with respect to the compounds according to Formula I, II or III, L1 is a single bond, n1 is 0, and R^{2c} is NHCOMe, or COOH.

[00136] In a particular embodiment, with respect to the compounds according to Formula I, II or III, L1 is CONH; n1 is 2 or 3; and R^{2c} is NMe_2, OMe, or NHCOMe.

[00137] In a particular embodiment, with respect to the compounds according to Formula I, II or III, L1 is selected from a single bond, -C(O)-, and -CON(R^{4a})-; n1 is 0, 1, 2, 3, or 4; and R^{2c} is substituted or unsubstituted C_1-C_6 alkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted C_3-C_7 cycloalkyl, or substituted or unsubstituted heterocycloalkyl.

[00138] In a particular embodiment, with respect to the compounds according to Formula I, II or III, L1 is selected from a single bond, -C(O)-, and -CON(R^{4a})-; n1 is 0, 1, 2, 3, or 4; and R^{2c} is C_1-C_6 alkyl.

[00139] In a particular embodiment, with respect to the compounds according to Formula I, II, or III, L1 is selected from a single bond, -C(O)-, and -CON(R^{4a})-; n1 is 0, 1, 2, 3, or 4; and R^{2c} is Me, Et, i-Pr, 1,3-dihydroxyprop-2-yl.

[00140] In a particular embodiment, with respect to the compounds according to Formula I, II or III, L1 is selected from a single bond, -C(O)-, - and -CON(R^{4a})-; n1 is 0, 1, 2, 3, or 4; and R^{2c} is substituted or unsubstituted C_3-C_7 cycloalkyl.

[00141] In a particular embodiment, with respect to the compounds according to Formula I, II or III, L1 is selected from a single bond, -C(O)-, - and -CON(R^{4a})-; n1 is 0, 1, 2, 3, or 4; and R^{2c} is substituted or unsubstituted cyclopropyl, substituted or unsubstituted cyclobutyl, substituted or unsubstituted cyclohexyl, or substituted or unsubstituted cyclopentyl.

[00142] In a particular embodiment, with respect to the compounds according to Formula I, II, or III, L1 is selected from a single bond, -C(O)-, and -CON(R^{4a})-; n1 is 0, 1, 2, 3, or 4; and R^{2c} is substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl.

[00143] In a particular embodiment, with respect to the compounds according to Formula I, II or III, L1 is selected from a single bond, -C(O)-, and -CON(R^{4a})-; n1 is 0, 1, 2, 3, or 4; and R^{2c} is substituted or unsubstituted Ph, substituted or unsubstituted pyridyl, substituted or unsubstituted pyrrolyl, substituted or unsubstituted pyrazolyl, substituted or unsubstituted imidazolyl, substituted or unsubstituted triazolyl, substituted or unsubstituted oxazolyl, substituted or unsubstituted thiazolyl, substituted or unsubstituted indolyl, substituted or unsubstituted indazolyl, substituted or unsubstituted benzimidazolyl, substituted or unsubstituted benzofuranyl, substituted or unsubstituted benzodioxanyl, substituted or unsubstituted benzoxazolyl, substituted or unsubstituted quinolinyl, or substituted or unsubstituted isoquinolinyl.

[00144] In a particular embodiment, with respect to the compounds according to Formula I, II or III, L1 is selected from a single bond, -C(O)-, and -CON(R^{4a})-; n1 is 0, 1, 2, 3, or 4; and R^{2c} is substituted or unsubstituted 4-7 membered heterocycloalkyl.

[00145] In a particular embodiment, with respect to the compounds according to Formula I, II or III, L1 is selected from a single bond, -C(O)-, and -CON(R^{4a})-; n1 is 0, 1, 2, 3, or 4; and R^{2c} is piperidinyl, morpholinyl, piperazinyl, or pyrrolidinyl, each of which may be unsubstituted or substituted with C_1-C_6 alkyl, acyl, phenyl, or OH.

[00146] In a particular embodiment, with respect to the compounds according to Formula I, II or III, wherein L1 is -CON(R^{4a})-, R^{4a} is H.

[00147] In a particular embodiment, with respect to the compounds according to Formula I, II or III, wherein L1 is CONH, n1 is 0, 1, 2 or 3.

[00148] In a particular embodiment, with respect to the compounds according to Formula I, II or III, wherein L1 is CONH, n1 is 0 or 1.

[00149] In a particular embodiment, with respect to the compounds according to Formula I, II or III, wherein L1 is CO, n1 is 0, 1, 2 or 3.

[00150] In a particular embodiment, with respect to the compounds according to Formula I, II, or III, wherein L1 is CO, n1 is 0 or 1.

[00151] In one embodiment, with respect to the compounds according to Formula I, II or III, the –Cy1-L1-$(CH_2)_{n1}$-R^{2c} is selected from:



wherein n1 and R^{2c} are as described for Formula I.

[00152] In one embodiment, with respect to the compounds according to Formula I, II or III, the –Cy1-L1-$(CH_2)_{n1}$-R^{2c} is selected from:



wherein n1 and R^{2c} are as described for Formula I.

[00153] In one embodiment, with respect to the compounds according to Formula I, II or III, the –Cy1-L1-$(CH_2)_{n1}$-R^{2c} is selected from:



wherein n1 and R^{2c} are as described for Formula I.

[00154] In one embodiment, with respect to the compounds according to Formula I, II or III, R^{2c} is a substituted or unsubstituted N-containing 4-7 membered heterocycloalkyl group or an N-containing substituted or unsubstituted 4-7 membered heteroaryl ring.

[00155] In one embodiment, with respect to the compounds according to Formula I, II or III, R^{2c} is:



[00156] In one embodiment, with respect to the compounds according to Formula I, II or III, R^{2c} is pyrazolyl, pyrrolyl, imidazolyl, or triazolyl.

[00157] In one embodiment, with respect to the compounds according to Formula I, II or III, n1 is 0, 1 or 2.

[00158] In one embodiment, with respect to the compounds according to Formula I, II or III, the –Cy1-L1-$(CH_2)_{n1}$-R^{2c} is selected from:



[00159] In a particular embodiment, with respect to the compounds according to Formula I, II or III, Cy2 is Ph; and m2 is 0.

[00160] In a particular embodiment, with respect to the compounds according to Formula I, II or III, Cy2 is Ph; m2 is 1, 2 or 3; and each R^{3a} is independently C_1-C_6 alkyl, C_1-C_6 haloalkyl, C_1-C_6 alkoxy, or halo.

[00161] In a particular embodiment, with respect to the compounds according to Formula I, II or III, Cy2 is Ph; m2 is 1, 2 or 3; and each R^{3a} is independently Cl, F, Me, Et, OMe, OEt, O-i-Pr, CF_3, OCF_3, $CONH_2$, $CONMe_2$, CONHMe, SO_2NH_2, SO_2NMe_2, CN, NHCOMe, COOH, OH or COOEt.

[00162] In another particular embodiment, with respect to the compounds according to Formula I, II or III, Cy2 is Ph; m2 is 1, 2 or 3; and each R^{3a} is $-CH_2$-NH-$(CH_2)_2OH$.

[00163] In one embodiment, the compound is according to Formula IVa, IVb, IVc, or IVd:



IVa ,



IVb ,



or

IVc



IVd ,

wherein n1 is 1, 2, or 3; R^{3a} is Cl, F, Me, Et, OMe, OEt, O-i-Pr, CF_3, OCF_3, OCH_2CN, $CONH_2$, $CONMe_2$, CONHMe, SO_2NH_2, SO_2NMe_2, CN, NHCOMe, COOH, OH or COOEt; and R^{2c} is substituted or unsubstituted C_3-C_7 heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.

[00164] In a particular embodiment, with respect to the compounds according to Formula I, II, III, IVa, IVb, IVc or IVd, R^{2c} is substituted or unsubstituted pyrrolidinyl, substituted or unsubstituted piperidinyl, substituted or unsubstituted piperazinyl, or substituted or unsubstituted morpholinyl.

[00165] In a particular embodiment, with respect to the compounds according to Formula I, II, III, IVa, IVb, IVc or IVd, R^{2c} is





or

[00166] In a particular embodiment, with respect to the compounds according to Formula I, II, III, IVa, IVb, IVc or IVd, R^{2c} is substituted or unsubstituted pyrazolyl, substituted or unsubstituted pyrrolyl, substituted

or unsubstituted imidazolyl, substituted or unsubstituted triazolyl, substituted or unsubstituted oxazolyl, substituted or unsubstituted benzimidazolyl, substituted or unsubstituted indolyl, or substituted or unsubstituted indazolyl.

[00167] In a particular embodiment, with respect to the compounds according to Formula I, II, III, IVa, IVb, IVc or IVd, R^{3a} is Cl, F, Me, Et, OMe, OEt, O-i-Pr, O-i-Pr, CF_3, OCF_3, SO_2NH_2, SO_2NMe_2, or CN.

[00168] In a particular embodiment, with respect to the compounds according to Formula I, II, III, IVa, IVb, IVc or IVd, R^{3a} is Cl, F, Me, or OMe.

[00169] In a particular embodiment, with respect to the compounds according to Formula I, II, III, IVa, IVb, IVc or IVd, R^{3a} is OMe.

[00170] In one embodiment the compound of the invention is not an isotopic variant.

[00171] In one embodiment, with respect to Formula I, the compound is selected from the compounds listed in Table 1.

[00172] In one aspect a compound of the invention according to any one of the embodiments herein described is present as the free base.

[00173] In one aspect a compound of the invention according to any one of the embodiments herein described is a pharmaceutically acceptable salt.

[00174] In one aspect a compound of the invention according to any one of the embodiments herein described is a solvate.

[00175] In one aspect a compound of the invention according to any one of the embodiments herein described is a solvate of a pharmaceutically acceptable salt.

[00176] While specified groups for each embodiment have generally been listed above separately, a compound of the invention includes one in which several or each embodiment in the above formula, as well as other formulae presented herein, is selected from one or more of particular members or groups designated respectively, for each variable. Therefore, this invention is intended to include all combinations of such embodiments within its scope.

[00177] In certain aspects, the present invention provides prodrugs and derivatives of the compounds according to the formulae above. Prodrugs are derivatives of the compounds of the invention, which have metabolically cleavable groups and become by solvolysis or under physiological conditions the compounds of the invention, which are pharmaceutically active, *in vivo*. Such examples include, but are not limited to, choline ester derivatives and the like, N-alkylmorpholine esters and the like.

[00178] Other derivatives of the compounds of this invention have activity in both their acid and acid derivative forms, but the acid sensitive form often offers advantages of solubility, tissue compatibility, or delayed release in the mammalian organism (see, Bundgard, H., Design of Prodrugs, pp. 7-9, 21-24, Elsevier, Amsterdam 1985). Prodrugs include acid derivatives well know to practitioners of the art, such as, for example, esters prepared by reaction of the parent acid with a suitable alcohol, or amides prepared by reaction

of the parent acid compound with a substituted or unsubstituted amine, or acid anhydrides, or mixed anhydrides. Simple aliphatic or aromatic esters, amides and anhydrides derived from acidic groups pendant on the compounds of this invention are preferred prodrugs. In some cases it is desirable to prepare double ester type prodrugs such as (acyloxy)alkyl esters or ((alkoxycarbonyl)oxy)alkylesters. Particularly useful are the C_1 to C_8 alkyl, C_2-C_8 alkenyl, aryl, C_7-C_{12} substituted aryl, and C_7-C_{12} arylalkyl esters of the compounds of the invention.

PHARMACEUTICAL COMPOSITIONS

[00179] When employed as pharmaceuticals, the compounds of this invention are typically administered in the form of a pharmaceutical composition. Such compositions can be prepared in a manner well known in the pharmaceutical art and comprise at least one active compound. Generally, the compounds of this invention are administered in a pharmaceutically effective amount. The amount of the compound actually administered will typically be determined by a physician, in the light of the relevant circumstances, including the condition to be treated, the chosen route of administration, the actual compound -administered, the age, weight, and response of the individual patient, the severity of the patient's symptoms, and the like.

[00180] The pharmaceutical compositions of this invention can be administered by a variety of routes including oral, rectal, transdermal, subcutaneous, intra-articular, intravenous, intramuscular, and intranasal. Depending on the intended route of delivery, the compounds of this invention are preferably formulated as either injectable or oral compositions or as salves, as lotions or as patches all for transdermal administration

[00181] The compositions for oral administration can take the form of bulk liquid solutions or suspensions, or bulk powders. More commonly, however, the compositions are presented in unit dosage forms to facilitate accurate dosing. The term "unit dosage forms" refers to physically discrete units suitable as unitary dosages for human subjects and other mammals, each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect, in association with a suitable pharmaceutical excipient, vehicle or carrier. Typical unit dosage forms include prefilled, premeasured ampules or syringes of the liquid compositions or pills, tablets, capsules or the like in the case of solid compositions. In such compositions, the furansulfonic acid compound is usually a minor component (from about 0.1 to about 50% by weight or preferably from about 1 to about 40% by weight) with the remainder being various vehicles or carriers and processing aids helpful for forming the desired dosing form.

[00182] Liquid forms suitable for oral administration may include a suitable aqueous or nonaqueous vehicle with buffers, suspending and dispensing agents, colorants, flavors and the like. Solid forms may include, for example, any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch; a lubricant such as magnesium stearate; a glidant such as

colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring.

[00183] Injectable compositions are typically based upon injectable sterile saline or phosphate-buffered saline or other injectable carriers known in the art. As before, the active compound in such compositions is typically a minor component, often being from about 0.05 to 10% by weight with the remainder being the injectable carrier and the like.

[00184] Transdermal compositions are typically formulated as a topical ointment or cream containing the active ingredient(s), generally in an amount ranging from about 0.01 to about 20% by weight, preferably from about 0.1 to about 20% by weight, preferably from about 0.1 to about 10% by weight, and more preferably from about 0.5 to about 15% by weight. When formulated as a ointment, the active ingredients will typically be combined with either a paraffinic or a water-miscible ointment base. Alternatively, the active ingredients may be formulated in a cream with, for example an oil-in-water cream base. Such transdermal formulations are well-known in the art and generally include additional ingredients to enhance the dermal penetration of stability of the active ingredients or the formulation. All such known transdermal formulations and ingredients are included within the scope of this invention.

[00185] The compounds of this invention can also be administered by a transdermal device. Accordingly, transdermal administration can be accomplished using a patch either of the reservoir or porous membrane type, or of a solid matrix variety.

[00186] The above-described components for orally administrable, injectable or topically administrable compositions are merely representative. Other materials as well as processing techniques and the like are set forth in Part 8 of Remington's Pharmaceutical Sciences, 17th edition, 1985, Mack Publishing Company, Easton, Pennsylvania, which is incorporated herein by reference.

[00187] The compounds of this invention can also be administered in sustained release forms or from sustained release drug delivery systems. A description of representative sustained release materials can be found in Remington's Pharmaceutical Sciences.

[00188] The following formulation examples illustrate representative pharmaceutical compositions that may be prepared in accordance with this invention. The present invention, however, is not limited to the following pharmaceutical compositions.

Formulation 1 - Tablets

[00189] A compound of the invention may be admixed as a dry powder with a dry gelatin binder in an approximate 1:2 weight ratio. A minor amount of magnesium stearate is added as a lubricant. The mixture is formed into 240-270 mg tablets (80-90 mg of active amide compound per tablet) in a tablet press.

Formulation 2 - Capsules

[00190] A compound of the invention may be admixed as a dry powder with a starch diluent in an approximate 1:1 weight ratio. The mixture is filled into 250 mg capsules (125 mg of active amide compound per capsule).

Formulation 3 - Liquid

[00191] A compound of the invention (125 mg), may be admixed with sucrose (1.75 g) and xanthan gum (4 mg) and the resultant mixture may be blended, passed through a No. 10 mesh U.S. sieve, and then mixed with a previously made solution of microcrystalline cellulose and sodium carboxymethyl cellulose (11:89, 50 mg) in water. Sodium benzoate (10 mg), flavor, and color are diluted with water and added with stirring. Sufficient water may then be added with stirring. Sufficient water is then added to produce a total volume of 5 mL.

Formulation 4 - Tablets

[00192] A compound of the invention may be admixed as a dry powder with a dry gelatin binder in an approximate 1:2 weight ratio. A minor amount of magnesium stearate is added as a lubricant. The mixture is formed into 450-900 mg tablets (150-300 mg of active amide compound) in a tablet press.

Formulation 5 - Injection

[00193] A compound of the invention may be dissolved or suspended in a buffered sterile saline injectable aqueous medium to a concentration of approximately 5 mg/mL.

Formulation 6 - Topical

[00194] Stearyl alcohol (250 g) and a white petrolatum (250 g) may be melted at about 75°C and then a mixture of a compound of the invention (50 g) methylparaben (0.25 g), propylparaben (0.15 g), sodium lauryl sulfate (10 g), and propylene glycol (120 g) dissolved in water (about 370 g) is added and the resulting mixture is stirred until it congeals.

METHODS OF TREATMENT

[00195] The present compounds may be used as therapeutic agents for the treatment of conditions in mammals that are causally related or attributable to aberrant activity of JAK. In particular, conditions related to aberrant activity of one or more of JAK1, JAK2, JAK3 and/or TYK2. Accordingly, a compound of the invention and pharmaceutical compositions of this invention find use as therapeutics for preventing and/or treating diseases involving cartilage degradation, bone and/or joint degradation, for example osteoarthritis; and/or conditions involving inflammation or immune responses, such as Crohn's disease, rheumatoid arthritis, psoriasis, allergic airways disease (e.g. asthma, rhinitis), juvenile idiopathic arthritis, colitis, inflammatory bowel diseases, endotoxin-driven disease states (e.g. complications after bypass surgery or chronic endotoxin states contributing to e.g. chronic cardiac failure), diseases involving impairment of cartilage turnover (e.g. diseases involving the anabolic stimulation of chondrocytes), congenital cartilage malformations, diseases

associated with hypersecretion of IL6 and transplantation rejection (e.g. organ transplant rejection). Inhibitors of JAK can also find application in the treatment of proliferative diseases. In particular the inhibitors of JAK find application in the treatment of cancers, especially leukaemias and solid tumours (e.g. uterine leiomyosarcoma, prostate cancer). In particular the conditions are selected from inflammatory conditions, conditions related to cartilage and/or joint degradation in mammals including humans. In another embodiment, the compounds and pharmaceutical compositions of this invention find use as therapeutics for preventing and/or treating proliferative disorders in mammals, including humans. In a specific embodiment the compound of the invention and pharmaceutical compositions thereof find use as therapeutics for preventing and/or treating cancer in mammals including humans.

[00196] In additional method of treatment aspects, this invention provides methods of treating a mammal susceptible to or afflicted with condition involving an immune response or an autoimmune disease. The methods comprise administering an effective condition-treating or condition-preventing amount of one or more of the pharmaceutical compositions or compound of the invention herein described. In a specific embodiment, the autoimmune disease is selected from COPD, asthma, systemic lupus erythematosis, type I diabetes mellitus and inflammatory bowel disease.

[00197] In another aspect the present invention provides a compound of the invention for use in the treatment, prevention or prophylaxis of a condition involving an autoimmune response or an autoimmune disease. In a specific embodiment, the autoimmune disease is selected from COPD, asthma, systemic lupus erythematosis, type I diabetes mellitus and inflammatory bowel disease.

[00198] In a method of treatment aspect, this invention provides a method of treatment, prevention or prophylaxis in a mammal susceptible to or afflicted with diseases involving impairment of cartilage turnover (e.g. a condition associated with, or diseases involving the anabolic stimulation of chondrocytes), for example, osteoarthritis, psoriatic arthritis, juvenile rheumatoid arthritis, gouty arthritis, septic or infectious arthritis, reactive arthritis, reflex sympathetic dystrophy, algodystrophy, Tietze syndrome or costal chondritis, fibromyalgia, osteochondritis, neurogenic or neuropathic arthritis, arthropathy, endemic forms of arthritis like osteoarthritis deformans endemica, Mseleni disease and Handigodu disease; degeneration resulting from fibromyalgia, systemic lupus erythematosus, scleroderma and ankylosing spondylitis, which method comprises administering a therapeutically effective amount of a compound of the invention, or one or more of the pharmaceutical compositions herein described.

[00199] In another aspect the present invention provides a compound of the invention for use in the treatment, prevention or prophylaxis of diseases involving impairment of cartilage turnover (e.g. a condition associated with, or diseases involving the anabolic stimulation of chondrocytes), for example, osteoarthritis, psoriatic arthritis, juvenile rheumatoid arthritis, gouty arthritis, septic or infectious arthritis, reactive arthritis, reflex sympathetic dystrophy, algodystrophy, Tietze syndrome or costal chondritis, fibromyalgia, osteochondritis, neurogenic or neuropathic arthritis, arthropathy, endemic forms of arthritis like osteoarthritis

deformans endemica, Mseleni disease and Handigodu disease; degeneration resulting from fibromyalgia, systemic lupus erythematosus, scleroderma and ankylosing spondylitis.

[00200] The present invention also provides a method of treatment of congenital cartilage malformations, including hereditary chondrolysis, chondrodysplasias and pseudochondrodysplasias, in particular, but without limitation, microtia, anotia, metaphyseal chondrodysplasia, and related disorders, which method comprises administering a therapeutically effective amount of a compound of the invention, or one or more of the pharmaceutical compositions herein described

[00201] In another aspect the present invention provides a compound of the invention for use in the treatment, prevention or prophylaxis of congenital cartilage malformations, including hereditary chondrolysis, chondrodysplasias and pseudochondrodysplasias, in particular, but without limitation, microtia, anotia, metaphyseal chondrodysplasia, and related disorders.

[00202] In another aspect, this invention provides a method of treating a mammal susceptible to or afflicted with a condition involving inflammation, which method comprises administering a therapeutically effective amount of a compound of the invention, or one or more of the pharmaceutical compositions herein described. In additional method of treatment aspects, this invention provides methods of treating a mammal susceptible to or afflicted with diseases and disorders which are mediated by or result in inflammation such as, for example rheumatoid arthritis and osteoarthritis, allergic airway disease (e.g. asthma, rhinitis), juvenile idiopathic arthritis, colitis, inflammatory bowel diseases, endotoxin-driven disease states (e.g. complications after bypass surgery or chronic endotoxin states contributing to e.g. chronic cardiac failure),, and related diseases involving cartilage, such as that of the joints, which method comprises administering a therapeutically effective amount of a compound of the invention, or one or more of the pharmaceutical compositions herein described. In a specific embodiment, the condition involving inflammation is selected from rheumatoid arthritis, osteoarthritis, allergic airway disease (e.g. asthma) and inflammatory bowel diseases. The methods comprise administering an effective condition-treating or condition-preventing amount of one or more of the pharmaceutical compositions or compounds herein described.

[00203] In another aspect, this invention provides a compound of the invention for use in the treatment, prevention or prophylaxis of a condition involving inflammation. In another aspect the present invention provides a compound of the invention for use in the treatment, prevention or prophylaxis of diseases and disorders which are mediated by or result in inflammation such as, for example rheumatoid arthritis and osteoarthritis, allergic airway disease (e.g. asthma, rhinitis), juvenile idiopathic arthritis, colitis, inflammatory bowel diseases, endotoxin-driven disease states (e.g. complications after bypass surgery or chronic endotoxin states contributing to e.g. chronic cardiac failure), and related diseases involving cartilage, such as that of the joints. In a specific embodiment, the condition involving inflammation is selected from rheumatoid arthritis, osteoarthritis, allergic airway disease (e.g. asthma) and inflammatory bowel diseases.

[00204] In further method of treatment aspects, this invention provides methods of treating a mammal susceptible to or afflicted with a proliferative disease, in particular cancer (e.g. solid tumors such as uterine leiomyosarcoma or prostate cancer), leukemia (e.g. AML or ALL), multiple myeloma and/or psoriasis, which method comprises administering a therapeutically effective amount of a compound of the invention, or one or more of the pharmaceutical compositions herein described. In further method of treatment aspects, this invention provides methods of treating a mammal susceptible to or afflicted with cancer (e.g. solid tumors such as uterine leiomyosarcoma or prostate cancer) and/or leukemias, which method comprises administering a therapeutically effective amount of a compound of the invention, or one or more of the pharmaceutical compositions herein described.

[00205] In another aspect the present invention provides a compound of the invention for use in the treatment, prevention or prophylaxis of a proliferative disease, in particular cancer (e.g. solid tumors such as uterine leiomyosarcoma or prostate cancer), leukemia (e.g. AML or ALL), multiple myeloma and/or psoriasis. In another aspect the present invention provides a compound of the invention for use in the treatment, prevention or prophylaxis of cancer (e.g solid tumors such as uterine leiomyosarcoma or prostate cancer) and/or leukemias.

[00206] In further method of treatment aspects, this invention provides methods of treating a mammal susceptible to or afflicted with diseases associated with hypersecretion of IL6, in particular Castleman's disease or mesangial proliferative glomerulonephritis, which method comprises administering a therapeutically effective amount of a compound of the invention, or one or more of the pharmaceutical compositions herein described.

[00207] In another aspect the present invention provides a compound of the invention for use in the treatment, prevention or prophylaxis of diseases associated with hypersecretion of IL6, in particular Castleman's disease or mesangial proliferative glomerulonephritis.

[00208] In further method of treatment aspects, this invention provides methods of treating a mammal susceptible to or afflicted with transplantation rejection, which method comprises administering a therapeutically effective amount of a compound of the invention, or one or more of the pharmaceutical compositions herein described. In a specific embodiment, the invention provides methods of treating organ transplant rejection, which method comprises administering a therapeutically effective amount of a compound of the invention, or one or more of the pharmaceutical compositions herein described.

[00209] In another aspect the present invention provides a compound of the invention for use in the treatment, prevention or prophylaxis of transplantation rejection. In a specific embodiment, the invention provides methods of treating organ transplant rejection.

[00210] As a further aspect of the invention there is provided the present compounds for use as a pharmaceutical especially in the treatment or prevention of the aforementioned conditions and diseases. Also

provided herein is the use of the present compounds in the manufacture of a medicament for the treatment or prevention of one of the aforementioned conditions and diseases.

[00211] A particular regimen of the present method comprises the administration to a subject in suffering from a disease involving inflammation, of an effective amount of a compound of the invention for a period of time sufficient to reduce the level of inflammation in the patient, and preferably terminate, the processes responsible for said inflammation. A special embodiment of the method comprises administering of an effective amount of a compound of the invention to a subject patient suffering from or susceptible to the development of rheumatoid arthritis, for a period of time sufficient to reduce or prevent, respectively, inflammation in the joints of said patient, and preferably terminate, the processes responsible for said inflammation.

[00212] A further particular regimen of the present method comprises the administration to a subject in suffering from a disease condition characterized by cartilage or joint degradation (e.g. osteoarthritis) of an effective amount of a compound of the invention for a period of time sufficient to reduce and preferably terminate, the self-perpetuating processes responsible for said degradation. A special embodiment of the method comprises administering of an effective amount of a compound of the invention to a subject patient suffering from or susceptible to the development of osteoarthritis, for a period of time sufficient to reduce or prevent, respectively, cartilage degradation in the joints of said patient, and preferably terminate, the self-perpetuating processes responsible for said degradation. In a particular embodiment said compounds exhibit cartilage anabolic and/or anti-catabolic properties.

[00213] Injection dose levels range from about 0.1 mg/kg/hour to at least 10 mg/kg/hour, all for from about 1 to about 120 hours and especially 24 to 96 hours. A preloading bolus of from about 0.1 mg/kg to about 10 mg/kg or more may also be administered to achieve adequate steady state levels. The maximum total dose is not expected to exceed about 2 g/day for a 40 to 80 kg human patient.

[00214] For the prevention and/or treatment of long-term conditions, such as degenerative conditions, the regimen for treatment usually stretches over many months or years so oral dosing is preferred for patient convenience and tolerance. With oral dosing, one to five and especially two to four and typically three oral doses per day are representative regimens. Using these dosing patterns, each dose provides from about 0.01 to about 20 mg/kg of the compound of the invention, with particular doses each providing from about 0.1 to about 10 mg/kg and especially about 1 to about 5 mg/kg.

[00215] Transdermal doses are generally selected to provide similar or lower blood levels than are achieved using injection doses.

[00216] When used to prevent the onset of an inflammatory condition, a compound of the invention will be administered to a patient at risk for developing the condition, typically on the advice and under the supervision of a physician, at the dosage levels described above. Patients at risk for developing a particular

condition generally include those that have a family history of the condition, or those who have been identified by genetic testing or screening to be particularly susceptible to developing the condition.

[00217] The compounds of the invention can be administered as the sole active agent or they can be administered in combination with other agents, including other compounds that demonstrate the same or a similar therapeutic activity, and that are determined to safe and efficacious for such combined administration. In a specific embodiment, co-administration of two (or more) agents allows for significantly lower doses of each to be used, thereby reducing the side effects seen.

[00218] In one embodiment, a compound of the invention is co-administered with another therapeutic agent for the treatment and/or prevention of a disease involving inflammation; particular agents include, but are not limited to, immunoregulatory agents e.g. azathioprine, corticosteroids (e.g. prednisolone or dexamethasone), cyclophosphamide, cyclosporin A, tacrolimus, Mycophenolate Mofetil, muromonab-CD3 (OKT3, e.g. Orthocolone®), ATG, aspirin, acetaminophen, ibuprofen, naproxen, and piroxicam.

[00219] In one embodiment, a compound of the invention is co-administered with another therapeutic agent for the treatment and/or prevention of arthritis (e.g. rheumatoid arthritis); particular agents include but are not limited to analgesics, non-steroidal anti-inflammatory drugs (NSAIDS), steroids, synthetic DMARDS (for example but without limitation methotrexate, leflunomide, sulfasalazine, auranofin, sodium aurothiomalate, penicillamine, chloroquine, hydroxychloroquine, azathioprine, and ciclosporin), and biological DMARDS (for example but without limitation Infliximab, Etanercept, Adalimumab, Rituximab, and Abatacept).

[00220] In one embodiment, a compound of the invention is co-administered with another therapeutic agent for the treatment and/or prevention of proliferative disorders; particular agents include but are not limited to: methotrexate, leukovorin, adriamycin, prenisone, bleomycin, cyclophosphamide, 5-fluorouracil, paclitaxel, docetaxel, vincristine, vinblastine, vinorelbine, doxorubicin, tamoxifen, toremifene, megestrol acetate, anastrozole, goserelin, anti- HER2 monoclonal antibody (e.g. Herceptin™), capecitabine, raloxifene hydrochloride, EGFR inhibitors (e.g. Iressa®, Tarceva™, Erbitux™), VEGF inhibitors (e.g. Avastin™), proteasome inhibitors (e.g. Velcade™), Glivec® or hsp90 inhibitors (e.g. 17-AAG). Additionally, a compound of the invention may be administered in combination with other therapies including, but not limited to, radiotherapy or surgery. In a specific embodiment the proliferative disorder is selected from cancer, myeloproliferative disease or leukaemia.

[00221] In one embodiment, a compound of the invention is co-administered with another therapeutic agent for the treatment and/or prevention of autoimmune diseases, particular agents include but are not limited to: glucocorticoids, cytostatic agents (e.g. purine analogs), alkylating agents, (e.g nitrogen mustards (cyclophosphamide), nitrosoureas, platinum compounds, and others), antimetabolites (e.g. methotrexate, azathioprine and mercaptopurine), cytotoxic antibiotics (e.g. dactinomycin anthracyclines, mitomycin C, bleomycin, and mithramycin), antibodies(e.g., anti-CD20, anti-CD25 or anti-CD3 (OTK3) monoclonal antibodies, Atgam® and Thymoglobuline®), cyclosporin, tacrolimus, rapamycin (sirolimus), interferons (e.g.

IFN-β), TNF binding proteins (e.g. infliximab (Remicade), etanercept (Enbrel), or adalimumab (Humira)), mycophenolate, Fingolimod, Myriocin.

[00222] In one embodiment, a compound of the invention is co-administered with another therapeutic agent for the treatment and/or prevention of transplantation rejection, particular agents include but are not limited to: calcineurin inhibitors (e.g. cyclosporin or tacrolimus (FK506)), mTOR inhibitors (e.g. sirolimus, everolimus), anti-proliferatives (e.g. azathioprine, mycophenolic acid), corticosteroids (e.g. prednisolone, hydrocortisone), Antibodies (e.g. monoclonal anti-IL-2Rα receptor antibodies, basiliximab, daclizumab), polyclonal anti-T-cell antibodies (e.g. anti-thymocyte globulin (ATG), anti-lymphocyte globulin (ALG)).

[00223] In one embodiment, a compound of the invention is co-administered with another therapeutic agent for the treatment and/or prevention of asthma and/or rhinitis and/or COPD, particular agents include but are not limited to: $beta_2$-adrenoceptor agonists (e.g. salbutamol, levalbuterol, terbutaline and bitolterol.), epinephrine (inhaled or tablets), anticholinergics (e.g. ipratropium bromide), glucocorticoids (oral or inhaled) Long-acting β_2-agonists (e.g. salmeterol, formoterol, bambuterol, and sustained-release oral albuterol), combinations of inhaled steroids and long-acting bronchodilators (e.g. fluticasone/salmeterol, budesonide/formoterol), leukotriene antagonists and synthesis inhibitors (e.g. montelukast, zafirlukast and zileuton), inhibitors of mediator release (e.g. cromoglycate and ketotifen), biological regulators of IgE response (e.g. omalizumab), antihistamines (e.g. ceterizine, cinnarizine, fexofenadine), vasoconstrictors (e.g. oxymethazoline, xylomethazoline, nafazoline and tramazoline).

[00224] Additionally, a compound of the invention may be administered in combination with emergency therapies for asthma and/or COPD, such therapies include oxygen or heliox administration, nebulized salbutamol or terbutaline (optionally combined with an anticholinergic (e.g. ipratropium), systemic steroids (oral or intravenous, e.g. prednisone, prednisolone, methylprednisolone, dexamethasone, or hydrocortisone), intravenous salbutamol, nonspecific beta-agonists, injected or inhaled (e.g. epinephrine, isoetharine, isoproterenol, metaproterenol), anticholinergics (IV or nebulized, e.g. glycopyrrolate, atropine, ipratropium), methylxanthines (theophylline, aminophylline, bamiphylline), inhalation anesthetics that have a bronchodilatory effect (e.g. isoflurane, halothane, enflurane), ketamine, intravenous magnesium sulfate.

[00225] In one embodiment, a compound of the invention is co-administered with another therapeutic agent for the treatment and/or prevention of IBD, particular agents include but are not limited to: glucocorticoids (e.g. prednisone, budesonide) synthetis disease modifying, immunomodulatory agents (e.g. methotrexate, leflunomide, sulfasalazine, mesalazine, azathioprine, 6-mercaptopurine and ciclosporin) and biological disease modifying, immunomodulatory agents (infliximab, adalimumab, rituximab, and abatacept).

[00226] In one embodiment, a compound of the invention is co-administered with another therapeutic agent for the treatment and/or prevention of SLE, particular agents include but are not limited to: Disease-modifying antirheumatic drugs (DMARDs) such as antimalarials (e.g. plaquenil, hydroxychloroquine), immunosuppressants (e.g. methotrexate and azathioprine), cyclophosphamide and mycophenolic acid;

immunosuppressive drugs and analgesics, such as nonsteroidal anti-inflammatory drugs, opiates (e.g. dextropropoxyphene and co-codamol), opioids (e.g. hydrocodone, oxycodone, MS Contin, or methadone) and the fentanyl duragesic transdermal patch.

[00227] In one embodiment, a compound of the invention is co-administered with another therapeutic agent for the treatment and/or prevention of psoriasis, particular agents include but are not limited to: topical treatments such as bath solutions, moisturizers, medicated creams and ointments containing coal tar, dithranol (anthralin), corticosteroids like desoximetasone (Topicort), fluocinonide, vitamin D_3 analogues (for example, calcipotriol), Argan oiland retinoids (etretinate, acitretin, tazarotene), systemic treatments such as methotrexate, cyclosporine, retinoids, tioguanine, hydroxyurea, sulfasalazine, mycophenolate mofetil, azathioprine, tacrolimus, fumaric acid esters or biologics such as Amevive, Enbrel, Humira, Remicade, Raptiva and ustekinumab (a IL-12 and IL-23 blocker). Additionally, a compound of the invention may be administered in combination with other therapies including, but not limited to phototherapy, or photochemotherapy (e.g. psoralen and ultraviolet A phototherapy (PUVA)).

[00228] By co-administration is included any means of delivering two or more therapeutic- agents to the patient as part of the same treatment regime, as will be apparent to the skilled person. Whilst the two or more agents may be administered simultaneously in a single formulation this is not essential. The agents may be administered in different formulations and at different times.

GENERAL SYNTHETIC PROCEDURES

General

[00229] The compounds of the invention can be prepared from readily available starting materials using the following general methods and procedures. It will be appreciated that where typical or preferred process conditions (i.e., reaction temperatures, times, mole ratios of reactants, solvents, pressures, etc.) are given, other process conditions can also be used unless otherwise stated. Optimum reaction conditions may vary with the particular reactants or solvent used, but such conditions can be determined by one skilled in the art by routine optimization procedures.

[00230] Additionally, as will be apparent to those skilled in the art, conventional protecting groups may be necessary to prevent certain functional groups from undergoing undesired reactions. The choice of a suitable protecting group for a particular functional group as well as suitable conditions for protection and deprotection are well known in the art. For example, numerous protecting groups, and their introduction and removal, are described in T. W. Greene and P. G. M. Wuts, *Protecting Groups in Organic Synthesis*, Second Edition, Wiley, New York, 1991, and references cited therein.

[00231] The following methods are presented with details as to the preparation of representative bicycloheteroaryls that have been listed hereinabove. The compounds of the invention may be prepared from known or commercially available starting materials and reagents by one skilled in the art of organic synthesis.

[00232] All reagents were of commercial grade and were used as received without further purification, unless otherwise stated. Commercially available anhydrous solvents were used for reactions conducted under inert atmosphere. Reagent grade solvents were used in all other cases, unless otherwise specified. Column chromatography was performed on silica gel 60 (35-70 μm). Thin layer chromatography was carried out using pre-coated silica gel F-254 plates (thickness 0.25 mm). ^{1}H NMR spectra were recorded on a Bruker DPX 400 NMR spectrometer (400 MHz). Chemical shifts (δ) for ^{1}H NMR spectra are reported in parts per million (ppm) relative to tetramethylsilane (δ 0.00) or the appropriate residual solvent peak, i.e. $CHCl_3$ (δ 7.27), as internal reference. Multiplicities are given as singlet (s), doublet (d), triplet (t), quartet (q), multiplet (m) and broad (br). Coupling constants (J) are given in Hz. Electrospray MS spectra were obtained on a Micromass platform LC/MS spectrometer. Column Used for all LCMS analysis: Waters Acquity UPLC BEH C18 1.7μm, 2.1mm ID x 50mm L (Part No.186002350)). Preparative HPLC: Waters XBridge Prep C18 5μm ODB 19mm ID x 100mm L (Part No.186002978). All the methods are using MeCN/H_2O gradients. H_2O contains either 0.1% TFA or 0.1% NH_3.

[00233] List of abbreviations used in the experimental section:

DCM	Dichloromethane
DiPEA	N,N-diisopropylethylamine
MeCN	Acetonitrile
BOC	tert-Butyloxy-carbonyl
MF	N,N-dimethylformamide
Cat.	Catalytic amount
TFA	Trifluoroacetic acid
THF	Tetrahydrofuran
NMR	Nuclear Magnetic Resonnance
DMSO	Dimethylsulfoxide
LC-MS	Liquid Chromatography-Mass Spectrometry
Ppm	part-per-million
Pd/C	Palladium on Charcoal 10%
PMB	Para-methoxy-benzyl
PyBOP	benzotriazol-1-yl-oxy-tris-pyrrolidino-phosphonium hexafluoroborate
EtOAc	ethyl acetate

APCI	atmospheric pressure chemical ionization
Rt	retention time
s	singlet
br s	broad singlet
m	multiplet
min	minute
mL	milliliter
μL	microliter
g	gram
mg	milligram
$PdCl_2$dppf	[1,1'-Bis(diphenylphosphino)ferrocene] dichloropalladium(II)
TEA	Triethylamine
MMP	Matrix Metallo Proteinase
NHAC	Normal Human Articular Chondrocytes
shRNA	short hairpin RNA
RNA	Ribonucleic acid

Ad-Si RNA	Adenoviral encoded siRNA
PBST	Phosphate buffered saline with Tween 3.2 mM Na2HPO4, 0.5 mM KH2PO4, 1.3 mM KCl, 135 mM NaCl, 0.05% Tween 20, pH 7.4
APMA	4-aminophenylmercuric acetate
DMEM	Dulbecco's Modified Eagle Medium
FBS	Fetal bovine serum

hCAR	human cellular adenovirus receptor
3- MOI	multiplicity of infection of 3
dNTP	deoxyribonucleoside triphosphate
QPCR	quantitative polymerase chain reaction
cDNA	copy deoxyribonucleic acid
GAPDH	Glyceraldehyde phosphate dehydrogenase

Synthetic Preparation of Compounds of the Invention

[00234] A compound of the invention can be produced according to the following scheme.

Method A

Scheme 1



[00235] wherein Ar is –Cy2-$(R^{3a})_{m2}$-; and Ar'is –Cy1-L1-$(CH_2)_{n1}$-R^{2c}; and Cy1, Cy2, L1, L2, n1, m2, R^{2c}, and R^{3a} are as described herein.

Step a. Preparation of 2-amino-5-Ar-triazolopyridine derivatives

[00236] An appropriate Ar substituted boronic acid derivative (2eq.) is added to a solution of 2-amino-8-bromo-triazolopyridine (Commercially available, BiofocusDPI) in dioxan/water (5:1). K_2CO_3 (2 eq.) and $PdCl_2$dppf (5%) are added to the mixture. The resulting mixture is heated in a microwave oven at 140°C for 15-45 min or heated in an oil bath at 90°C for 4 to 16 h until the reaction goes to completion (monitored by LCMS). Water is added and the mixture is extracted with ethyl acetate. The organic layers are combined, dried over anhyd. $MgSO_4$ and evaporated *in vacuo* to yield the crude product. The crude product is then purified by flash chromatography to give the corresponding 2-amino-5-Ar-triazolopyridine derivative (**2**).

Step b. Preparation of 5-Ar-2-iodo-triazolopyridine derivatives

[00237] A mixture of the above 2-amino-5-Ar-triazolopyridine derivative (**2**) (0.416 mmol) and $NaNO_2$ in DMSO (57 mg, 0.832 mmol in 250 µL of DMSO) is treated dropwise with a solution of 57% aqueous HI (273 µL, 2.08 mmol) in DMSO (250 µL) at 35 °C with agitation. The mixture is stirred at 35 °C for 10 minutes or until the reaction goes to completion (monitored by LCMS), and then it is transferred to a solution containing K_2CO_3 (500 mg) in 2 mL of water. The reaction mixture is extracted with ethyl acetate and the extracts are combined, washed with water and dried over anhyd. magnesium sulfate. The organic solvent is removed under high vacuum to yield the crude product. The crude product is then purified by flash chromatography to give the corresponding 5-Ar-2-iodo-triazolopyridine derivative (**3**).

Step c. Preparation of 2-Ar'-5-Ar-triazolopyridine derivatives

[00238] A mixture of the above 5-Ar-2-iodo-triazolopyridine derivative (**3**) (1 eq), $CsCO_3$ (5eq), $Pd(OAc)_2$ (0.1 eq), BINAP (0.1 eq), an appropriate Ar'-NH_2 derivative (1.5 eq) and toluene is sonicated for 5 minutes under nitrogen. Afterward, the reaction is left in a sealed tube at 120°C or in a flasked equipped with a cooling system. The crude mixture is extracted with ethyl acetate and the extracts are combined, washed with water and dried over anhyd. magnesium sulfate. The organic solvent is removed under high vacuum to yield the crude product. The crude product is then purified by preparative HPLC to give the corresponding 2-Ar'-5-Ar-triazolopyridine derivative (**4**).

Compounds of the invention:

Compound 1

[00239] This compound was prepared via Method A using 4-methoxyphenylboronic acid and 4'-aminoacetanilide.

Compound 2

[00240] This compound was prepared via Method A using 4-methoxyphenylboronic acid and 3-aminopyridine.

Compound 3

[00241] This compound was prepared via Method A using 4-methoxyphenylboronic acid and 4-aminopyridine.

Compound 4

[00242] This compound was prepared via Method A using 4-methoxyphenylboronic acid and aniline.

Compound 5

[00243] This compound was prepared via Method A using 4-methoxyphenylboronic acid and p-tolylamine.

Compound 6

[00244] This compound was prepared via Method A using 4-methoxyphenylboronic acid and 4-(1H-pyrazol-1-yl)aniline.

Compound 7

[00245] This compound was prepared via Method A using 4-methoxyphenylboronic acid and 4-ethyl-phenylamine.

Compound 8

[00246] This compound was prepared via Method A using 4-methoxyphenylboronic acid and 4-[1,2,4]triazol-1-yl-phenylamine.

Compound 9

[00247] This compound was prepared via Method A using 4-methoxyphenylboronic acid and 6-morpholin-4-yl-pyridin-3-ylamine.

Compound 10

[00248] This compound was prepared via Method A using 4-methoxyphenylboronic acid and 4-morpholin-4-yl-phenylamine.

Compound 11

[00249] This compound was prepared via Method A using 4-methoxyphenylboronic acid and (4-amino-phenyl)-morpholin-4-yl-methanone.

Compound 12

[00250] This compound was prepared via Method A using 4-methoxyphenylboronic acid and 6-(4-methylpiperazin-1-yl)pyridin-3-amine.

Compound 13

[00251] This compound was prepared via Method A using 4-methoxyphenylboronic acid and 4-pyridin-3-ylaniline.

Compound 14

[00252] This compound was prepared via Method A using 4-methoxyphenylboronic acid and 6-methoxy-pyridin-3-ylamine.

Compound 15



Step a

[00253] A mixture of 5-Bromo-[1,2,4]triazolo[1,5-a]pyridin-2-ylamine (1 eq), Cs_2CO_3 (5eq), $Pd(OAc)_2$ (0.1 eq), Xantphos (0.1 eq.), Iodobenzene (1.5 eq) and 1,4-dioxane were sonicated for 5 minutes under nitrogen. Afterwards, the reaction was left in a sealed tube at 100°C or in a flasked equipped with a cooling system for 5 hrs. The crude mixture was extracted with ethyl acetate and the extracts were combined, washed with water and dried over anhydrous magnesium sulfate. The organic solvent was removed under high vacuum to yield the crude product. The crude product was purified by flash chromatography.

Step 2:

[00254] 4-methylcarboxylate phenylboronic acid (1.2eq.) was added to a solution of (5-Bromo-[1,2,4]triazolo[1,5-a]pyridin-2-yl)-phenyl-amine DMF/water (5:1). CsF (2 eq.) and $Pd(Ph_3P)_2Cl_2$ (cat.) were added to the mixture. The resulting mixture was heated in an oil bath at 150°C for 16 h until the reaction was

complete (monitored by LCMS). HCl solution was added and the mixture was extracted with ethyl acetate. The organic layers were combined, dried over anhydrous $MgSO_4$ and evaporated in vacuo to yield the crude product.

Compound 16



Step a

[00255] A mixture of 5-Bromo-[1,2,4]triazolo[1,5-a]pyridin-2-ylamine (1 eq), Cs_2CO_3 (5eq), $Pd(OAc)_2$ (0.1 eq), Xantphos (0.1 eq.), Iodobenzene (1.5 eq) and 1,4-dioxane was sonicated for 5 minutes under nitrogen. Afterwards, the reaction was left in a sealed tube at 100°C or in a flasked equipped with a cooling system for 5 hrs. The crude mixture was extracted with ethyl acetate and the extracts were combined, washed with water and dried over anhydrous magnesium sulfate. The organic solvent was removed under high vacuum to yield the crude product. The crude product was purified by flash chromatography.

Step b

[00256] 4-Carboxyphenylboronic acid (1.2eq.) was added to a solution of (5-bromo-[1,2,4]triazolo[1,5-a]pyridin-2-yl)-phenyl-amine DMF/water (5:1). CsF (2 eq.) and $Pd(Ph_3P)_2Cl_2$ (cat.) were added to the mixture. The resulting mixture was heated in an oil bath at 150°C for 16 h until the reaction was complete (monitored by LCMS). HCl solution was added and the mixture was extracted with ethyl acetate. The organic layers were combined, dried over anhydrous $MgSO_4$ and evaporated in vacuo to yield the crude product.

Compound 17



Step a:

[00257] A mixture of 5-bromo-[1,2,4]triazolo[1,5-a]pyridin-2-ylamine (1 eq), Cs_2CO_3 (5eq), $Pd(OAc)_2$ (0.1 eq), Xantphos (0.1 eq.), 4-Iodo-benzoic acid methyl ester (1.5 eq) and 1,4-dioxane was sonicated for 5 minutes under nitrogen. Afterwards, the reaction was left in a sealed tube at 100°C or in a flasked equipped with a cooling system for 5 hrs. The crude mixture was extracted with ethyl acetate and the extracts were combined, washed with water and dried over anhydrous magnesium sulfate. The organic solvent was removed under high vacuum to yield the crude product. The crude product was purified by flash chromatography.

Step b

[00258] 4-Isopropoxyphenylboronic acid (1.2eq.) was added to a solution of 4-(5-bromo-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)-benzoic acid methyl ester in 1,4-dioxane/water (5:1). K_2CO_3 (2 eq.) and $PdCl_2$dppf (cat.) were added to the mixture. The resulting mixture was heated in an oil bath at 90°C for 4 to 16 h until the reaction went to completion (monitored by LCMS). Water was added and the mixture was extracted with ethyl acetate. The organic layers were combined, dried over anhydrous $MgSO_4$ and evaporated in vacuo to yield the crude product.

Step c:

[00259] 4-[5-(4-Isopropoxy-phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino]-benzoic acid methyl ester is mixed with LiOH 2N (3 eq) in acetone. The reaction mixture was heated at 50°C for 1 hr. The reaction was allowed to cool to room temperature and HCl 1N was added to acidic pH. The precipitate was filtered and washed with water, dried under vaccum. The product was purified by preparative HPLC

Compound 18

[00260] A mixture of 5-(4-Methoxy-phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamine (1 eq), Cs_2CO_3 (5eq), $Pd(OAc)_2$ (0.1 eq), Xantphos (0.1 eq), 2-iodo-pyridine (1.5 eq) and 1,4-dioxane was sonicated for 5

minutes under nitrogen. Afterwards, the reaction was left in a sealed tube at 100°C or in a flasked equipped with a cooling system for 16 hrs. The crude mixture was extracted with ethyl acetate and the extracts were combined, washed with water and dried over anhydrous magnesium sulfate. The organic solvent was removed under vacuum to yield the crude product. The crude product was then purified by preparative HPLC.

Compound 19

[00261] This compound was produced using the same procedure as described for Compound 17.

Compound 20

[00262] A solution of Compound 19 (1eq.) in DMF was treated with CDI (1.5 eq) and NH3 solution in dioxane. The reaction was stirred at room temperature for 16hr. After completion of the reaction, the product was purified by preparative HPLC.

Compound 21

[00263] This compound was produced using the same procedure as described for Compound 17 without the last step.

Compound 23



Step 1

[00264] A mixture of 5-bromo-[1,2,4]triazolo[1,5-a]pyridin-2-ylamine (1 eq), Cs_2CO_3 (5eq), $Pd(OAc)_2$ (0.1 eq), Xantphos (0.1 eq.), 4-iodo-benzoic acid methyl ester (1.5 eq) and 1,4-dioxane was sonicated for 5 minutes under nitrogen. Afterwards, the reaction was left in a sealed tube at 100°C or in a flasked equipped with a cooling system for 5 hrs. The crude mixture was extracted with ethyl acetate and the extracts were combined, washed with water and dried over anhydrous magnesium sulfate. The organic solvent was removed under high vacuum to yield the crude product. The crude product was purified by flash chromatography.

Step 2

[00265] 4-hydroxyphenylboronic acid (1.2eq.) was added to a solution of 4-(5-Bromo-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)-benzoic acid methyl ester DMF/water (5:1). CsF (2 eq.) and $Pd(Ph_3P)_2Cl_2$ (cat.) were added to the mixture. The resulting mixture was heated in an oil bath at 150°C for 16 h until the reaction went to completion (monitored by LCMS). HCl solution was added and the mixture was extracted with ethyl acetate. The organic layers were combined, dried over anhydrous $MgSO_4$ and evaporated *in vacuo* to yield the crude product.

Step 3

[00266] 4-[5-(4-Hydroxy-phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino]-benzoic acid methyl ester (1eq.), bromo-acetonitrile (1.5 eq.) and K_2CO_3 (1.5 eq) were mixed together in DMF. The resulting mixture was stirred at 60°C for 16 hrs. Water solution was added and the mixture was extracted with ethyl acetate. The organic layers were combined, dried over anhydrous $MgSO_4$ and evaporated *in vacuo* to yield the crude product. The final product was isolated by preparative HPLC.

Compound 24



Step a

[00267] 4-Methoxyphenylboronic acid (1.2eq.) was added to a solution of (5-bromo-[1,2,4]triazolo[1,5-a]pyridin-2-yl)-phenyl-amine DMF/water (5:1). CsF (2 eq.) and $Pd(Ph_3P)_2Cl_2$ (cat.) were added to the mixture. The resulting mixture was heated in an oil bath at 150°C for 16 h until the reaction went to completion (monitored by LCMS). HCl solution was added and the mixture was extracted with ethyl acetate. The organic layers were combined, dried over anhydrous $MgSO_4$ and evaporated *in vacuo* to yield the crude product.

Step b

[00268] Benzoyl isothiocyanate (1.2 eq) was added to a solution 5-Bromo-[1,2,4]triazolo[1,5-a]pyridin-2-ylamine (1eq) in acetone at room temperature. The resulting mixture was stirred for 4 hrs at room temperature. 10% NaOH aqueous solution was then added and the reaction. The mixture was heated to 100°C for 1.5 hr. The solvent was evaporated. Water was added and extracted with EtOAc. The organic phase was dried over $MgSO_4$ and evaporated under reduced pressure. The crude was used in the next step without further purification.

Step c

[00269] 2-Chloro-3-oxo-butyric acid methyl ester (1.2 eq.) was added to a solution of [5-(4-methoxy-phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl]-thiourea (1eq) in MeOH. The resulting solution was heated to 70°C until completion of the reaction. The solvent was evaporated under reduced pressure and the crude was purified by preparative HPC to afford the expected product.

Compound 25



Step 1

[00270] A mixture of 5-bromo-[1,2,4]triazolo[1,5-a]pyridin-2-ylamine (1 eq), Cs_2CO_3 (5eq), $Pd(OAc)_2$ (0.1 eq), Xantphos (0.1 eq.), 4-Iodo-benzoic acid methyl ester (1.5 eq) and 1,4-dioxane was sonicated for 5 minutes under nitrogen. Afterwards, the reaction was left in a sealed tube at 100°C or in a flasked equipped with a cooling system for 5 hrs. The crude mixture was extracted with ethyl acetate and the extracts were combined, washed with water and dried over anhydrous magnesium sulfate. The organic solvent was removed under high vacuum to yield the crude product. The crude product was purified by flash chromatography.

Step 2:

[00271] 4-hydroxyphenylboronic acid (1.2eq.) was added to a solution of 4-(5-Bromo-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)-benzoic acid methyl esterDMF/water (5:1). CsF (2 eq.) and $Pd(Ph_3P)_2Cl_2$ (cat.) were added to the mixture. The resulting mixture was heated in an oil bath at 150°C for 16 h until the reaction went to completion (monitored by LCMS). HCl solution was added and the mixture was extracted with ethyl acetate. The organic layers were combined, dried over anhydrous $MgSO_4$ and evaporated *in vacuo* to yield the crude product.

Step 3

[00272] 4-[5-(4-Hydroxy-phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino]-benzoic acid methyl ester (1eq.) was added to a solution of LiOH (2eq.) in acetone. The reaction was stirred at 60°C for 1.5hr. The excess of solvent was evaporated. HCl solution was added and the mixture was extracted with ethyl acetate. The organic layers were combined, dried over anhydrous $MgSO_4$ and evaporated in vacuo to yield the crude product. The resulting mixture was dissolved in DMF, CDI (1.5 eq) and NH_4OH (2eq) were added. The reaction was allowed to stir at room temperature for 16hr. The solvent was evaporated and the crude mixture was purified by preparative HPLC.

Compound 26

[00273] Compound 17 was dissolved in DMF, CDI (1.5 eq) and NH_4OH (2eq) were added. The reaction was allowed to stir at room temperature for 16hr. The solvent was evaporated and the crude mixture was purified by preparative HPLC.

Compound 27



Step 1:

[00274] A mixture of 5-Bromo-[1,2,4]triazolo[1,5-a]pyridin-2-ylamine (1 eq), Cs_2CO_3 (5eq), $Pd(OAc)_2$ (0.1 eq), Xantphos (0.1 eq.), 4-Iodo-benzoic acid methyl ester (1.5 eq) and 1,4-dioxane was sonicated for 5

minutes under nitrogen. Afterwards, the reaction was left in a sealed tube at 100°C or in a flasked equipped with a cooling system for 5 hrs. The crude mixture was extracted with ethyl acetate and the extracts were combined, washed with water and dried over anhydrous magnesium sulfate. The organic solvent was removed under high vacuum to yield the crude product. The crude product was purified by flash chromatography.

Step 2:

[00275] 4-hydroxyphenylboronic acid (1.2eq.) was added to a solution of 4-(5-Bromo-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)-benzoic acid methyl esterDMF/water (5:1). CsF (2 eq.) and $Pd(Ph_3P)_2Cl_2$ (cat.) were added to the mixture. The resulting mixture was heated in an oil bath at 150°C for 16 h until the reaction went to completion (monitored by LCMS). HCl solution was added and the mixture was extracted with ethyl acetate. The organic layers were combined, dried over anhydrous $MgSO_4$ and evaporated *in vacuo* to yield the crude product.

Step 3

[00276] 4-[5-(4-Hydroxy-phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino]-benzoic acid methyl ester (1eq.), Bromo-acetonitrile (1.5 eq.) and K2CO3 (1.5 eq) were mixed together in DMF. The resulting mixture was stirred at 60°C for 16 hrs. Water solution was added and the mixture was extracted with ethyl acetate. The organic layers were combined, dried over anhydrous $MgSO_4$ and evaporated *in vacuo* to yield the crude product. The final product was isolated by preparative HPLC.

Step 4

[00277] 4-[5-(4-Cyanomethoxy-phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino]-benzoic acid methyl ester 1eq.) was added to a solution of LiOH (2eq.) in acetone. The reaction was stirred at 60°C for 1.5hr. The excess of solvent was evaporated. HCl solution was added and the mixture was extracted with ethyl acetate. The organic layers were combined, dried over anhydrous $MgSO_4$ and evaporated in vacuo to yield the crude product. The resulting mixture was dissolved in DMF, CDI (1.5 eq) and NH_4OH (2eq) were added. The reaction was allowed to stir at room temperature for 16hr. The solvent was evaporated and the crude mixture is purified by preparative HPLC.

Compound 28

[00278] This compound was prepared via Method A using 4-methoxyphenylboronic acid and 4-amino-benzoic acid methyl ester.

Compound 29

[00279] This compound was prepared via Method A using 4-methoxyphenylboronic acid and 2,4-difluoro-3-methoxy-phenylamine.

Compound 30

[00280] This compound was prepared via Method A using 4-methoxyphenylboronic acid and benzooxazol-6-ylamine.

Compound 31

[00281] This compound was prepared via Method A using 4-methoxyphenylboronic acid and 4-[4-(4-fluoro-phenyl)-piperazin-1-yl]-phenylamine.

Compound 32

[00282] This compound was prepared via Method A using 4-methoxyphenylboronic acid and 4-amino-benzoic acid

Compound 33

[00283] This compound was prepared via Method A using 4-methoxyphenylboronic acid and 4-(4-isopropyl-piperazin-1-yl)-phenylamine.

Compound 34

[00284] This compound was prepared via Method A using 4-methoxyphenylboronic acid and 4-pyrazol-1-ylmethyl-phenylamine.

Compound 35

[00285] This compound was prepared via Method A using 4-methoxyphenylboronic acid and 4-imidazol-1-ylmethyl-phenylamine.

Compound 36

[00286] This compound was prepared via Method A using 4-methoxyphenylboronic acid and 4-[1,2,4]triazol-1-ylmethyl-phenylamine.

Compound 37

[00287] This compound was prepared via Method A using 4-methoxyphenylboronic acid and N-(3-amino-phenyl)-acetamide.

Compound 38

[00288] This compound was prepared via Method A using 4-methoxyphenylboronic acid and 4-Oxazol-5-yl-phenylamine.

Compound 39



Step a:

[00289] 4-[5-(4-Methoxy-phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino]-benzoic acid methyl ester (1eq.) prepared by method A was mixed with KOH 2N (3 eq) in DMSO in a microwave tube. The reaction mixture was subjected to microwave: 300 W, T=150°C; P<150 PSI for 1 hr. The reaction was allowed to cool to room temperature and HCl 1N was added to acidic pH. The precipitate was filtered and washed with water, dried under vaccum and used in the next step without further purification.

Step b:

[00290] 4-[5-(4-Methoxy-phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino]-benzoic acid (1eq.), EDC (1.2 eq), HOBt (1.2 eq.) and 1-Methyl-piperazine (1.2 eq.) were mixed in DMF at room tempretaure. The resulting mixture was stirred at room tempretaure for 16 hrs. The reaction was dissolved in DMSO, filtered and purified by preparative HPLC to afford the expected product.

Compound 40

[00291] This compound was prepared using the same method as described for Compound 39 using 4-methyl-piperidine.

Compound 41

[00292] This compound was prepared using the same method as described for Compound 39 using piperidine.

Compound 42

[00293] This compound was prepared using the same method as described for Compound 39 using N*1*,N*1*-dimethyl-propane-1,3-diamine.

Compound 43

[00294] This compound was prepared using the same method as described for Compound 39 using cyclohexylamine.

Compound 44

[00295] This compound was prepared using the same method as described for Compound 39 using 3-methoxy-propylamine.

Compound 45

[00296] This compound was prepared using the same method as described for Compound 39 using pyridin-3-ylamine.

Compound 46

[00297] This compound was prepared using the same method as described for Compound 39 using C-pyridin-3-yl-methylamine.

Compound 47

[00298] This compound was prepared using the same method as described for Compound 39 using C-pyridin-2-yl-methylamine.

Compound 49

[00299] This compound was prepared using the same method as described for Compound 39 using benzylamine.

Compound 50

[00300] This compound was prepared using the same method as described for Compound 39 using isopropylamine.

Compound 51

[00301] This compound was prepared using the same method as described for Compound 39 using 2-pyrrolidin-1-yl-ethylamine.

Compound 52

[00302] This compound was prepared using the same method as described for Compound 39 using 3,5-dimethyl-isoxazol-4-ylamine.

Compound 53

[00303] This compound was prepared using the same method as described for Compound 39 using piperidin-4-ol.

Compound 54

[00304] This compound was prepared using the same method as described for Compound 39 using 1-methyl-piperidin-4-ylamine.

Compound 55

[00305] This compound was prepared using the same method as described for Compound 39 using 2,3-dihydro-1H-isoindole.

Compound 56



Step a: (5-Bromo-[1,2,4]triazolo[1,5-a]pyridin-2-yl)-(4-nitro-phenyl)-amine

[00306] A mixture of 5-Bromo-[1,2,4]triazolo[1,5-a]pyridin-2-ylamine (1 eq), Cs_2CO_3 (5eq), $Pd(OAc)_2$ (0.1 eq), BINAP (0.1 eq), 1-Iodo-4-nitro-benzene (1.5 eq) and 1,4-dioxan was sonicated for 5 minutes under nitrogen. Afterwards, the reaction was left in a sealed tube at 120°C or in a flasked equipped with a cooling system for 16 hrs. The crude mixture was extracted with ethyl acetate and the extracts were combined, washed with water and dried over anhydrous magnesium sulfate. The organic solvent was removed under high vacuum to yield the crude product. The crude product was then purified by preparative HPLC to give the corresponding (5-Bromo-[1,2,4]triazolo[1,5-a]pyridin-2-yl)-(4-nitro-phenyl)-amine.

Step b:

[00307] (5-Bromo-[1,2,4]triazolo[1,5-a]pyridin-2-yl)-(4-nitro-phenyl)-amine (1 eq.) and $SnCl_2$ (5eq.) were mixed together in ethanol. The reaction mixture was stirred at 80°C for 4 hours. The resulting solution was filtered and the mother liquor was basified with NaOH 1N and extracted with EtOAc. The organic layer was dried and evaporated to afford 800 mg of a first batch. The filtrated green solid was taken up in NaOH 1N and extracted with EtOAc. The organic layer was dried over $MgSO_4$ and evaporated to afford the reduced compound. The compound was used in the next step without further purification.

Step c: N-[4-(5-Bromo-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)-phenyl]-acetamide

[00308] Acetic anhydride (1eq.) was added dropwise to a solution of N-(5-bromo-[1,2,4]triazolo[1,5-a]pyridin-2-yl)-benzene-1,4-diamine (1 eq.) in THF at 0°C. The reaction mixture was stirred at room temperature for 2 hours. The reaction mixture was quenched with a solution of $NaHCO_3$ sat. and extracted with EtOAc. The organic layer was dried over $MgSO_4$ and concentrated to afford a residue containing the expected acetamide. Water was added to the resulting solid to obtain a suspension of the title compound which was then filtered to afford N-[4-(5-bromo-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)-phenyl]-acetamide

Step d:

[00309] 2-dimethylamino-pyrimidine-5-boronic acid pinacol ester (2eq.) was added to a solution of N-[4-(5-bromo-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)-phenyl]-acetamide in dioxan/water (5:1) (or EtOH). K_2CO_3 (2 eq.) and $PdCl_2$dppf (cat.) were added to the mixture. The resulting mixture was heated in an oil bath at 90°C for 4 to 16 h until the reaction went to completion (monitored by LCMS). Water was added and the mixture was extracted with ethyl acetate. The organic layers were combined, dried over anhydrous $MgSO_4$ and evaporated in vacuo to yield the crude product. The crude product was then purified by preparative HPLC.

Compound 57

[00310] This compound was prepared using the same method as described for Compound 56 using N,N-dimethylbenzamide-3-boronic acid in step d.

Compound 58

[00311] This compound was prepared using the same method as described for Compound 56 using 4-fluorophenylboronic acid in step d.

Compound 59

[00312] This compound was prepared using the same method as described for Compound 56 using 3-chloro-4-fluorophenylboronic acid in step d.

Compound 60

[00313] This compound was prepared using the same method as described for Compound 56 using 3-(trifluoromethyl)phenylboronic acid in step d.

Compound 61

[00314] This compound was prepared using the same method as described for Compound 56 using 4-ethoxy-3-fluorophenylboronic acid in step d.

Compound 62

[00315] This compound was prepared using the same method as described for Compound 56 using 3,4-dimethoxyphenylboronic acid in step d.

Compound 63

[00316] This compound was prepared using the same method as described for Compound 56 using 4-cyanophenylboronic acid in step d.

Compound 64

[00317] This compound was prepared using the same method as described for Compound 56 using 3-cyanophenylboronic acid in step d.

Compound 65

[00318] This compound was prepared using the same method as described for Compound 56 using 4-(trifluoromethyl)phenylboronic acid in step d.

Compound 66

[00319] This compound was prepared using the same method as described for Compound 56 using 3,4-difluorophenylboronic acid in step d.

Compound 67

[00320] This compound was prepared using the same method as described for Compound 56 using 3-(trifluoromethoxy)phenylboronic acid in step d.

Compound 68

[00321] This compound was prepared using the same method as described for Compound 56 using 3,5-difluorophenylboronic acid in step d.

Compound 69

[00322] This compound was prepared using the same method as described for Compound 56 using 3-chlorophenylboronic acid in step d.

Compound 70

[00323] This compound was prepared using the same method as described for Compound 56 using 3-fluorophenylboronic acid in step d.

Compound 71

[00324] This compound was prepared using the same method as described for Compound 56 using 4-chlorophenylboronic acid in step d.

Compound 72

[00325] This compound was prepared using the same method as described for Compound 56 using 4-isopropoxy-phenyl-borane in step d.

Compound 73

[00326] This compound was prepared using the same method as described for Compound 56 using 3,4,5-trifluorophenylboronic acid in step d.

Compound 74

[00327] This compound was prepared using the same method as described for Compound 39 using N*1*,N*1*-dimethyl-ethane-1,2-diamine.

Compound 75

[00328] This compound was prepared using the same method as described for Compound 39 using methyl-(2-pyridin-2-yl-ethyl)-amine.

Compound 76

[00329] This compound was prepared using the same method as described for Compound 39 using 6-chloro-pyridin-3-ylamine.

Compound 77

[00330] This compound was prepared using the same method as described for Compound 39 using C-(1,5-dimethyl-1H-pyrazol-3-yl)-methylamine.

Compound 78

[00331] This compound was prepared using the same method as described for Compound 39 using C-(1,3,5-trimethyl-1H-pyrazol-4-yl)-methylamine.

Compound 79

[00332] This compound was prepared using the same method as described for Compound 39 using methyl-(3-methyl-3H-imidazol-4-ylmethyl)-amine.

Compound 80

[00333] This compound was prepared using the same method as described for Compound 39 using (1,5-dimethyl-1H-pyrazol-3-ylmethyl)-methyl-amine.

Compound 81

[00334] This compound was prepared using the same method as described for Compound 39 using (hydroxymethyl-amino)-methanol.

Compound 82

[00335] This compound was prepared using the same method as described for Compound 39 using N-(2-Amino-ethyl)-acetamide.

Compound 83

[00336] This compound was prepared using the same method as described for Compound 39 using C-(2,5-dimethyl-2H-pyrazol-3-yl)-methylamine.

Compound 84

[00337] This compound was prepared using the same method as described for Compound 39 using C-(1-ethyl-piperidin-4-yl)-methylamine.

Compound 85

[00338] This method was prepared via Method A using 3-amino-benzoic acid ethyl ester.

Compound 86

[00339] This compound was prepared using the same method as described for Compound 56 using naphthalene-2-boronic acid in step d.

Compound 87

[00340] This compound was prepared using the same method as described for Compound 39 using 1-piperazin-1-yl-ethanone.

Compound 88

[00341] This compound was prepared using the same method as described for Compound 39 using 2-amino-acetamide.

Compound 89

[00342] This compound was prepared using the same method as described for Compound 39 using N-(5-amino-pyridin-2-yl)-acetamide.

Compound 90

[00343] This compound was prepared using the same method as described for Compound 39 using N*1*,N*1*-diethyl-ethane-1,2-diamine.

Compound 91

[00344] This compound was prepared using the same method as described for Compound 39 using 1-methyl-1H-pyrazol-3-ylamine.

Compound 92

[00345] This compound was prepared using the same method as described for Compound 39 using 2-methoxy-pyridin-3-ylamine.

Compound 93

[00346] This compound was prepared using the same method as described for Compound 39 using 5-cyclopropyl-2-methyl-2H-pyrazol-3-ylamine.

Compound 94



Step a:

[00347] 3-[5-(4-Methoxy-phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino]-benzoic acid methyl ester (1eq.) prepared by method A was mixed with KOH 2N (3 eq) in DMSO in a microwave tube. The reaction mixture was subjected to microwave: 300 W, T=150°C; P<150 PSI for 1 hr. The reaction was allowed to cool to room temperature and HCl 1N was added to acidic pH. The precipitate was filtered and washed with water, dried under vaccum and purified by preparative HPLC.

Compound 95



Step a

[00348] A mixture of 5-Bromo-[1,2,4]triazolo[1,5-a]pyridin-2-ylamine (1 eq), Cs_2CO_3 (5eq), $Pd(OAc)_2$ (0.1 eq), BINAP (0.1 eq), 4-Iodo-benzoic acid ethyl ester (1.5 eq) and 1,4-dioxane was sonicated for 5 minutes under nitrogen. Afterwards, the reaction was left in a sealed tube at 120°C or in a flasked equipped with a cooling system for 16 hrs. The crude mixture was extracted with ethyl acetate and the extracts were combined, washed with water and dried over anhydrous magnesium sulfate. The organic solvent was removed under high vacuum to yield the crude product. The product was used in the next step without futher purification.

Step b

[00349] N[4-(4,4,5,5,-tetramethyl-1,3,2-dioxaborolan-2-yl)-methanesulfonamide (2eq.) was added to a solution of 4-(5-Bromo-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)-benzoic acid ethyl ester in 1,4-dioxane/water (5:1) (or EtOH). K_2CO_3 (2 eq.) and $PdCl_2$dppf (cat.) were added to the mixture. The resulting mixture was heated in an oil bath at 90°C for 4 to 16 h until the reaction went to completion (monitored by LCMS). Water was added and the mixture was extracted with ethyl acetate. The organic layers were combined, dried over anhydrous $MgSO_4$ and evaporated in vacuo to yield the crude product. The crude product was used in the next step without further purification.

Step c

[00350] 4-[5-(4-Methanesulfonylamino-phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino]-benzoic acid ethyl ester (1eq.) prepared by method A was mixed with KOH 2N (3 eq) in DMSO in a microwave tube. The reaction mixture was heated at 100°C for 16 hrs. The reaction was allowed to cool to room temperature and HCl 1N was added to acidic pH. The precipitate was filtered and washed with water and methanol.

Compound 96

[00351] This compound was prepared using the same method as for compound 95 using [3-(4,4,5,5-Tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenyl]-methanol.

Compound 97

[00352] This compound was prepared using the same method as for compound 95 using 2,4-dimethoxyphenylboronic acid.

Compound 98

[00353] This compound was prepared using the same method as for compound 95 using Benzenesulfonamide-4-boronic acid pinacol ester.

Compound 99

[00354] This compound was prepared using the same method as for compound 95 using 3-(methoxymethyl)phenylboronic acid.

Compound 100

[00355] This compound was prepared using the same method as described for Compound 39 using methyl-(1-methyl-pyrrolidin-3-yl)-amine.

Compound 101

[00356] This compound was prepared using the same method as described for Compound 39 using 2-ethyl-5-methyl-2H-pyrazol-3-ylamine.

Compound 102

[00357] This compound was prepared using the same method as described for Compound 39 using 1-methyl-piperazine.

Compound 103

[00358] This compound was prepared using the same method as described for Compound 39 using piperidine.

Compound 104

[00359] This compound was prepared using the same method as described for Compound 39 using 3,5-dimethyl-isoxazol-4-ylamine.

Compound 105

[00360] This compound was prepared using the same method as described for Compound 39 using 2-pyrrolidin-1-yl-ethylamine.

Compound 106

[00361] This compound was prepared using the same method as described for Compound 39 using N*1*,N*1*-dimethyl-propane-1,3-diamine.

Compound 107

[00362] This compound was prepared using the same method as described for Compound 39 using 1-piperazin-1-yl-ethanone.

Compound 108

[00363] This compound was prepared using the same method as described for Compound 39 using N-(2-amino-ethyl)-acetamide.

Compound 109

[00364] This compound was prepared using the same method as described for Compound 39 using C-pyridin-2-yl-methylamine.

Compound 110

[00365] This compound was prepared using the same method as described for Compound 39 using 1-methyl-piperidin-4-ylamine.

Compound 111

[00366] This compound was prepared using the same method as described for Compound 39 using C-pyridin-3-yl-methylamine.

Compound 112

[00367] This compound was prepared using the same method as described for Compound 39 using benzylamine.

Compound 118

[00368] This compound was prepared using the same method as described for Compound 39 using 3-pyrazol-1-yl-propylamine.

Compound 119

[00369] This compound was prepared using the same method as the one used for Compound 95 using 1H-Pyrazole-5-boronic acid.

Compound 120

[00370] This compound was prepared using the same method as the one used for Compound 95 using 3-(dihydroxyborane pinacol ester)phenyldimethylsulfonamide.

Compound 121

[00371] This compound was prepared using the same method as the one used for Compound 95 using 4-(methoxymethyl)phenylboronic acid.

Compound 122

[00372] This compound was prepared via Method A using 4-amino-benzamide.

Compound 123

[00373] This compound was prepared via Method A using 3-amino-benzamide.

Compound 127

[00374] This compound was prepared via Method A using pyridin-3-ylamine.

Compound 128



[00375] 4,4,5,5-Tetramethyl-2-(1H-pyrazol-4-yl)-1,3,2-dioxaborolane (2 eq) was added to a solution of N(6-chloro-pyridin-3-yl)-[5-(4-methoxy-phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl]-amine prepared by method A (1eq) in dioxan/water (5:1). K_2CO_3 (2 eq.) and $PdCl_2$dppf (cat.) were added to the mixture. The resulting mixture was subjected to microwave (300 W; P<150 PSI and T= 150°C) for 1 hr. The reaction went to completion (monitored by LCMS). Water was added and the mixture was extracted with ethyl acetate. The organic layers were combined, dried over anhydrous $MgSO_4$ and evaporated *in vacuo* to yield the crude product. The crude product was then purified by preparative HPLC.

Compound 129

[00376] This compound was prepared using the same method as described for Compound 128 using 4-acetamidophenylboronic acid.

Compound 130

[00377] This compound was prepared using the same method as described for Compound 128 using 2-(4-methylpiperazin-1-yl)pyridine-4-boronic acid pinacol ester.

Compound 131

[00378] This compound was prepared using the same method as described for Compound 128 using 4-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]morpholine.

Compound 132

[00379] This compound was prepared using the same method as described for Compound 128 using 4-(hydroxymethyl)phenylboronic acid.

Compound 133

[00380] This compound was prepared using the same method as described for Compound 128 using 2-(4-morpholino)pyridine-5-boronic acid pinacol ester.

Compound 134

[00381] This compound was prepared using the same method as described for Compound 128 using N-[3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]methanesulfonamide.

Compound 135

[00382] This compound was prepared using the same method as described for Compound 128 using 3-(N-Methylaminocarbonyl)benzeneboronic acid.

Compound 136

[00383] This compound was prepared using the same method as described for Compound 128 using benzamide-3-boronic acid.

Compound 137

[00384] This compound was prepared using the same method as described for Compound 128 using 4-(4-Morpholinomethyl)-phenylboronic acid pinacol ester hydrochloride.

Compound 138

[00385] This compound was prepared via Method A using 4-methoxyphenyl boronic acid and 4-fluoro aniline.

Compound 139



Step a

[00386] 4-Methoxyphenylboronic acid (1.2eq.) was added to a solution of (5-bromo-[1,2,4]triazolo[1,5-a]pyridin-2-yl)-phenyl-amine DMF/water (5:1). CsF (2 eq.) and $Pd(Ph_3P)_2Cl_2$ (cat.) were added to the mixture. The resulting mixture was heated in an oil bath at 150°C for 16 h until the reaction went to completion (monitored by LCMS). HCl solution was added and the mixture was extracted with ethyl acetate. The organic layers were combined, dried over anhydrous $MgSO_4$ and evaporated *in vacuo* to yield the crude product.

Step b

[00387] Benzoyl isothiocyanate (1.2 eq) was added to a solution 5-bromo-[1,2,4]triazolo[1,5-a]pyridin-2-ylamine (1eq) in acetone at room temperature. The resulting mixture was stirred for 4 hrs at room temperature. 10% NaOH aqueous solution was the added and the reaction. The mixture was allowed to heat to 100°C for 1.5 hr. The solvent was evaporated. Water was added and extracted with EtOAc. The organic phase was dried over $MgSO_4$ and evaporated under reduced pressure. The crude was used in the next step without further purification.

Step c

[00388] Chloro-acetic acid methyl ester (1.2 eq.) was added to a solution of [5-(4-methoxy-phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl]-thiourea (1eq) in EtOH. The resulting solution was subjected to microwave: T=120°C for 1hr. The solvent was evaporated under reduced pressure and the crude was purified by preparative HPC to afford the expected product.

Compound 140

[00389] This compound was prepared via the same procedure as described for Compound 139 using 2-chloro-propionic acid methyl ester in step c.

Compound 141



Step a

[00390] A mixture of 5-bromo-[1,2,4]triazolo[1,5-a]pyridin-2-ylamine (1 eq), Cs_2CO_3 (5eq), $Pd(OAc)_2$ (0.1 eq), Xantphos (0.1 eq.), 4-Iodo-benzoic acid methyl ester (1.5 eq) and 1,4-dioxane was sonicated for 5 minutes under nitrogen. Afterwards, the reaction was left in a sealed tube at 100°C or in a flasked equipped with a cooling system for 5 hrs. The crude mixture was extracted with ethyl acetate and the extracts were combined, washed with water and dried over anhydrous magnesium sulfate. The organic solvent was removed under high vacuum to yield the crude product. The crude product was purified by flash chromatography if necessary.

Step b

[00391] 4-(5-Bromo-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)-benzoic acid methyl ester (1eq) was heated in a solution of LiOH (2 eq) in MeOH at 60°C until completion of the reaction. The excess solvent was evaporated. The resulting solution was acidified with HCl 2N. The organics were extracted with ethyl actetate, dried over $MgSO_4$ and evaporated under reduced pressure. The crude was used without further purification.

Step c

[00392] 4-(5-Bromo-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)-benzoic acid (1eq.), CDI (1.2 eq) and dimethyl amine (2 eq.) were mixed in DMF at room tempretaure. The resulting mixture was stirred at room temperature for 16 hrs. Water was added. The organics were extracted with ethyl actetate, dried over $MgSO_4$ and evaporated under reduced pressure. The crude was used without further purification.

Step d

[00393] 4-Methoxyphenylboronic acid (1.2eq.) was added to a solution of 4-(5-bromo-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)-N,N-dimethyl-benzamideDMF/water (5:1). CsF (2 eq.) and $Pd(Ph_3P)_2Cl_2$ (cat.) were added to the mixture. The resulting mixture was heated in an oil bath at 150°C for 16 h until the reaction went to completion (monitored by LCMS). HCl solution was added and the mixture was extracted with ethyl acetate. The organic layers were combined, dried over anhydrous $MgSO_4$ and evaporated in vacuo to yield the crude product. Purification by preparative HPLC afforded the expected product.

Compound 142

[00394] This compound was prepared using the same procedure as described for Compound 141 using methyl amine in step c.

Compound 143

[00395] This compound was prepared via Method A using 4-methoxyphenyl boronic acid and 3-fluoro-phenylamine.

Compound 144

[00396] This compound was prepared using the same method as described for Compound 24 using chloro-acetaldehyde in the last step.

Compound 145

[00397] This compound was prepared via Method A using 4-methoxyphenyl boronic acid 1-(4-Amino-phenyl)-ethanone.

Compound 146



Step a

[00398] Compound 24 (1eq) was heated in a solution of LiOH (2 eq) in MeOH at 60°C until completion of the reaction. The excess solvent was evaporated. The resulting solution was acidified with HCl

2N. The organics were extracted with ethyl acetate, dried over $MgSO_4$ and evaporated under reduced pressure. The crude was used without further purification.

Step b

[00399] 2-[5-(4-Methoxy-phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino]-4-methyl-thiazole-5-carboxylic acid (1eq.), CDI (1.2 eq) and dimethyl amine (2 eq.) were mixed in DMF at room temperature. The resulting mixture was stirred at room tempretaure for 16 hrs. The reaction was dissolved in DMSO, filtered and purified by preparative HPLC to afford the expected product.

Compound 147

[00400] This compound was prepared via Method A using 4-methoxyphenyl boronic acid and 3,4,5-trimethoxy-phenylamine.

Compound 148

[00401] This compound was prepared via Method A using 4-methoxyphenyl boronic acid and 2-(4-amino-phenyl)-propan-2-ol.

Compound 149

[00402] O-Methyl-hydroxylamine (2eq.) was added to a solution of Compound 145 (1eq) and NaOAc (2eq) in methanol. The reaction was heated at 80°C until completion. Solvent was evaporated and water was added to the resulting mixture. The organics were extracted with ethyl actetate, dried over $MgSO_4$ and evaporated under reduced pressure. The crude was purified by preparative HPLC to afford the expected product.

Compound 150

[00403] This compound was prepared via Method A using 5-amino-pyridine-2-carbonitrile.

Compound 151

[00404] Hydroxylamine (2eq.) was added to a solution of Compound 145 (1eq) and NaOAc (2eq) in methanol. The reaction was heated at 80°C until completion. Solvent was evaporated and water was added to the resulting mixture. The organics were extracted with ethyl actetate, dried over $MgSO_4$ and evaporated under reduced pressure. The crude was purified by preparative HPLC to afford the expected product.

Compound 152

[00405] $NaBH_4$ (2eq) was added to a solution of compound 145 (1eq) in MeOH. The reaction was allowed to stir at room temperature until completion of the reaction. Water was added and the mixture was extracted with ethyl acetate. The organic layers were combined, dried over anhydrous $MgSO_4$ and evaporated *in vacuo* to yield the crude product. Purification by preparative HPLC afforded the expected product.

Compound 153

[00406] Compound 150 (1eq) was added to a solution of LiOH (1eq) in acetone. The reaction mixture was allowed to stir at 50°C for 4 days. The solvent was evaporated under reduced pressure and the crude mixture was purified by preparative HPLC.

Compound 154

[00407] Sodium azide (1.5 eq) is added to a solution compound 150 (1eq) in DMF and NH4Cl (2eq). The reaction is stirred at 100°C for 16 hrs. The crude mixture is purified by preparative HPLC.

Compound 155

[00408] The compound can be made via Method C using cyclopropylamine and 4-formylphenylboronic acid followed by this step:



Step b

[00409] To a solution of N-cyclopropyl-4-[5-(4-formyl-phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino]-benzamide (1 eq) and 1-amino-propan-2-ol (1.2 eq) in a mixture of CH_2Cl_2/AcOH 10:1 is added PS-NMe_3BH_3CN (polymer supported cyanoborohydride) (2.5 eq). The reaction mixture was shaken for 14h at room temperature then filtered. The filtrate was concentrated *in vacuo* and purified by flash column chromatography (Gradient, CH_2Cl_2 to CH_2Cl_2/MeOH [10:1]) to afford the desired product.

[00410] The exemplary compounds that have been or can be prepared according to the synthetic methods described herein are listed in Table I below. The NMR spectral data of some representative compounds of the invention is given in Table II.

[00411] **Table I**

Cpd #	Structure	Name	MW	MH+
1		*N*-{4-[5-(4-Methoxy-phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino]-phenyl}-acetamide	373.2	374.0
2		[5-(4-Methoxy-phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl]-pyridin-3-yl-amine	347.1	318.1
3		[5-(4-Methoxy-phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl]-pyridin-4-yl-amine	317.1	318.0
4		[5-(4-Methoxy-phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl]-phenyl-amine	316.1	317.0
5		[5-(4-Methoxy-phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl]-*p*-tolyl-amine	330.1	331.0
6		[5-(4-Methoxy-phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl]-(4-pyrazol-1-yl-phenyl)-amine	382.2	383.0
7		(4-Ethyl-phenyl)-[5-(4-methoxy-phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl]-amine	344.2	345.1

Cpd #	Structure	Name	MW	MH+
8		[5-(4-Methoxy-phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl]-(4-1,2,4-triazol-1-yl-phenyl)-amine	383.1	384.0
9		[5-(4-Methoxy-phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl]-(6-morpholin-4-yl-pyridin-3-yl)-amine	402.2	403.1
10		[5-(4-Methoxy-phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl]-(4-morpholin-4-yl-phenyl)-amine	401.2	402.1
11		{4-[5-(4-Methoxy-phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino]-phenyl}-morpholin-4-yl-methanone	429.2	430.0
12		[5-(4-Methoxy-phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl]-[6-(4-methyl-piperazin-1-yl)-pyridin-3-yl]-amine	415.2	416.1
13		[5-(4-Methoxy-phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl]-(4-pyridin-3-yl-phenyl)-amine	393.2	394.0
14		[5-(4-Methoxy-phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl]-(6-methoxy-pyridin-3-yl)-amine	347.1	348.0

Cpd #	Structure	Name	MW	MH+
15		methyl 4-(2-(phenylamino)-[1,2,4]triazolo[1,5-a]pyridin-5-yl)benzoate	344.1	344.4
16		4-(2-(phenylamino)-[1,2,4]triazolo[1,5-a]pyridin-5-yl)benzoic acid	330.1	330.3
17		4-(5-(4-isopropoxyphenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)benzoic acid	388.2	388.4
18		5-(4-methoxyphenyl)-N-(pyridin-2-yl)-[1,2,4]triazolo[1,5-a]pyridin-2-amine	317.1	317.4
19		4-(5-(4-(trifluoromethoxy)phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)benzoic acid	414.1	414.3

Cpd #	Structure	Name	MW	MH+
20		4-(5-(4-(trifluoromethoxy)phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)benzamide	413.1	413.4
21		5-(6-fluoropyridin-2-yl)-N-phenyl-[1,2,4]triazolo[1,5-a]pyridin-2-amine	305.1	305.3
23		methyl 4-(5-(4-(cyanomethoxy)phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)benzoate	399.1	399.4
24		methyl 2-(5-(4-methoxyphenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)-4-methylthiazole-5-carboxylate	395.1	395.4
25		4-(5-(4-hydroxyphenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)benzamide	345.1	345.4

Cpd #	Structure	Name	MW	MH+
26		4-(5-(4-isopropoxyphenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)benzamide	387.2	387.4
27		4-(5-(4-(cyanomethoxy)phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)benzamide	384.1	384.4
28		methyl 4-(5-(4-methoxyphenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)benzate	374.1	374
29		N-(2,4-difluoro-3-methoxyphenyl)-5-(4-methoxyphenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-amine	382.1	382
30		N-(5-(4-methoxyphenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl)benzo[d]oxazol-6-amine	357.1	357

Cpd #	Structure	Name	MW	MH+
31		N-(4-(4-(4-fluorophenyl)piperazin-1-yl)phenyl)-5-(4-methoxyphenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-amine	494.2	495
32		4-(5-(4-methoxyphenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)benzoic acid	360.1	360
33		N-(4-(4-isopropylpiperazin-1-yl)phenyl)-5-(4-methoxyphenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-amine	442.2	443
34		N-(4-((1H-pyrazol-1-yl)methyl)phenyl)-5-(4-methoxyphenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-amine	396.2	396
35		N-(4-((1H-imidazol-1-yl)methyl)phenyl)-5-(4-methoxyphenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-amine	396.2	396
36		N-(4-((1H-1,2,4-triazol-1-yl)methyl)phenyl)-5-(4-methoxyphenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-amine	397.2	397

Cpd #	Structure	Name	MW	MH+
37		N-(3-(5-(4-methoxyphenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)phenyl)acetamide	373.2	373
38		5-(4-methoxyphenyl)-N-(4-(oxazol-5-yl)phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-amine	383.1	383
39		(4-(5-(4-methoxyphenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)phenyl)(4-methylpiperazin-1-yl)methanone	442.2	443
40		(4-(5-(4-methoxyphenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)phenyl)(4-methylpiperidin-1-yl)methanone	441.2	442
41		(4-(5-(4-methoxyphenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)phenyl)(piperidin-1-yl)methanone	427.2	428
42		N-(3-(dimethylamino)propyl)-4-(5-(4-methoxyphenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)benzamide	444.2	445
43		N-cyclohexyl-4-(5-(4-methoxyphenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)benzamide	441.2	442

Cpd #	Structure	Name	MW	MH+
44		4-(5-(4-methoxyphenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)-N-(3-methoxypropyl)benzamide	431.2	432
45		4-(5-(4-methoxyphenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)-N-(pyridin-3-yl)benzamide	436.2	436
46		4-(5-(4-methoxyphenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)-N-(pyridin-3-ylmethyl)benzamide	450.2	451
47		4-(5-(4-methoxyphenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)-N-(pyridin-2-ylmethyl)benzamide	450.2	451
49		N-isopropyl-4-(5-(4-methoxyphenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)benzamide	449.2	450
50		4-(5-(4-methoxyphenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)-N-(2-(pyrrolidin-1-yl)ethyl)benzamide	401.2	401
51		N-(3,5-dimethylisoxazol-4-yl)-4-(5-(4-methoxyphenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)benzamide	456.2	457

Cpd #	Structure	Name	MW	MH+
52		(4-hydroxypiperidin-1-yl)(4-(5-(4-methoxyphenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)phenyl)methanone	454.2	454
53		4-(5-(4-methoxyphenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)-N-(1-methylpiperidin-4-yl)benzamide	443.2	444
54		isoindolin-2-yl(4-(5-(4-methoxyphenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)phenyl)methanone	456.2	457
55		N-(4-(5-(2-(dimethylamino)pyrimidin-5-yl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)phenyl)acetamide	461.2	462
56		3-(2-(4-acetamidophenylamino)-[1,2,4]triazolo[1,5-a]pyridin-5-yl)-N,N-dimethylbenzamide	388.2	388
57		N-(4-(5-(4-fluorophenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)phenyl)acetamide	414.2	414
58		N-(4-(5-(3-chloro-4-fluorophenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)phenyl)acetamide	361.1	361

Cpd #	Structure	Name	MW	MH+
59		N-(4-(5-(3-(trifluoromethyl)phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)phenyl)acetamide	395.1	396
60		N-(4-(5-(4-ethoxy-3-fluorophenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)phenyl)acetamide	411.1	411
61		N-(4-(5-(3,4-dimethoxyphenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)phenyl)acetamide	405.2	405
62		N-(4-(5-(4-cyanophenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)phenyl)acetamide	403.2	403
63		N-(4-(5-(3-cyanophenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)phenyl)acetamide	368.1	368
64		N-(4-(5-(4-(trifluoromethyl)phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)phenyl)acetamide	368.1	368

Cpd #	Structure	Name	MW	MH+
65		N-(4-(5-(3,4-difluorophenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)phenyl)acetamide	411.1	411
66		N-(4-(5-(3-(trifluoromethoxy)phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)phenyl)acetamide	379.1	379
67		N-(4-(5-(3,5-difluorophenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)phenyl)acetamide	427.1	427
68		N-(4-(5-(3-chlorophenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)phenyl)acetamide	379.1	379
69		N-(4-(5-(3-fluorophenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)phenyl)acetamide	377.1	378
70		N-(4-(5-(4-chlorophenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)phenyl)acetamide	361.1	361

Cpd #	Structure	Name	MW	MH+
71		N-(4-(5-(4-isopropoxyphenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)phenyl)acetamide	377.1	378
72		N-(4-(5-(3,4,5-trifluorophenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)phenyl)acetamide	401.2	401
73		N-(2-(dimethylamino)ethyl)-4-(5-(4-methoxyphenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)benzamide	397.1	397
74		4-(5-(4-methoxyphenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)-N-methyl-N-(2-(pyridin-2-yl)ethyl)benzamide	430.2	431
75		4-(5-(4-methoxyphenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)-N-(6-methoxypyridin-3-yl)benzamide	478.2	479
76		N-((1,5-dimethyl-1H-pyrazol-3-yl)methyl)-4-(5-(4-methoxyphenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)benzamide	466.2	467
77		4-(5-(4-methoxyphenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)-N-((1,3,5-trimethyl-1H-pyrazol-4-yl)methyl)benzamide	467.2	468

Cpd #	Structure	Name	MW	MH+
78		4-(5-(4-methoxyphenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)-N-methyl-N-((1-methyl-1H-imidazol-5-yl)methyl)benzamide	481.2	482
79		N-((1,5-dimethyl-1H-pyrazol-3-yl)methyl)-4-(5-(4-methoxyphenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)-N-methylbenzamide	467.2	468
80		N-(1,3-dihydroxypropan-2-yl)-4-(5-(4-methoxyphenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)benzamide	481.2	482
81		N-(2-acetamidoethyl)-4-(5-(4-methoxyphenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)benzamide	433.2	433
82		N-((1,3-dimethyl-1H-pyrazol-5-yl)methyl)-4-(5-(4-methoxyphenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)benzamide	444.2	444
83		N-((1-ethylpiperidin-4-yl)methyl)-4-(5-(4-methoxyphenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)benzamide	467.2	468
84		ethyl 3-(5-(4-methoxyphenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)benzate	484.3	485

Cpd #	Structure	Name	MW	MH+
85		N-(4-(8-(naphthalen-2-yl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)phenyl)acetamide	388.2	388
86		1-(4-(4-(5-(4-methoxyphenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)benzoyl)piperazin-1-yl)ethanone	393.2	393
87		N-(2-amino-2-oxoethyl)-4-(5-(4-methoxyphenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)benzamide	470.2	471
88		N-(6-acetamidopyridin-3-yl)-4-(5-(4-methoxyphenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)benzamide	416.2	416
89		4-(5-(4-methoxyphenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)-N-(2-(piperidin-1-yl)ethyl)benzamide	493.2	494
90		4-(5-(4-methoxyphenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)-N-(1-methyl-1H-pyrazol-3-yl)benzamide	470.2	471
91		4-(5-(4-methoxyphenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)-N-(2-methoxypyridin-3-yl)benzamide	439.2	439

Cpd #	Structure	Name	MW	MH+
92		N-(3-cyclopropyl-1-methyl-1H-pyrazol-5-yl)-4-(5-(4-methoxyphenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)benzamide	466.2	467
93		3-(5-(4-methoxyphenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)benzic acid	479.2	480
94		4-(5-(4-(methylsulfonamido)phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)benzic acid	360.1	360
95		4-(5-(3-(hydroxymethyl)phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)benzic acid	423.1	423
96		4-(5-(2,4-dimethoxyphenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)benzic acid	360.1	360
97		4-(5-(4-sulfamoylphenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)benzic acid	390.1	390

Cpd #	Structure	Name	MW	MH+
98		4-(5-(3-(methoxymethyl)phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)benzic acid	409.1	409
99		4-[5-(3-Methoxymethyl-phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino]-benzoic acid	374.1	374
100		N-(2-Ethyl-5-methyl-2H-pyrazol-3-yl)-4-[5-(4-methoxy-phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino]-benzamide	456.2	457
101		{3-[5-(4-Methoxy-phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino]-phenyl}-(4-methyl-piperazin-1-yl)-methanone	467.2	468
102		{3-[5-(4-Methoxy-phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino]-phenyl}-piperidin-1-yl-methanone	442.2	443
103		N-(3,5-Dimethyl-isoxazol-4-yl)-3-[5-(4-methoxy-phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino]-benzamide	427.2	428
104		3-[5-(4-Methoxy-phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino]-N-(2-pyrrolidin-1-yl-ethyl)-benzamide	454.2	454

Cpd #	Structure	Name	MW	MH+
105		N-(3-Dimethylamino-propyl)-3-[5-(4-methoxy-phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino]-benzamide	456.2	457
106		1-(4-{3-[5-(4-Methoxy-phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino]-benzoyl}-piperazin-1-yl)-ethanone	444.2	445
107		N-(2-Acetylamino-ethyl)-3-[5-(4-methoxy-phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino]-benzamide	470.2	471
108		3-[5-(4-Methoxy-phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino]-N-pyridin-2-ylmethyl-benzamide	444.2	444
109		3-[5-(4-Methoxy-phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino]-N-(1-methyl-piperidin-4-yl)-benzamide	450.2	451
110		3-[5-(4-Methoxy-phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino]-N-pyridin-3-ylmethyl-benzamide	456.2	457
111		N-Benzyl-3-[5-(4-methoxy-phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino]-benzamide	450.2	451

Cpd #	Structure	Name	MW	MH+
112		N-(4-(8-(1H-indol-5-yl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)phenyl)acetamide	449.2	450
118		4-(5-(1H-pyrazol-5-yl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)benzic acid	467.2	468
119		4-[5-(2H-Pyrazol-3-yl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino]-benzoic acid	320,1	320
120		4-(5-(3-(N,N-dimethylsulfamoyl)phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)benzic acid	437.1	437
121		4-(5-(4-(methoxymethyl)phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)benzic acid	374.1	374
122		4-(5-(4-methoxyphenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)benzamide	359.1	359

Cpd #	Structure	Name	MW	MH+
123		3-(5-(4-methoxyphenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)benzamide	359.1	359
127		5-(4-methoxyphenyl)-N-(pyridin-3-yl)-[1,2,4]triazolo[1,5-a]pyridin-2-amine	317.1	317
128		[5-(4-Methoxy-phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl]-[6-(1H-pyrazol-4-yl)-pyridin-3-yl]-amine	383.1	383
129		N-(4-{5-[5-(4-Methoxy-phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino]-pyridin-2-yl}-phenyl)-acetamide	450.2	451
130		5-(4-methoxyphenyl)-N-(6'-(4-methylpiperazin-1-yl)-2,3'-bipyridin-5-yl)-[1,2,4]triazolo[1,5-a]pyridin-2-amine	492.2	493

Cpd #	Structure	Name	MW	MH+
131		5-(4-methoxyphenyl)-N-(6-(4-morpholinophenyl)pyridin-3-yl)-[1,2,4]triazolo[1,5-a]pyridin-2-amine	478.2	479
132		(4-(5-(5-(4-methoxyphenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)pyridin-2-yl)phenyl)methanol	423.2	423
133		5-(4-methoxyphenyl)-N-(6'-morpholino-2,3'-bipyridin-5-yl)-[1,2,4]triazolo[1,5-a]pyridin-2-amine	479.2	480
134		N-(3-(5-(5-(4-methoxyphenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)pyridin-2-yl)phenyl)methanesulfonamide	486.1	487
135		3-(5-(5-(4-methoxyphenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)pyridin-2-yl)-N-methylbenzamide	450.2	451

Cpd #	Structure	Name	MW	MH+
136		4-(5-(5-(4-methoxyphenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)pyridin-2-yl)benzamide	436.2	436
137		5-(4-methoxyphenyl)-N-(6-(4-(morpholinomethyl)phenyl)pyridin-3-yl)-[1,2,4]triazolo[1,5-a]pyridin-2-amine	492.2	493
138		(4-Fluoro-phenyl)-[5-(4-methoxy-phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl]-amine	334.35	335
139		2-[5-(4-Methoxy-phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino]-thiazol-4-one	339.377	340
140		2-[5-(4-Methoxy-phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino]-5-methyl-thiazol-4-one	353.404	354
141		4-[5-(4-Methoxy-phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino]-N,N-dimethyl-benzamide	387.443	388

Cpd #	Structure	Name	MW	MH+
142		4-[5-(4-Methoxy-phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino]-N-methyl-benzamide	373.416	374
143		(3-Fluoro-phenyl)-[5-(4-methoxy-phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl]-amine	334.354	336
144		[5-(4-Methoxy-phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl]-thiazol-2-yl-amine	323.378	324
145		1-{4-[5-(4-Methoxy-phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino]-phenyl}-ethanone	358.401	359
146		2-[5-(4-Methoxy-phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino]-4-methyl-thiazole-5-carboxylic acid dimethylamide	408.484	409
147		[5-(4-Methoxy-phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl]-(3,4,5-trimethoxy-phenyl)-amine	406.442	407

Cpd #	Structure	Name	MW	MH+
148		2-{4-[5-(4-Methoxy-phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino]-phenyl}-propan-2-ol	374.444	375
149		1-{4-[5-(4-Methoxy-phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino]-phenyl}-ethanone O-methyl-oxime	387.443	
150		5-[5-(4-Methoxy-phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino]-pyridine-2-carbonitrile	342.362	343
151		1-{4-[5-(4-Methoxy-phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino]-phenyl}-ethanone oxime	373.416	374
152		1-{4-[5-(4-Methoxy-phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino]-phenyl}-ethanol	360.417	361
153		5-[5-(4-Methoxy-phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino]-pyridine-2-carboxylic acid amide	360.377	361

Cpd #	Structure	Name	MW	MH+
154		[5-(4-Methoxy-phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl]-[6-(1H-tetrazol-5-yl)-pyridin-3-yl]-amine	385.39	386
155		N-Cyclopropyl-4-(5-{4-[(2-hydroxy-ethylamino)-methyl]-phenyl}-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)-benzamide	442.52	N/A

[00412] **Table II: NMR Data of Representative Compounds of the Invention**

Cpd #	(δ) NMR data
1	(DMSO, 400 MHz) δ (ppm): 9.76 (s, 1H); 9.51 (s, 1H); 8.04 (d, *J*: 8.8 Hz , 2H); 7.60 (m, *J*: 9.0, 8.8, 7.4 Hz, 3H); 7.51 (dd, *J*: 8.8, 1.2 Hz, 1H); 7.44 (d, *J*: 9.2 Hz, 2H); 7.14 (d, *J*: 8.9 Hz, 2H); 7.13 (dd, *J*: 7.32, 1.3 Hz, 1H); 3.87 (s, 3H); 2.01 (s, 3H).
2	($CDCl_3$, 400 MHz) δ (ppm): 11.77 (s, 1H); 9.53 (s, 1H); 8.50 (d, *J*: 4.3 Hz, 1H); 8.25 (d, *J*: 7.3 Hz, 1H); 7.98 (d, *J*: 8.7 Hz, 2H); 7.93 (t, *J*: 8.0 Hz, 1H); 7.79 (m, 1H); 7.68 (d, *J*: 8.6 Hz, 1H); 7.40 (d, *J*: 7.6 Hz, 1H); 7.24 (d, *J*: 8.5 Hz, 2H); 3.98 (s, 3H).
3	(CD_3OD, 400 MHz) δ (ppm): 8.46 (d, *J*: 7.4 Hz, 2H); 8.03 (d, *J*: 9.2 Hz, 2H); 7.78 (dd, *J*: 8.8, 7.6 Hz, 1H); 7.65 (dd, *J*: 8.9, 1.3 Hz, 1H); 7.53 (bp, 1H); 7.40 (bp, 1H); 7.29 (dd, *J*: 7.3, 1.3 Hz, 1H); 7.28 (bp, 1H); 7.15 (d, *J*: 8.9 Hz, 2H); 3.93 (s, 3H).
4	($CDCl_3$, 400 MHz) δ (ppm): 9.13 (s, 1H); 7.97 (d, *J*: 8.9 Hz, 1H); 7.94 (d, *J*: 8.8 Hz, 1H); 7.76 (m, 2H); 7.60 (d, *J*: 7.8 Hz, 1H); 7.55 (d, *J*: 8.8 Hz, 1H); 7.32 (m, 3H); 7.10 (d, *J*: 8.9 Hz, 2H); 7.05 (t, 1H); 3.94 (s, 3H).
5	(DMSO, 400 MHz) δ (ppm): 9.47 (s, 1H); 8.05 (d, *J*: 8.8 Hz, 2H); 7.62 (dd, *J*: 8.6, 7.4 Hz, 1H); 7.58 (d, *J*: 8.5 Hz, 2H); 7.51 (dd, *J*: 8.8, 1.3 Hz, 1H); 7.14 (d, *J*: 8.9 Hz, 2H); 7.14 (dd, *J*: 7.4, 1.4 Hz, 1H); 7.07 (bp, *J*: 8.1 Hz, 2H); 3.87 (s, 3H); 2.24 (s, 3H).
6	(DMSO, 400 MHz) δ (ppm): 9.80 (s, 1H); 8.36 (d, *J*: 2.0 Hz, 1H); 8.06 (d, *J*: 8.8 Hz, 1H); 7.80 (d, *J*: 8.8 Hz, 2H); 7.72 (d, *J*: 9.1 Hz, 2H); 7.68 (d, *J*: 1.5 Hz, 2H); 7.65 (dd, *J*: 8.5, 7.3 Hz, 1H); 7.56 (dd, *J*: 9.4, 1.0 Hz, 1H); 7.17 (d, *J*: 8.8 Hz, 2H); 6.50 (t, *J*: 2.1 Hz, 1H); 3.88 (s, 3H).

Cpd #	(δ) NMR data
7	(DMSO, 400 MHz) δ (ppm): 9.49 (s, 1H); 8.05 (d, *J*: 8.9 Hz, 2H); 7.62 (dd, *J*: 8.9, 7.6 Hz, 1H); 7.59 (d, *J*: 8.5 Hz, 2H); 7.51 (d, *J*: 8.8 Hz, 1H); 7.15 (d, *J*: 8.8 Hz, 2H); 7.15 (dd, *J*: 7.3, 1.3 Hz, 1H); 7.10 (d, *J*: 8.2 Hz, 2H); 3.88 (s, 3H); 1.158 (t, *J*: 7.6 Hz, 3H).
8	(DMSO, 400 MHz) δ (ppm): 9.93 (s, 1H); 9.15 (s, 1H); 8.18 (s, 1H); 8.06 (d, *J*: 8.8, 7.6 Hz, 2H); 7.85 (d, *J*: 9.2 Hz, 2H); 7.74 (d, *J*: 8.9 Hz, 2H); 7.66 (dd, *J*: 8.9, 7.4 Hz, H); 7.57 (dd, *J*: 8.9, 1.1 Hz, 1H); 7.18 (d, *J*: 0.9 Hz, H); 7.17 (d, *J*: 8.8 Hz, 2H); 3.88 (s, 3H).
15	(^{1}H, DMSO) 3.96 (3H, s, CH_3), 6.90 (1H, dd, ArH), 7.28-7.33 (3H, m, ArH), 7.69-7.72 (4H, m, ArH), 8.19 (2H, d, ArH), 8.26 (2H, d, ArH), 9.68 (1H, s, NH)
16	(^{1}H, DMSO) 6.90 (1H, dd, ArH), 7.27-7.33 (3H, m, ArH), 7.65-7.74 (4H, m, ArH), 8.17 (2H, d, ArH), 8.23 (2H, d, ArH), 9.67 (1H, s, NH) (OH too broad - not visible).
17	(^{1}H, DMSO) 1.37 (6H, d, CH3), 4.82 (1H, heptet, CH), 7.18 (2H, d, ArH), 7.24 (1H, dd, ArH), 7.63 (1H, dd, ArH), 7.70 (1H, dd, ArH), 7.82 (2H, d, ArH), 7.92 (2H, d, ArH), 8.07 (2H, d, ArH), 10.16 (1H, s, NH) (OH too broad - not visible)
18	(^{1}H, DMSO) 3.91 (3H, s, OMe), 6.94 (1H, dt, ArH), 7.16-7.25 (3H, m, ArH) 7.62 (1H, d, ArH), 7.70 (1H, m, ArH), 7.77 (1H, t, ArH), 8.09 (2H, d, ArH), 8.15 (1H, d, ArH), 8.27 (1H, br d, ArH), 10.07 (1H, br s, NH)
19	(^{1}H, DMSO) 7.33 (1H, dd, ArH), 7.76 (2H, d, ArH), 7.74-7.75 (2H, m, ArH), 7.80 (2H, d, ArH), 7.90 (2H, d, ArH), 8.23 (2H, d, ArH), 10.20 (1H, s, NH), 12.47 (1H, s, OH)
20	(^{1}H, DMSO) 7.13 (1H, bs, NH), 7.31 (1H, dd, ArH), 7.65 (2H, d, ArH), 7.70-7.82 (5H, m, ArH and NH), 7.86 (2H, d, ArH), 8.23 (2H, d, ArH), 10.04 (1H, s, NH)
21	(^{1}H, DMSO) 6.94 (1H, dd, ArH), 7.34 (2H, dd, ArH), 7.43 (1H, dd, ArH), 7.74-7.80 (5H, m, ArH), 8.35 (1H, q, ArH), 8.98 (1H, dd, ArH), 9.78 (1H, s, NH)
22	(^{1}H, DMSO) 3.90 (3H, s, OMe), 7.16 (2H, d, ArH), 7.33 (1H, dd, ArG), 7.72 (1 H, d, Ar), 7.76-7.81 (1 H, m, Ar), 7.99 (2 H, d, Ar), 8.96 (1 H, br, NH), 9.39 (1 H, br, NH), 11.11 (1 H, br, NH)
24	(^{1}H, DMSO) 2.57 (3H, s, Me), 3.83 (3H, s, OMe), 3.92 (3H, s, OMe), 7.18 (2H, d, ArH), 7.35 (1H, dd, ArH), 7.74-7.80 (2H, m, ArH), 8.12 (2H, d, ArH) 12.2 (1H, br, NH)
25	(^{1}H, DMSO) 7.01 (2H, d, ArH), 7.12 (1H, bs, NH), 7.18 (1H, d, ArH), 7.58 (1H, d, ArH), 7.67 (1H, dd, ArH), 7.77 (2H, d, ArH), 7.77 (1H, bs, NH), 7.85 (2H, d, ArH), 7.98 (2H, d, ArH), 9.98 (1H, s, OH or NH), 10.04 (1H, s, OH or NH).
26	(^{1}H, DMSO) 1.37 (6H, d, CH_3), 4.80 (1H, qn, CH), 7.11 (1H, bs, NH), 7.17 (2H, d, ArH), 7.22 (1H, dd, ArH), 7.61 (1H, dd, ArH), 7.67 (1H, dd, ArH), 7.77 (2H, d, ArH), 7.77 (1H, bs, NH), 7.86 (2H, d, ArH), 8.07 (2H, d, ArH), 10.00 (1H, s, NH).

Cpd #	(δ) NMR data
27	(^{1}H, DMSO) 5.35 (2H, s, CH_2), 7.12 (1H, bs, NH), 7.26 (1H, d, ArH), 7.34 (2H, d, ArH), 7.65 (1H, d, ArH), 7.71 (1H, dd, ArH), 7.76 (1H, bs, NH), 7.76 (2H, d, ArH), 7.86 (2H, d, ArH), 7.14 (2H, d, ArH), 10.02 (1H, s, ArH)
30	(^{1}H, DMSO) 9.97 (1H, s, NH), 8.55 (1H, s, ArH), 8.32 (1H, s, ArH), 8.06 (2H, d, ArH), 7.69 (2H, m, ArH), 7.60 (1H, d, ArH), 7.52 (1H, dd, ArH), 7.17 (3H, m, ArH), 3.89 (3H, s, CH_3).
31	(^{1}H, DMSO) 9.32 (1H, s, NH), 8.06 (2H, d, ArH), 7.60 (3H, m, ArH), 7.49 (1H, d, ArH), 7.17-6.95 (9H, m, ArH), 3.88 (3H, s, CH3), 3.22 (8H, m, 4xCH_2).
32	(^{1}H, DMSO) 10.1 (1H, s, NH), 8.05 (2H, d, ArH), 7.87 (2H, d, ArH), 7.66 (1H, m, ArH), 7.59 (1H, d, ArH), 7.19 (3H, m, ArH), 3.87 (3H, s, CH_3).
34	(^{1}H, DMSO) 9.63 (1H, s, NH), 8.03 (2H, d, ArH), 7.74 (1H, s, ArH), 7.63 (3H, m, arH), 7.51 (1H, d, ArH), 7.43 (1H, s, ArH), 7.15 (5H, m, arH), 6.24 (1H, s, ArH), 5.22 (2H, s, CH_2), 3.87 (3H, s, CH_3).
35	(^{1}H, DMSO) 9.77 (1H, s, NH), 9.18 (1H, s, ArH), 8.03 (2H, d, ArH), 7.75 (3H, m, arH), 7.65 (2H, m, arH), 7.53 (1H, d, ArH), 7.36 (2H, d, ArH), 7.17 (3H, m, ArH), 5.32 (2H, s, CH_2), 3.87 (3H, s, CH_3).
36	(^{1}H, DMSO) 9.68 (1H, s, ArH), 8.61 (1H, s, NH), 8.03 (2H, d, ArH), 7.97 (1H, s, ArH), 7.65 (3H, m, ArH), 7.52 (1H, d, ArH), 7.25 (2H, d, ArH), 7.14 (3H, m, ArH), 5.31 (2H, s, CH_2), 3.87 (3H, s, CH_3).
37	(^{1}H, DMSO) 9.83 (1H, s, NH), 9.57 (1H, s, NH), 8.08 (2H, d, ArH), 7.90 (1H, s, ArH), 7.62 (1H, dd, ArH), 7.51 (1H, d, ArH), 7.37 (1H, d, ArH), 7.13 (5H, m, ArH), 3.87 (3H, s, CH_3), 2.05 (3H, s, CH_3)
38	(^{1}H, DMSO) 9.87 (1H, s, NH), 8.34 (1H, s, ArH), 8.05 (2H, d, ArH), 7.79 (2H, d, ArH), 7.65 (3H, m, ArH), 7.56 (1H, d, ArH), 7.49 (1H, s, ArH), 7.17 (3H, m, ArH), 3.87 (3H, s, CH_3),.
39	(^{1}H, DMSO) 9.97 (1H, s, NH), 8.04 (2H, d, ArH), 7.77 (2H, d, ArH), 7.66 (1H, m, ArH), 7.56 (1H, d, ArH), 7.42 (2H, d, ArH), 7.18 (3H, m, ArH), 4.23 (2H, b, 2xCH), 3.87 (3H, s, CH_3), 3.43 (2H, under water peak, 2xCH), 3.27 (2H, b, 2xCH), 3.08 (2H, b, 2xCH), 2.83 (3H, s, CH_3).
40	(^{1}H, DMSO) 9.87 (1H, s, NH), 8.05 (2H, d, ArH), 7.73 (2H, d, ArH), 7.64 (1H, dd, ArH), 7.55 (1H, d, ArH), 7.31 (2H, d, ArH), 7.15 (3H, m, ArH), 3.87 (3H, s, CH_3), 3.87 (3H, s, CH3), 3.4 (2H, under water peak, 2xCH), 2.87 (2H, b, 2xCH), 1.61 (3H, b, 3xCH), 1.06 (2H, m, 2xCH), 0.92 (3H, d, CH_3)
41	(^{1}H, DMSO) 9.87 (1H, s, NH), 8.05 (2H, d, ArH), 7.73 (2H, d, ArH), 7.65 (1H, dd, ArH), 7.56 (1H, d, ArH), 7.31 (2H, d, ArH), 7.17 (3H, m, ArH), 3.87 (3H, s, CH_3), 3.34 (4H, b, 2xCH_2), 1.61 (2H, b, CH_2), 1.50 (4H, b, 2xCH_2).

Cpd #	(δ) NMR data
42	(^{1}H, DMSO) 9.98 (1H, s, NH), 8.39 (1H, t, NH), 8.04 (2H, d, ArH), 7.80 (2H, d, ArH), 7.74 (2H, d, ArH), 7.66 (1H, dd, ArH), 7.57 (1H, d, ArH), 7.18 (3H, m, ArH), 3.88 (3H, s, CH_3), 3.34 (2H, m, CH_2), 3.08 (2H, m, CH_2), 2.79 (3H, s, CH_3), 2.78 (3H, s, CH_3), 1.87 (2H, m, CH_2).
43	(^{1}H, DMSO) 9.92 (1H, s, NH), 8.05 (2H, d, ArH), 7.91 (1H, d, ArH), 7.78 (2H, d, ArH), 7.71 (2H, d, ArH), 7.66 (2H, d, ArH), 7.64 (1H, dd, ArH), 7.56 (1H, d, ArH), 7.17 (3H, m, ArH), 3.87 (3H, s, CH_3), 3.75 (1H, b, CH), 1.72-1.59 (4H, b, 2xCH_2), 1.14 (6H, m, 3xCH_2).
44	(^{1}H; DMSO) 9.93 (1H, s, NH), 8.20 (1H, t, NH), 8.05 (2H, d, ArH), 7.78 (2H, d, ArH), 7.72 (2H, d, ArH), 7.66 (1H, m, ArH), 7.57 (1H, d, ArH), 7.18 (3H, m, ArH), 3.87 (3H, s, CH_3), 3.4 (4H, under water peak, 2xCH_2), 3.24 (3H, s, CH_3), 1.74 (2H, m, CH_2).
45	(^{1}H, DMSO) 10.46 (1H, s, NH), 10.13 (1H, s, NH), 9.11 (1H, d, ArH), 8.40 (2H, m, ArH), 8.05 (2H, d, ArH), 7.97 (2H, d, ArH), 7.83 (2H, d, ArH), 7.64 3H, m, ArH), 7.19 (3H, m, ArH), 3.88 (3H, s, CH_3),
46	(^{1}H, DMSO) 10.0 (1H, s, NH), 8.94 (1H, t, NH), 8.72 (1H, s, ArH), 8.64 (1H, d, ArH), 8.13 (1H, d, ArH), 8.04 (2H, d, ArH), 7.84 (2H, d, ArH), 7.75 (2H, d, ArH), 7.66 (2H, m, ArH), 7.56 (1H, d, ArH), 7.17 (3H, m, ArH), 4.56 (2H, d, CH_2), 3.87 (3H, s, CH_3)
47	(^{1}H, DMSO) 10.02 (1H, s, NH), 9.00 (1H, t, NH), 8.65 (1H, d, ArH), 8.12 (1H, m, ArH), 8.05 (2H, d, ArH), 7.87 (2H, d, ArH), 7.77 (2H, d, ArH), 7.68-7.56 (4H, m, ArH), 7.18 (3H, m, ArH), 4.66 (2H, d, CH_2), 3.87 (3H, s, CH_3),
49	(^{1}H, DMSO) 9.97 (1H, s, NH), 8.79 (1H, t, NH), 8.05 (2H, d, ArH), 7.85 (2H, d, ArH), 7.74 (2H, d, ArH), 7.66 (1H, dd, ArH), 7.56 (1H, d, ArH), 7.32 (4H, m, ArH), 7.26 (4H, m, ArH), 4.47 (2H, d, ArH), 3.87 (3H, s, CH_3)
50	(^{1}H, DMSO), 9.92 (1H, s, NH), 8.05 (2H, d, ArH), 7.93 (1H, d, NH), 7.79 (2H, d, ArH), 7.72 (2H, d, ArH), 7.65 (1H, d, ArH), 7.56 (1H, d, ArH), 7.19 (3H, m, ArH), 4.10 (1H, m, CH), 3.88 (3H, s, CH_3), 1.16 (6H, d, 2xCH_3)
51	(^{1}H, DMSO) 10.0 (1H, s, NH), 8.53 (1H, t, NH), 8.04 (2H, d, ArH), 7.82 (2H, d, ArH), 7.75 (2H, d, ArH), 7.65 (1H, dd, ArH), 7.56 (1H, d, ArH), 7.16 (3H, m, ArH), 3.87 (3H, s, CH3), 3.74 (2H, m, CH_2), 3.34 (2H, m, CH_2), 3.06 (2H, b, CH_2), 2.02 (2H, b, CH_2), 1.87 (2H, b, CH_2)
52	(^{1}H, DMSO) 10.06 (1H, s, NH), 9.54 (1H, s, NH), 8.05 (2H, d, ArH), 7.92 (2H, d, ArH), 7.80 (2H, d, ArH), 7.67 (1H, m, ArH), 7.59 (1H, d, ArH), 7.18 (3H, m, ArH), 3.87 (3H, s, CH_3), 2.29 (3H, s, CH_3), 2.12 (3H, s, CH_3).

Cpd #	(δ) NMR data
53	(^{1}H, DMSO) 9.87 (1H, s, NH), 8.05 (2H, d, ArH), 7.73 (2H, d, ArH), 7.65 (1H, dd, ArH), 7.56 (1H, d, ArH), 7.32 (2H, d, ArH), 7.14 (3H, m, ArH), 3.87 (3H, s, CH_3), 3.8 (1H, very broad, CH), 3.73 (2H, m, 2xCH), 3.17 (2H, m, 2xCH), 1.73 (2H, m, CH_2), 1.35 (2H, m, CH_2)
54	(^{1}H, DMSO) 9.93 (1H, s, NH), 8.04 (2H, d, ArH), 7.96 (1H, d, NH), 7.79 (2H, d, ArH), 7.71 (2H, d, ArH), 7.64 (1H, dd, ArH), 7.56 (1H, d, ArH), 7.17 (3H, m, ArH), 3.85 (3H, s, CH_3), 3.76 (1H, m, CH), 2.79 (2H, b, CH_2), 2.18 (3H, s, CH_3), 1.99 (2H, b, CH_2), 1.76 (2H, b, CH_2), 1.58 (2H, m, CH_2).
55	(^{1}H, DMSO), 9.94 (1H, s, NH), 8.06 (2H, d, ArH), 7.78 (2H, d, ArH), 7.68-7.56 (4H, m, ArH), 7.4 (1H, b, ArH), 7.28 (2H, b, ArH), 7.17 (3H, m, ArH), 7.03 (1H, b, ArH), 4.87 (4H, s, 2xCH_2), 3.87 (3H, s, CH_3).
71	(^{1}H, DMSO) 9.72 (1H, s, NH), 9.51 (1H, s, NH), 8.09 (2H, d, ArH), 7.66 (3H, m, ArH), 7.58 (3H, m, ArH), 7.43 (2H, d, ArH), 7.19 (1h, m, Arh), 2.00 (3H, s, CH_3).
72	(^{1}H, DMSO) 9.72 (1H, s, NH), 9.47 (1h, s, NH), 8.02 (2H, d, ArH), 7.60 (3H, m, ArH), 7.49 (2h, d, ArH), 7.43 (1H, d, ArH), 7.12 (3H, m, ArH), 4.7§ (1H, m, CH), 2.00 (3H, s, CH_3), 1.33 (6H, d, 2xCH_3).
74	(^{1}H, DMSO) 10.01 (1H, s, NH), 8.47 (1H, t, NH), 8.04 (2H, d, ArH), 7.79 (4H, m, ArH), 7.66 (1H, m, ArH), 7.57 (1H, d, ArH), 7.18 (3H, m, ArH), 3.88 (3H, s, CH3), 3.59 (2H, m, CH_2), 3.25 (2H, m, CH_2), 2.86 (3H, s, CH_3), 2.85 (3H, s, CH_3).
76	(^{1}H,DMSO) 10.06 (1H, s, NH), 10.03 (1H, s, NH), 8.50 (1H, s, ArH), 8.05 (3H, m, ArH), 7.93 (2H, d, ArH), 7.80 (2H, d, ArH), 7.66 (1H, m, ArH), 7.58 (1H, d, ArH), 7.18 (3H, m, ArH), 6.83 (1H, d, ArH), 3.88 (3H, s, CH_3), 3.84 (3H, s, CH_3).
77	(^{1}H, DMSO) 9.94 (1H, s, NH), 8.56 (1H, t, NH), 8.06 (2H, d, ArH), 7.82 (2H, d, ArH), 7.72 (2H, d, ArH), 7.65 (1H, dd, ArH), 7.57 (1H, d, ArH), 7.17 (3H, m, ArH).
78	(^{1}H, DMSO) 9.92 (1H, s, NH), 8.34 (1H, t, NH), 8.04 (2H, d, ArH), 7.78 (2H, d, ArH), 7.71 (2H, d, ArH), 7.67 (1H, m, ArH), 7.56 (1H, d, ArH), 7.15 (3H, m, ArH), 4.18 (2H, d, CH_2), 3.87 (3H, s, CH_3), 3.62 (3H, s, CH_3), 2.23 (3H, s, CH_3), 2.13 (3H, s, CH_3).
79	(^{1}H, DMSO) 9.93 (1H, s, NH), 9.07 (1H, s, ArH), 8.04 (2H, d, ArH), 7.76 (2h, d, ArH), 7.73 (1H, s, ArH), 7.70 (1H, m, ArH), 7.56 (1H, d, ArH), 7.44 (2H, d, ArH), 7.16 (3H, m, ArH), 4.73 (2H, s, CH_2), 3.87 (3H, s, CH_3), 3.8 (3H, under water peak, CH_3), 2.96 (3h, s, CH_3).
80	(^{1}H, DMSO) 9.90 (1H, s, NH), 8.04 (2H, d, ArH), 7.75 (2H, d, ArH), 7.65 (1H, dd, ArH), 7.56 (1H, d, ArH), 7.39 (2H, d, ArH), 7.19 (3H, m, ArH), 6.02 (1h, s, ArH), 4.62 (2H, s, CH_2), 3.87 (3H, s, CH_3), 2.91 (3H, s, CH_3), 2.12 (3H, s, CH_3).

Cpd #	(δ) NMR data
81	(^{1}H, DMSO) 9.93 (1H, s, NH), 8.05 (2H, d, ArH), 7.80 (2H, d, ArH), 7.72 (2H, d, ArH), 7.67 (2H, m, ArH, NH), 7.56 (1H, d, ArH), 7.17 (3H, m, ArH), 3.95 (1H, m, CH), 3.88 (2H, s, CH_3), 3.53 (4H, d, 2xCH_2).
82	(^{1}H, DMSO) 9.95 (1H, s, NH), 8.27 (1H, t, NH), 8.04 (2H, d, ArH), 7.97 (1H, t, NH), 7.78 (2H, d, ArH), 7.74 (2h, d, ArH), 7.65 (1H, m, ArH), 7.57 (1H, d, ArH), 7.17 (3H, m, ArH), 3.88 (3H, s, CH_3), 3.29 (2H, m, CH_2), 3.20 (2H, m, CH_2), 1.18 (3H, s, CH_3)
83	(^{1}H, DMSO) 9.97 (1H, s, NH), 8.68 (1H, t, NH), 8.04 (2H, d, ArH), 7.81 (2H, d, ArH), 7.73 (2H, d, ArH), 7.64 (1H, m, ArH), 7.57 (1h, d, ArH), 7.17 (3h, m, ArH), 5.92 1H, s, ArH), 4.42 (2H, d, CH_2), 3.87 (3H, s, CH_3), 3.73 (3H, s, CH_3), 2.08 (3H, s, CH_3)
84	(^{1}H, DMSO) 9.96 (1H, s, NH), 8.33 (1H, t, NH), 8.04 (2H, d, ArH), 7.79 (2H, d, ArH), 7.73 (2H, d, ArH), 7.65 (1H, m, ArH), 7.56 (1H, d, ArH), 7.17 (3H, m, ArH), 3.88 (3H, s, CH_3), 3.35 (1H, m, CH), 3.10 (2H, m, CH_2), 3.05 (2h, m, CH_2), 2.83 (2H, m, CH_2), 1.86 (3H, b, 3xCH), 1.40 (2H, m, CH_2), 1.20 (3H, t, CH_3)
85	(^{1}H, DMSO) 9.86 (1H, s, NH), 8.43 (1H, s, ArH), 8.09 (2H, d, ArH), 7.89 (1H, d, ArH), 7.65 (1H, m, ArH), 7.55 (1H, d, ArH), 7.46 (1H, d, ArH), 7.42 (1H, m, ArH), 7.18 (3H, m, ArH), 4.31 (2H, q, CH_2), 3.87 (3H, s, CH_3), 2.30 (3H, CH_3)
87	(^{1}H, $CDCl_3$), 8.01 (2H, d, ArH), 7.84 (1H, m, ArH), 7.77 (2H, d, ArH), 7.62 1H, d, ArH), 7.47 (2H, d, Arh), 7.32 (1H, d, Arh), 7.14 (2H, d, ArH), 3.7 (3H, s, CH_3), 3.66 (8H, b, 4xCH_2), 2.16 (3H, s, CH_3).
88	(^{1}H, DMSO), 9.97 (1H, s, NH), 8.84 (1H, t, NH), 8.05 (2H, d, ArH), 7.82 (2H, d, ArH), 7.74 (2H, d, ArH), 7.66 (1h, m, ArH), 7.57 (1H, d, ArH), 7.17 (3H, m, ArH), 3.88 (3H, s, CH_3), 3.80 (2H, d, CH_2).
89	(^{1}H, DMSO) 10.40 (1H, s, NH), 10.11 (1H, s, NH), 10.07 (1H, s, NH), 8.70 (1H, s, ArH), 8.05 (4H, m, ArH), 7.94 (2H, d, ArH), 7.81 (2H, d, ArH), 7.67 (1H, m, ArH), 7.59 (1H, d, ArH), 7.19 (3H, m, ArH), 3.88 (3H, s, CH_3), 2.08 (3H, s, CH_3).
91	(^{1}H, DMSO) 10.50 (1H, s, NH), 10.02 (1H, s, NH), 8.05 (2H, d, ArH), 7.97 (2h, d, ArH), 7.76 (2H, d, ArH), 7.66 (1h, m, arH), 7.59 (éh, d, arH), 7.17 (3H, m, ArH), 6.5è (1H, s, ArH), 3.88 (3H, s, CH_3), 3.78 (3h, s, CH_3).
92	(^{1}H, DMSO) 10.08 (1H, s, NH), 9.29 (1H, s, NH), 8.14 (1H, d, ArH), 8.06 (2H, d, ArH), 7.96 (3H, m, ArH), 7.81 (2H, d, ArH), 7.66 (1H, m, ArH), 7.59 (1H, d, ArH), 7.19 (3H, m, arh), 7.03 (1H, m, ArH), 3.94 (3H, s, CH_3), 3.88 (3H, s, CH_3).

Cpd #	(δ) NMR data
93	(^{1}H, DMSO) 10.08 (1H, s, NH), 9.96 (1H, s, NH), 8.05 (2H, d, ArH), 7.91 (2H, d, ArH), 7.80 (2h, d, ArH), 7.67 (1H, m, ArH), 7.58 (1H, d, ArH), 7.19 (3H, m, ArH), 5.96 (1H, s, ArH), 3.88 (3H, s, CH_3), 3.57 (3H, s, CH_3), 1.82 (1H, m, CH), 0.83 (2H, m, CH_2), 0.62 (2H, m, CH_2).
94	(^{1}H, DMSO) 9.83 (1H, s, NH), 8.50 (1H, s, ArH), 8.13 (2H, d, ArH), 7.81 (1H, d, ArH), 7.64 (1H, dd, ArH), 7.55 (1H, d, ArH), 7.45 (1H, d, Arh), 7.38 (1H, m, ArH), 7.21 (1H, d, ArH), 7.15 (2H, d, ArH), 3.88 (3H, s, CH_3)
101	(^{1}H, DMSO) 10.08 (1H, s, NH), 9.92 (1H, s, NH), 8.05 (2H, d, ArH), 7.91 (2H, d, ArH), 7.80 (2H, d, ArH), 7.67 (1H, dd, ArH), 7.59 (1H, d, ArH), 7.15 (3H, m, ArH), 5.96 (1H, s, ArH), 3.03 (5H, m, CH_2, CH_3), 2.14 (3H, s, CH_3), 1.28 (3H, t, CH_3).
102	(^{1}H, DMSO) 9.84 (1H, s, NH), 8.06 (2H, d, ArH), 7.87 (1H, m, ArH), 7.74 (1H, d, ArH), 7.64 (1H, dd, ArH), 7.57 (1H, d, ArH), 7.37 (1H, m, ArH), 7.19 (3h, m, ArH), 3.87 (3H, s, CH_3), 3.5 (4H, under water peak, 2xCH_2), 3.08 (4H, b, 2xCH_2), 2.84 (3H, s, CH_3).
103	(^{1}H, DMSO) 9.77 (1H, s, NH), 8.04 (2H, d, ArH), 7.82 (1H, s, ArH), 7.64 (2H, m, ArH), 7.55 (1H, d, ArH), 7.31 (1H, m, ArH), 7.16 (3H, m, ArH), 6.82 (1H, d, ArH), 3.87 (3H, s, CH_3), 3.57 (2H, b, 2xCH), 3.2 (2H, under water peak, 2xCH), 1.60 (6H, b, 3xCH_2).
104	(^{1}H, DMSO) 9.83 (1H, s, NH), 9.71 (1H, s, NH), 8.35 (1H, s, ArH), 8.11 (2H, d, ArH), 7.84 (1H, d, ArH), 7.66 (1H, m, ArH), 7.55 (1H, d, ArH), 7.42 (2H, m, ArH), 7.20 (1h, d, ArH), 7.12 (2H, d, ArH), 3.82 (3H, s, CH_3), 2.31 (3h, s, CH_3), 2.13 (3H, s, CH_3).
106	(^{1}H, DMSO), 9.77 (1H, s, NH), 8.50 (1H, t, NH), 8.21 (1H, s, ArH), 8.11 (2H, d, ArH), 7.84 (1h, d, ArH), 7.84 (1H, m, ArH), 7.54 (1H, d, ArH), 7.36 (2H, m, ArH), 7.19 (3H, m, ArH), 3.88 (3H, s, CH3), 3.35 (2H, m, CH_2), 3.10 (2H, m, CH_2), 2.79 (6H,2xs, 2xCH_3), 1.90 (2H, m, CH_2).
107	(^{1}H, DMSO), 9.81 (1H, s, NH), 8.03 (2H, d, ArH), 7.89 (1H, s, ArH), 7.67 (1H, m, ArH), 7.56 (1H, d, ArH), 7.34 (1H, m, ArH), 7.14 (3H, m, ArH), 6.90 (1H, d, ArH), 3.86 (3H, s, CH_3), 3.45 (8H, b partially under water peak, 4xCH_2), 2.01 (3H, b, CH_3).
108	(^{1}H, DMSO) 9.74 (1H, s, NH), 8.36 (1H, t, NH), 8.20 (1H, s, ArH), 8.11 (2H, d, ArH), 7.95 (1H, t, NH), 7.81 (1H, d, ArH), 7.64 (1H, dd, ArH), 7.56 (1H, d, ArH), 7.29 (2H, m, ArH), 7.14 (3h, m, ArH), 3.85 (3H, s, CH_3), 3.34 (2H, under water peak, CH_2), 3.24 (2H, m, CH2), 1.81 (3H, s, CH_3).
109	(^{1}H, DMSO) 9.78 (1H, s, NH), 9.01 (1H, t, NH), 8.57 (1H, d, ArH), 8.3 (1H, s, ArH), 8.11 (2H, d, ArH), 7.88 (1H, t, ArH), 7.84 (1H, d, ArH), 7.64 (1H, dd, ArH), 7.55 (1H, d, ArH), 7.43 (4H, m, ArH), 7.19 (1H, d, ArH), 7.14 (2H, d, ArH), 4.63 (2H, d, CH_2), 3.83 (3H, s, CH_3).

Cpd #	(δ) NMR data
110	(^{1}H, DMSO) 9.77 (1H, b, NH), 8.36 (1H, d, NH), 8.20 (1H, m, ArH), 8.09 (2H, d, ArH), 7.82 (1H, d, Arh), 7.64 (1H, m, ArH), 7.55 (1H, d, arH), 7.34 (2H, m, ArH), 7.19 (3H, m, ArH), 3.87 (3H, s, CH_3), 3.47 (1H, b, CH), 3.32 (1H, b, CH), 3.07 (3H, b, 3xCH), 2.79 (3H, s, CH_3), 2.05 (2H, b, CH_2), 1.77 (2H, b, CH_2).
111	(^{1}H, DMSO) 9.78 (1H, s, NH), 9.02 (1H, t, NH), 8.66 (1H, s, arH), 8.57 (1H, d, ArH), 8..29 (1H, s, ArH), 8.11 (2H, d, ArH), 7.96 (1H, d, ArH), 7.80 (1H, m, arH), 7.64 (1H, dd, ArH), 7.56 (2H, m, ArH), 7.37 (2H, d, ArH), 7.18 (3H, m, ArH), 4.54 (2H, d, CH_2), 3.84 (3H, s, CH_3).
112	(^{1}H, DMSO) 9.76 (1H, s, NH), 8.91 (1H, t, NH), 8.27 (1H, s, ArH), 8.11 (2H, d, ArH), 7.82 (1H, m, ArH), 7.64 (1H, dd, ArH), 7.55 (1H, d, ArH), 7.35 (5H, m, ArH), 7.14 (5H, m, ArH), 4.48 (2H, d, CH_2), 3.84 (3H, s, CH_3).
122	(^{1}H, DMSO) 9.95 (1H, s, NH), 8.05 (2H, d, ArH), 7.81 (2H, d, ArH), 7.72 (2H, d, ArH), 7.66 (1H, dd, ArH), 7.58 (1H, d, ArH), 7.17 (3H, m, ArH), 3.88 (3H, s, CH3).
123	(^{1}H, DMSO) 9.73 (1H, s, NH), 8.26 (1H, s, ArH), 8.13 (2H, d, Arh), 7.77 (1H, b, NH), 7.75 (1H, d, ArH), 7.64 (1H, m, ArH), 7.55 (1H, d, ArH), 7.30 (3H, m, NH, ArH), 7.19 (3H, m, ArH), 3.87 (3H, s, CH_3).
127	(^{1}H, DMSO), 9.85 (1H, b, NH), 8.80 (1H, s, NH), 8.15 (6H, m, ArH), 7.67 (1H, dd, ArH), 7.56 (1H, d, ArH), 7.16 (3H, m, ArH), 3.88 (3H, s, CH_3).
128	(^{1}H, DMSO) 10.16 (1H, s, NH), 8.97 (1H, s, ArH), 8.33 (3H, m, ArH), 8.06 (3H, tapp, ArH), 7.98 (2H, d, ArH), 7.69 (1H, m, ArH), 7.60 (1H, d, ArH), 7.19 (3H, m, ArH), 3.89 (3H, s, CH_3), 3.24 (3H, s, CH_3).
132	(^{1}H, DMSO) 9.99 (1H, s, NH), 8.91 (1H, s, ArH), 8.25 (1H, d, ArH), 8.05 (2H, d, ArH), 7.99 (1H, d, ArH), 7.90 (1H, d, ArH), 7.67 (1H, dd, ArH), 7.58 (1H, d, ArH), 7.39 (2H, d, ArH), 7.19 (3H, m, ArH), 4.54 (2H, s, CH_2), 3.89 (3H, s, CH_3).
134	(^{1}H, DMSO) 10.05 (1H, s, NH), 9.78 (1H, s, NH), 8.93 (1H, s, ArH), 8.28 (1H, d, Arh), 8.05 (2H, d, ArH), 7.89 (2H, m, ArH), 7.73 (1H, d, ArH), 7.68 (1H, m, ArH), 7.60 (1H, d, ArH), 7.44 (1H, m, ArH), 7.21 (4H, m, ArH), 3.89 (3h, s, CH_3), 3.02 (3H, s, CH_3).
135	(^{1}H, DMSO), 10.04 (1H, s, NH), 8.96 (1H, s, ArH), 8.53 (1H, m, NH), 8.47 (1H, s, ArH), 8.30 (1H, d, ArH), 8.18 (1H, d, ArH), 8.07 (2H, d, ArH), 7.98 (1H, d, ArH), 7.80 (1H, d, ArH), 7.68 (1H, dd, ArH), 7.61 (1H, d, ArH), 7.58 (1H, m, ArH), 7.19 (3H, m, ArH), 3.89 (3H, s, CH_3), 2.83 (3H, d, CH_3).

Cpd #	(δ) NMR data
137	^{1}H NMR δ (ppm)(DMSO-d$_6$): (9.98 (1H, b, NH), 8.91 (1H, s, ArH), 8.25 (1h, d, ArH), 8.05 (2H, d, ArH), 7.99 (2H, d, ArH), 7.90 (1H, d, ArH), 7.67 (1H, dd, ArH), 7.59 (1H, d, ArH), 7.38 (2H, d, ArH), 7.18 (3H, m, ArH), 3.89 (3H, s, CH_3), 3.60 (4H, m, 2xCH_2), 3.50 (2H, s, CH_2), 2.38 (4H, m, 2xCH_2).
138	^{1}H NMR δ (ppm)(DMSO-d$_6$): 3.91 (3 H, s, CH_3), 7.10-7.21 (5 H, m, ArH), 7.56 (1 H, d, ArH), 7.62-7.69 (1 H, m, ArH), 7.69-7.76 (2 H, m, ArH), 8.07 (1 H, s, ArH), 8.09 (1 H, s, ArH), 9.67 (1 H, s, NH).
139	^{1}H NMR δ (ppm)(DMSO-d$_6$): 3.90 (3 H, s, CH_3), 4.04 (2 H, s, CH_2), 7.16 (2 H, d, ArH), 7.34 (1 H, dd, ArH), 7.69-7.75 (2 H, m, ArH), 8.10 (2 H, d, ArH), 12.05 (1 H, s, NH).
140	^{1}H NMR δ (ppm)(DMSO-d$_6$): 1.56 (3 H, d, CH_3), 3.90 (3 H, s, CH_3), 4.31 (1 H, q, CH), 7.16 (2 H, d, ArH), 7.33 (1 H, dd, ArH), 7.66-7.76 (2 H, m, ArH), 8.10 (2 H, d, ArH), 12.04 (1 H, s, NH).
141	^{1}H NMR δ (ppm)(DMSO-d$_6$): 3.00 (6 H, s, CH_3), 3.91 (3 H, s, CH_3), 7.16-7.23 (3 H, m, ArH), 7.40 (2 H, d, ArH), 7.60 (1 H, dd, ArH), 7.69 (1 H, dd, ArH), 7.77 (2 H, d, ArH), 8.09 (2 H, d, ArH), 9.93 (1 H, s, NH).
142	^{1}H NMR δ (ppm)(DMSO-d$_6$): 2.80 (3 H, d, CH_3), 3.92 (3 H, s, CH_3), 7.14-7.27 (3 H, m, ArH), 7.61 (1 H, d, ArH), 7.64-7.73 (1 H, m, ArH), 7.77 (2 H, d, ArH), 7.81 (2 H, d, ArH), 8.09 (2 H, d, ArH), 8.22 (1 H, d, NH), 9.99 (1 H, s, NH).
143	^{1}H NMR δ (ppm)(DMSO-d$_6$): 3.91 (3 H, s, CH_3), 6.70 (1 H, td, ArH), 7.14-7.25 (3 H, m, ArH), 7.32 (1 H, q, ArH), 7.43 (1 H, d, ArH), 7.61 (1 H, d, ArH), 7.64-7.77 (2 H, m, ArH), 8.07 (2 H, d, ArH), 9.94 (1 H, s, NH).
144	^{1}H NMR δ (ppm)(DMSO-d$_6$): 3.91 (3 H, s, CH_3), 7.11 (1 H, d, ArH), 7.20 (2 H, d, ArH), 7.30 (1 H, dd, ArH), 7.39 (1 H, d, ArH), 7.65 (1 H, dd, ArH), 7.74 (1 H, dd, ArH), 8.15 (2 H, d, ArH), NH not visible.
145	^{1}H NMR δ (ppm)(DMSO-d$_6$): 3.92 (3 H, s, CH_3), 7.21 (2 H, d, ArH), 7.25 (1 H, dd, ArH), 7.64 (1 H, dd, ArH), 7.72 (1 H, dd, ArH), 7.83 (2 H, d, ArH), 7.95 (2 H, d, ArH), 8.09 (2 H, d, ArH), 10.23 (1 H, s, NH), 3 H under DMSO.

Cpd #	(δ) NMR data
146	^{1}H NMR δ (ppm)(DMSO-d$_6$): 2.27 (3 H, s, CH_3), 3.05 (6 H, s, CH_3), 3.90 (3 H, s, CH_3), 7.16 (2 H, d, ArH), 7.29 (1 H, d, ArH), 7.66 (1 H, d, ArH), 7.70-7.77 (1 H, m, ArH), 8.11 (2 H, d, ArH), NH not visible.
147	^{1}H NMR δ (ppm)(DMSO-d$_6$): 3.63 (3 H, s, CH_3), 3.78 (6 H, s, CH_3), 3.89 (3 H, s, CH_3), 7.13 (4 H, d, ArH), 7.17 (1 H, dd, ArH), 7.53 (1 H, dd, ArH), 7.66 (1 H, dd, ArH), 8.10 (2 H, d, ArH), 9.50 (1 H, s, NH).
148	^{1}H NMR δ (ppm)(DMSO-d$_6$): 1.44 (6 H, s, CH_3), 3.91 (3 H, s, CH_3), 4.86 (1 H, s, OH), 7.14-7.21 (3 H, m, ArH), 7.38 (2 H, d, ArH), 7.55 (1 H, dd, ArH), 7.60-7.68 (3 H, m, ArH), 8.09 (2 H, d, ArH), 9.52 (1 H, s, NH).
149	^{1}H NMR δ (ppm)(DMSO-d$_6$): 2.18 (3 H, s, CH_3), 3.92 (6 H, d, CH_3), 7.16-7.23 (3 H, m, ArH), 7.57-7.64 (3 H, m, ArH), 7.64-7.71 (1 H, m, ArH), 7.75 (2 H, d, ArH), 8.09 (2 H, d, ArH), 9.87 (1 H, s, NH).
150	^{1}H NMR δ (ppm)(DMSO-d$_6$): 3.91 (3 H, s, CH_3), 7.20 (2 H, d, ArH), 7.28 (1 H, d, ArH), 7.68 (1 H, d, ArH), 7.70-7.79 (1 H, m, ArH), 7.99 (1 H, d, ArH), 8.06 (2 H, d, ArH), 8.38 (1 H, dd, ArH), 8.97 (1 H, s, ArH), 10.66 (1 H, s, NH).
151	^{1}H NMR δ (ppm)(DMSO-d$_6$): 2.16 (3 H, s, CH_3), 3.91 (3 H, s, CH_3), 7.17-7.22 (3 H, m, ArH), 7.55-7.63 (3 H, m, ArH), 7.68 (1 H, dd, ArH), 7.74 (2 H, d, ArH), 8.09 (2 H, d, ArH), 9.82 (1 H, s, OH), 10.92 (1 H, s, NH).
152	^{1}H NMR δ (ppm)(DMSO-d$_6$): 1.34 (3 H, d, CH_3), 3.91 (3 H, s, CH_3), 4.67-4.71 (1 H, m, CH), 5.00 (1 H, d, OH), 7.16-7.21 (3 H, m, ArH), 7.27 (2 H, d, ArH), 7.55 (1 H, dd, ArH), 7.63-7.68 (3 H, m, ArH), 8.09 (2 H, d, ArH), 9.56 (1 H, s, NH).
153	(^{1}H, DMSO) 3.92 (3 H, s, CH_3), 7.20 (2 H, d, ArH), 7.25 (1 H, d, ArH), 7.41 (1 H, s, NH), 7.65 (1 H, d, ArH), 7.73 (1 H, dd, ArH), 7.92 (1 H, s, NH), 8.02 (1 H, d, ArH), 8.08 (2 H, d, ArH), 8.32 (1 H, d, ArH), 8.90 (1 H, s, ArH), 10.32 (1 H, s, NH).
154	δH(400 MHz; DMSO-d$_6$) 3.92 (3 H, s, CH_3), 7.17-7.23 (2 H, m, ArH), 7.24 (1 H, dd, ArH), 7.64 (1 H, dd, ArH), 7.72 (1 H, dd, ArH), 8.06-8.10 (2 H, m, ArH), 8.12 (1 H, d, ArH), 8.34 (1 H, dd, ArH), 9.02 (1 H, d, ArH), 10.25 (1 H, s, NH).

Biological Examples

Example 1 – *in vitro* assays

Example 1.1 JAK1 inhibition assay

[00413] Recombinant human JAK1 catalytic domain (amino acids 850-1154; catalog number 08-144) was purchased from Carna Biosciences. 10 ng of JAK1 was incubated with 12.5 µg polyGT substrate (Sigma catalog number P0275) in kinase reaction buffer (15 mM Tris-HCl pH 7.5, 1 mM DTT, 0.01% Tween-20, 10 mM $MgCl_2$, 2 µM non-radioactive ATP, 0.25 µCi 33P-gamma-ATP (GE Healthcare, catalog number AH9968) final concentrations) with or without 5µL containing test compound or vehicle (DMSO, 1% final concentration), in a total volume of 25 µL, in a polypropylene 96-well plate (Greiner, V-bottom). After 45 min at 30 °C, reactions were stopped by adding of 25 µL/well of 150 mM phosphoric acid. All of the terminated kinase reaction was transferred to prewashed (75 mM phosphoric acid) 96 well filter plates (Perkin Elmer catalog number 6005177) using a cell harvester (Perkin Elmer). Plates were washed 6 times with 300 µL per well of a 75 mM phosphoric acid solution and the bottom of the plates was sealed. 40 µL/well of Microscint-20 was added, the top of the plates was sealed and readout was performed using the Topcount (Perkin Elmer). Kinase activity was calculated by subtracting counts per minute (cpm) obtained in the presence of a positive control inhibitor (10 µM staurosporine) from cpm obtained in the presence of vehicle. The ability of a test compound to inhibit this activity was determined as:

[00414] Percentage inhibition = ((cpm determined for sample with test compound present – cpm determined for sample with positive control inhibitor) divided by (cpm determined in the presence of vehicle – cpm determined for sample with positive control inhibitor)) * 100%.

[00415] Dose dilution series were prepared for the compounds enabling the testing of dose-response effects in the JAK1 assay and the calculation of the IC_{50} for each compound. Each compound was routinely tested at concentration of 20µM followed by a 1/3 serial dilution, 8 points (20µM - 6.67µM - 2.22µM - 740nM - 247nM - 82nM - 27nM - 9nM) in a final concentration of 1% DMSO. When potency of compound series increased, more dilutions were prepared and/or the top concentration were lowered (e.g. 5 µM, 1 µM).

[00416] Semi-quantitative score:

* > 1001 nM

** 501-1000 nM

*** 101-500 nM

**** 0.01-100 nM

N/A – not available

[00417] **TABLE III: JAK1 IC_{50} Values of Compounds**

Cpd#	JAK1 IC50 nM
1	****

Cpd#	JAK1 IC50 nM
2	N/A

Cpd#	JAK1 IC50 nM
3	****
4	****
5	***
6	***
7	***
8	***
9	****
10	****
11	****
12	****
13	***
14	***
15	**
16	***
17	****
18	N/A
19	****
20	****
21	***
23	****
24	*
25	****

Cpd#	JAK1 IC50 nM
26	****
27	****
28	**
29	**
30	****
31	***
32	****
33	****
34	****
35	****
36	****
37	****
38	***
39	****
40	***
41	****
42	****
43	****
44	****
45	****
46	****
47	****

Cpd#	JAK1 IC50 nM
49	****
50	****
51	****
52	****
53	****
54	****
55	***
56	**
57	***
58	****
59	***
60	****
61	****
62	***
63	****
64	****
65	****
66	****
67	***
68	****
69	****
70	****

Cpd#	JAK1 IC50 nM
71	****
72	****
73	****
74	****
75	****
76	***
77	****
78	****
79	****
80	****
81	****
82	****
83	****
84	****
85	**
86	**
87	****
88	****
89	****
90	****
91	****
92	***

Cpd#	JAK1 IC50 nM
93	***
94	***
95	****
96	****
97	***
98	****
99	****
100	****
101	****
102	****
103	***
104	***
105	****
106	****
107	****
108	****
109	****
110	****
111	****
112	***
118	****
119	***

Cpd#	JAK1 IC50 nM
120	***
121	****
122	****
123	****
127	****
128	***
129	**
130	****
131	***
132	***
133	***
134	***
135	***
136	***
137	***
138	***
139	*
140	*
141	****
142	****
143	***
144	**

Cpd#	JAK1 IC50 nM
145	****
146	**
147	****
148	****
149	***

Cpd#	JAK1 IC50 nM
150	***
151	****
152	****
153	****
154	****

Example 1.2 JAK2 inhibition assay

[00418] Recombinant human JAK2 catalytic domain (amino acids 808-1132; catalog number PV4210) was purchased from Invitrogen. 0.025mU of JAK2 was incubated with 2.5 µg polyGT substrate (Sigma catalog number P0275) in kinase reaction buffer (5 mM MOPS pH 7.5, 9 mM MgAc, 0.3mM EDTA, 0.06% Brij and 0.6 mM DTT, 1 µM non-radioactive ATP, 0.25 µCi 33P-gamma-ATP (GE Healthcare, catalog number AH9968) final concentrations) with or without 5µL containing test compound or vehicle (DMSO, 1% final concentration), in a total volume of 25 µL, in a polypropylene 96-well plate (Greiner, V-bottom). After 90 min at 30 °C, reactions were stopped by adding of 25 µL/well of 150 mM phosphoric acid. All of the terminated kinase reaction was transferred to prewashed (75 mM phosphoric acid) 96 well filter plates (Perkin Elmer catalog number 6005177) using a cell harvester (Perkin Elmer). Plates were washed 6 times with 300 µL per well of a 75 mM phosphoric acid solution and the bottom of the plates was sealed. 40 µL/well of Microscint-20 was added, the top of the plates was sealed and readout was performed using the Topcount (Perkin Elmer). Kinase activity was calculated by subtracting counts per minute (cpm) obtained in the presence of a positive control inhibitor (10 µM staurosporine) from cpm obtained in the presence of vehicle. The ability of a test compound to inhibit this activity was determined as:

[00419] Percentage inhibition = ((cpm determined for sample with test compound present – cpm determined for sample with positive control inhibitor) divided by (cpm determined in the presence of vehicle – cpm determined for sample with positive control inhibitor)) * 100% .

[00420] Dose dilution series were prepared for the compounds enabling the testing of dose-response effects in the JAK2 assay and the calculation of the IC_{50} for each compound. Each compound was routinely tested at concentration of 20µM followed by a 1/3 serial dilution, 8 points (20µM - 6.67µM - 2.22µM - 740nM - 247nM - 82nM - 27nM - 9nM) in a final concentration of 1% DMSO. When potency of compound series increased, more dilutions were prepared and/or the top concentration was lowered (e.g. 5 µM, 1 µM).

[00421] Semi-quantitative score:

> 1001 nM

501-1000 nM

101-500 nM

0.01-100 nM

[00422] **TABLE IV: JAK2 IC_{50} Values of Compounds**

Cpd#	JAK2 IC50 nM
1	####
2	##
3	####
4	####
5	####
6	####
7	###
8	####
9	####
10	####
11	####
12	####
13	####
14	###
15	####
16	####
17	####
18	#

Cpd#	JAK2 IC50 nM
19	####
20	####
21	###
23	####
24	#
25	####
26	####
27	####
28	####
29	####
30	####
31	####
32	####
33	####
34	####
35	####
36	####
37	####

Cpd#	JAK2 IC50 nM
38	####
39	####
40	####
41	####
42	####
43	####
44	####
45	####
46	####
47	####
49	####
50	####
51	####
52	####
53	####
54	####
55	####
56	###
57	####
58	####
59	####
60	####

Cpd#	JAK2 IC50 nM
61	####
62	####
63	####
64	####
65	####
66	####
67	####
68	####
69	####
70	####
71	####
72	####
73	####
74	####
75	####
77	####
78	####
79	####
80	####
81	####
82	####
83	####

Cpd#	JAK2 IC50 nM
84	####
85	###
86	###
87	####
88	####
89	####
90	####
91	####
92	####
93	####
94	####
95	####
96	####
97	####
98	####
99	####
100	####
101	####
102	####
103	####
104	####
105	####

Cpd#	JAK2 IC50 nM
106	####
107	####
108	####
109	####
110	####
111	####
112	###
118	####
119	###
120	####
121	####
122	####
123	####
127	####
128	####
129	###
130	####
131	###
132	###
133	###
134	####
135	####

Cpd#	JAK2 IC50 nM
136	###
137	####
138	####
139	#
140	#
141	####
142	####
143	####
144	####
145	####

Cpd#	JAK2 IC50 nM
146	###
147	####
148	####
149	####
150	####
151	####
152	####
153	####
154	####

Example 1.3 JAK3 inhibition assay

[00423] Recombinant human JAK3 catalytic domain (amino acids 781-1124; catalog number PV3855) was purchased from Invitrogen. 0.025mU of JAK3 was incubated with 2.5 µg polyGT substrate (Sigma catalog number P0275) in kinase reaction buffer (25 mM Tris pH 7.5, 0.5 mM EGTA, 0.5 mM Na3VO4, 5 mM b-glycerolphosphate, 0.01% Triton X-100, 1 µM non-radioactive ATP, 0.25 µCi 33P-gamma-ATP (GE Healthcare, catalog number AH9968) final concentrations) with or without 5µL containing test compound or vehicle (DMSO, 1% final concentration), in a total volume of 25 µL, in a polypropylene 96-well plate (Greiner, V-bottom). After 105 min at 30 °C, reactions were stopped by adding of 25 µL/well of 150 mM phosphoric acid. All of the terminated kinase reaction was transferred to prewashed (75 mM phosphoric acid) 96 well filter plates (Perkin Elmer catalog number 6005177) using a cell harvester (Perkin Elmer). Plates were washed 6 times with 300 µL per well of a 75 mM phosphoric acid solution and the bottom of the plates was sealed. 40 µL/well of Microscint-20 was added, the top of the plates was sealed and readout was performed using the Topcount (Perkin Elmer). Kinase activity was calculated by subtracting counts per minute (cpm) obtained in the presence of a positive control inhibitor (10 µM staurosporine) from cpm obtained in the presence of vehicle. The ability of a test compound to inhibit this activity was determined as:

[00424] Percentage inhibition = ((cpm determined for sample with test compound present – cpm determined for sample with positive control inhibitor) divided by (cpm determined in the presence of vehicle – cpm determined for sample with positive control inhibitor)) * 100%.

[00425] Dose dilution series were prepared for the compounds enabling the testing of dose-response effects in the JAK3 assay and the calculation of the IC_{50} for each compound. Each compound was routinely tested at concentration of 20μM followed by a 1/3 serial dilution, 8 points (20μM - 6.67μM - 2.22μM - 740nM - 247nM - 82nM - 27nM - 9nM) in a final concentration of 1% DMSO. When potency of compound series increased, more dilutions were prepared and/or the top concentration was lowered (e.g. 5 μM, 1 μM).

[00426] Semi-quantitative score:

+> 1001 nM

++ 501-1000 nM

+++ 101-500 nM

++++ 0.01-100 nM

[00427] **TABLE V: JAK3 IC_{50} Values of Compounds**

Cpd#	JAK3 IC_{50}
1	+++
3	++
4	+++
9	++++
12	+
17	++++
27	+
30	+++
32	++++
33	++++
35	++++

Cpd#	JAK3 IC_{50}
37	++++
39	++++
42	++++
44	++++
46	++++
49	++++
50	++++
51	++++
52	++++
54	++++
58	++++

Cpd#	JAK3 IC_{50}
61	++++
63	+++
66	+++
68	+++
69	++++
70	+++
71	++++
72	++++
74	++++
79	++++
82	++++

Cpd#	JAK3 IC_{50}
84	++++
87	++++
88	++++
90	++++
95	++++
98	++++
102	+++
116	++++
121	+++
124	++++

Example 1.4 TYK2 inhibition assay

[00428] Recombinant human TYK2 catalytic domain (amino acids 871-1187; catalog number 08-147) was purchased from Carna biosciences. 5 ng of TYK2 was incubated with 12.5 µg polyGT substrate (Sigma catalog number P0275) in kinase reaction buffer (25 mM Hepes pH 7.5, 100 mM NaCl, 0.2 mM Na3VO4, 0.1% NP-40, 0.1 µM non-radioactive ATP, 0.125 µCi 33P-gamma-ATP (GE Healthcare, catalog number AH9968) final concentrations) with or without 5µL containing test compound or vehicle (DMSO, 1% final concentration), in a total volume of 25 µL, in a polypropylene 96-well plate (Greiner, V-bottom). After 90 min at 30 °C, reactions were stopped by adding of 25 µL/well of 150 mM phosphoric acid. All of the terminated kinase reaction was transferred to prewashed (75 mM phosphoric acid) 96 well filter plates (Perkin Elmer catalog number 6005177) using a cell harvester (Perkin Elmer). Plates were washed 6 times with 300 µL per well of a 75 mM phosphoric acid solution and the bottom of the plates was sealed. 40 µL/well of Microscint-20 was added, the top of the plates was sealed and readout was performed using the Topcount (Perkin Elmer). Kinase activity was calculated by subtracting counts per minute (cpm) obtained in the presence of a positive control inhibitor (10 µM staurosporine) from cpm obtained in the presence of vehicle. The ability of a test compound to inhibit this activity was determined as:

[00429] Percentage inhibition = ((cpm determined for sample with test compound present – cpm determined for sample with positive control inhibitor) divided by (cpm determined in the presence of vehicle – cpm determined for sample with positive control inhibitor)) * 100%.

[00430] Dose dilution series were prepared for the compounds enabling the testing of dose-response effects in the TYK2 assay and the calculation of the IC_{50} for each compound. Each compound was routinely tested at concentration of 20μM followed by a 1/3 serial dilution, 8 points (20μM - 6.67μM - 2.22μM - 740nM - 247nM - 82nM - 27nM - 9nM) in a final concentration of 1% DMSO. When potency of compound series increased, more dilutions were prepared and/or the top concentration was lowered (e.g. 5 μM, 1 μM).

[00431] Semi-quantitative score:

- > 1001 nM
--501-1000 nM
--- 101-500 nM
---- 0.01-100 nM

[00432] **TABLE VI: TYK2 IC_{50} Values of Compounds**

Cpd #	TYK2 IC50 nM	Cpd #	TYK2 IC50 nM
1	-	42	--
4	-	44	-
9	-	46	-
10	-	48	-
11	-	49	-
32	--	50	-
33	--	51	--
34	-	52	-
35	-	54	---
36	-	58	-
37	-	61	-
39	--	66	-

Cpd #	TYK2 IC50 nM
68	-
69	-
70	-
71	-
72	-
74	--
79	--
82	-
84	--

Cpd #	TYK2 IC50 nM
87	--
88	--
90	--
95	--
98	---
102	-
122	-
127	-

Example 2. Cellular assays

Example 2.1 JAK-STAT signalling assay:

[00433] HeLa cells were maintained in Dulbecco's Modified Eagle's Medium (DMEM) containing 10% heat inactivated fetal calf serum, 100 U/mL penicillin and 100 µg/mL streptomycin. HeLa cells were used at 70 % confluence for transfection. 20,000 cells in 87 µL cell culture medium were transiently transfected with 40 ng pSTAT1(2)-luciferase reporter (Panomics), 8 ng of LacZ reporter as internal control reporter and 52 ng of pBSK using 0.32 µL Jet-PEI (Polyplus) as transfection reagent per well in 96-well plate format. After overnight incubation at 37°C, 10% CO_2, transfection medium was removed. 75 µL of DMEM + 1.5% heat inactivated fetal calf serum was added. 15 µL of compound at 6.7x concentration was added for 60 min and then 10 µL of human OSM (Peprotech) at 33 ng/mL final concentration.

[00434] All compounds were tested in duplicate starting from 20 µM followed by a 1/3 serial dilution, 8 doses in total (20 µM – 6.6 µM – 2.2 µM – 740 nM – 250 nM – 82 nM – 27 nM – 9 nM) in a final concentration of 0.2% DMSO.

[00435] After overnight incubation at 37°C, 10% CO_2 cells were lysed in 100 µL lysis buffer/well (PBS, 0.9 mM $CaCl_2$, 0.5 mM MgCl2, 5% Trehalose, 0.025% Tergitol NP9, 0.15% BSA).

[00436] 40 µL of cell lysate was used to read β-galactosidase activity by adding 180 µL βGal solution (30µl ONPG 4mg/mL + 150 µL β-Galactosidase buffer (0.06 M Na_2HPO_4, 0.04 M NaH_2PO_4, 1 mM $MgCl_2$)) for 20 min. The reaction was stopped by addition of 50 µL Na_2CO_3 1 M. Absorbance was read at 405 nm.

[00437] Luciferase activity was measured using 40 µL cell lysate plus 40 µl of Steadylite® as described by the manufacturer (Perkin Elmer), on the Envision (Perkin Elmer).

[00438] 10 µM of a pan-JAK inhibitor was used as a positive control (100% inhibition). As negative control 0.5% DMSO (0% inhibition) was used. The positive and negative controls were used to calculate z' and 'percent inhibition' (PIN) values.

[00439] Percentage inhibition = ((fluorescence determined in the presence of vehicle - fluorescence determined for sample with test compound present) divided by (fluorescence determined in the presence of vehicle – fluorescence determined for sample without trigger)) * 100 %.

[00440] PIN values were plotted for compounds tested in dose-response and EC_{50} values were derived.

* > 1001 nM

**501-1000 nM

*** 1-500 nM

N/A – not available

[00441] **TABLE VII: STAT signalling EC_{50} Values of Compounds**

Cpd #	EC_{50} (nM)
1	***
3	*
4	*
9	**
10	*
11	**
12	*
17	***
19	**
20	***
23	***
25	***
26	***
27	****
30	*
32	**

Cpd #	EC_{50} (nM)
33	***
34	*
35	*
36	**
37	**
39	**
41	*
42	***
43	*
44	****
45	***
46	***
47	***
49	***
50	***
51	***

Cpd #	EC_{50} (nM)
52	***
53	**
54	***
58	**
60	**
61	***
63	*
64	*
65	**
66	**
68	***
69	***
70	***
71	***
72	***
73	**
74	*
75	**
77	***
78	***
79	**
80	**
81	***
82	***
83	***
84	***
87	***
88	***
89	**

Cpd #	EC_{50} (nM)
90	**
91	***
95	N/A
96	N/A
98	N/A
99	*
100	**
101	*
102	*
105	*
106	*
107	*
108	N/A
109	N/A
110	*
111	*
118	*
121	*
122	***
123	*
127	*
130	N/A
141	***
142	***
145	***
147	***
148	***
151	**
152	***

Cpd #	EC_{50} (nM)
153	***

Cpd #	EC_{50} (nM)
154	*

Example 2.2 OSM/IL-1β signaling Assay

[00442] OSM and IL-1β were shown to synergistically upregulate MMP13 levels in the human chondrosarcoma cell line SW1353. The cells were seeded in 96 well plates at 15,000 cells/well in a volume of 120 µL DMEM (Invitrogen) containing 10% (v/v) FBS and 1% penicillin/streptomycin (InVitrogen) incubated at 37°C 5% CO_2. Cells were preincubated with 15 µL compound in M199 medium with 2% DMSO 1 hr before triggering with 15 µL OSM and IL-1β to reach 25 ng/mL OSM and 1 ng/mL IL-1β, and MMP13 levels were measured in conditioned medium 48 hours after triggering. MMP13 activity was measured using an antibody capture activity assay. For this purpose, 384 well plates (NUNC, 460518, MaxiSorb black) were coated with 35 µL of a 1.5 µg/mL anti-human MMP13 antibody (R&D Systems, MAB511) solution for 24 hours at 4°C. After washing the wells 2 times with PBS + 0.05% Tween, the remaining binding sites were blocked with 100 µL 5% non-fat dry milk (Santa Cruz, sc-2325, Blotto) in PBS for 24 hours at 4°C. Next, the wells were washed 2 times with PBS + 0.05% Tween and 35 µL of 1/10 dilution of culture supernatant containing MMP13 in 100-fold diluted blocking buffer was added and incubated for 4 hours at room temperature. Next the wells were washed twice with PBS + 0.05% Tween followed by MMP13 activation by addition of 35 µL of a 1.5 mM 4-Aminophenylmercuric acetate (APMA) (Sigma, A9563) solution and incubation at 37 °C for 1 hour. The wells were washed again with PBS + 0.05% Tween and 35 µL MMP13 substrate (Biomol, P-126, OmniMMP fluorogenic substrate) was added. After incubation for 24 hours at 37°C fluorescence of the converted substrate was measured in a Perkin Elmer Wallac EnVision 2102 Multilabel Reader (wavelength excitation: 320 nm, wavelength emission: 405 nm).

[00443] Percentage inhibition = ((fluorescence determined in the presence of vehicle - fluorescence determined for sample with test compound present) divided by (fluorescence determined in the presence of vehicle – fluorescence determined for sample without trigger)) * 100 %.

* > 1001 nM

**501-1000 nM

*** 1-500 nM

N/A – not available

[00444] **TABLE VIII: MMP13 EC_{50} Values of Compounds**

Cpd #	EC_{50} (nM)
1	***
3	**

Cpd #	EC_{50} (nM)
4	*
9	***

Cpd #	EC_{50} (nM)
10	*
11	***
12	*
17	*
20	***
21	*
23	*
25	*
26	***
30	*
31	N/A
32	**
33	N/A
34	*
35	*
36	*
37	*
39	**
41	*
42	***
43	N/A
44	N/A
45	*
46	***
47	**
49	*
50	*
51	**
52	*
53	*

Cpd #	EC_{50} (nM)
54	*
56	N/A
58	*
60	*
61	**
63	*
64	N/A
65	**
66	*
68	*
69	*
70	*
71	***
72	***
73	*
74	***
75	*
77	***
78	***
79	***
80	*
82	***
83	***
84	***
87	*
88	***
89	N/A
90	**
91	N/A
95	*

Cpd #	EC_{50} (nM)
96	*
98	N/A
99	*
100	*
101	N/A
102	*
105	N/A
106	N/A
107	*
108	N/A
109	N/A
110	N/A
111	*
118	*

Cpd #	EC_{50} (nM)
121	*
122	***
123	N/A
127	*
130	N/A
141	****
142	****
145	*
147	*
148	***
151	*
152	***
153	*
154	*

Example 2.3 PBL Proliferation assay

[00445] Human peripheral blood lymphocytes (PBL) are stimulated with IL-2 and proliferation measured using a BrdU incorporation assay. The PBL are first stimulated for 72 hrs with PHA to induce IL-2 receptor, fasted for 24 hrs to stop cell proliferation followed by IL-2 stimulation for another 72 hrs (including 24hr BrdU labeling). Cells are preincubated with test compounds 1 hr before IL-2 addition. Cells are cultured in RPMI 1640 containing 10% (v/v) FBS.

Example 3. *In vivo* models

Example 3.1 CIA model

3.1.1 Materials

[00446] Completed Freund's adjuvant (CFA) and incomplete Freund's adjuvant (IFA) were purchased from Difco. Bovine collagen type II (CII), lipopolysaccharide (LPS), and Enbrel were obtained from Chondrex (Isle d'Abeau, France); Sigma (P4252, L'Isle d'Abeau, France), Whyett (25mg injectable syringe, France) Acros Organics (Palo Alto, CA), respectively. All other reagents used were of reagent grade and all solvents were of analytical grade.

3.1.2 Animals

[00447] Dark Agouti rats (male, 7-8 weeks old) were obtained from Harlan Laboratories (Maison-Alfort, France). DBA/1J mice (male, 7 weeks old) were obtained from Centre d'Elevage et de Reproduction JANVIER (CERJ) (Laval, France). Rats and mice were kept on a 12 hours light/dark cycle (0700 - 1900). The temperature was maintained at 22°C, and food and water were provided *ad libitum*.

3.1.3 Collagen induced arthritis (CIA)

[00448] One day before the experiment, CII solution (2 mg/mL) was prepared with 0.05 M acetic acid and stored at 4°C. Just before the immunization, equal volumes of adjuvant (IFA) and CII were mixed by a homogenizer in a pre-cooled glass bottle in an ice water bath. Extra adjuvant and prolonged homogenization might be required if an emulsion is not formed.

[00449] Mice: 0.1 mL of the emulsion was injected intradermally at the base of the tail of each mouse on day 1, a second booster intradermal injection (CII solution at 1 mg/mL in CFA 0.1 mL saline) was performed on day 21. This immunization method was modified from published methods (David D Brand Kary A Latham, & Edward F Rosloniec. Collagen-induced arthritis. Nature Methods 2 (5): 1269-1275, 2007).

[00450] Rat: 0.2 mL of the emulsion was injected intradermally at the base of the tail of each rat on day 1, a second booster intradermal injection (CII solution at 2 mg/mL in CFA 0.1 mL saline) was performed on day 9. This immunization method was modified from published methods (Sims NA *et al.*, (2004) Targeting osteoclasts with zoledronic acid prevents bone destruction in collagen-induced arthritis, Arthritis Rheum. 50 2338-2346; Jou *et al.*, 2005).

3.1.4 Study design

[00451] The therapeutic effects of the test compounds were tested in the rat or mouse CIA model. Animals were randomly divided into equal groups and each group contained 10 animals. All rats were immunized on day 1 and boosted on day 9. All mice were immunized on day 1 and boosted on day 21. Therapeutic dosing lasted from day 16 to day 30. The negative control group was treated with vehicle (MC 0,5%) and the positive control group with Enbrel (10 mg/kg, 3x week., s.c.). A compound of interest was typically tested at 3 doses, e.g. 3, 10, 30 mg/kg, p.o.

3.1.5 Clinical assessment of arthritis

[00452] Arthritis was scored according the method of Khachigian 2006, Lin *et al* 2007 and Nishida *et al.* 2004). The swelling of each of the four paws was ranked with the arthritic score as follows: 0-no symptoms; 1-mild, but definite redness and swelling of one type of joint such as the ankle or wrist, or apparent redness and swelling limited to individual digits, regardless of the number of affected digits; 2-moderate redness and swelling of two or more types of joints; 3-severe redness and swelling of the entire paw including digits; 4-maximally inflamed limb with involvement of multiple joints (maximum cumulative clinical arthritis score 16 per animal) (Nishida *et al.*, 2004).

3.1.6 Change in body weight (%) after onset of arthritis

[00453] Clinically, body weight loss is associated with arthritis (Shelton *et al.*, 2005; Argiles *et al.*, 1998; Rall, 2004; Walsmith *et al.*, 2004) Hence, changes in body weight after onset of arthritis could be used as a non-specific endpoint to evaluate the effect of therapeutics in the rat model. The change in body weight (%) after onset of arthritis was calculated as follows:

[00454] Mice: $$\frac{\text{Body Weight}_{(week6)} - \text{Body Weight}_{(week5)}}{\text{Body Weight}_{(week5)}} \times 100\%$$

[00455] Rats: $$\frac{\text{Body Weight}_{(week4)} - \text{Body Weight}_{(week3)}}{\text{Body Weight}_{(week3)}} \times 100\%$$

3.1.7 Radiology

[00456] X-ray photos were taken of the hind paws of each individual animal. A random blind identity number was assigned to each of the photos, and the severity of bone erosion was ranked by two independent scorers with the radiological Larsen's score system as follows: 0- normal with intact bony outlines and normal joint space; 1- slight abnormality with any one or two of the exterior metatarsal bones showing slight bone erosion; 2-definite early abnormality with any three to five of the exterior metatarsal bones showing bone erosion; 3-medium destructive abnormality with all the exterior metatarsal bones as well as any one or two of the interior metatarsal bones showing definite bone erosions; 4-severe destructive abnormality with all the metatarsal bones showing definite bone erosion and at least one of the inner metatarsal joints completely eroded leaving some bony joint outlines partly preserved; 5-mutilating abnormality without bony outlines. This scoring system is a modification from Salvemini *et al.*, 2001; Bush *et al.*, 2002; Sims *et al.*, 2004; Jou *et al.*, 2005.

3.1.8 Histology

[00457] After radiological analysis, the hind paws of mice were fixed in 10% phosphate-buffered formalin (pH 7.4), decalcified with rapid bone decalcifiant for fine histology (Laboratories Eurobio) and embedded in paraffin. To ensure extensive evaluation of the arthritic joints, at least four serial sections (5 µm thick) were cut and each series of sections were 100 µm in between. The sections were stained with hematoxylin and eosin (H&E). Histologic examinations for synovial inflammation and bone and cartilage damage were performed double blind. In each paw, four parameters were assessed using a four-point scale. The parameters were cell infiltration, pannus severity, cartilage erosion and bone erosion. Scoring was performed as follows: 1-normal, 2-mild, 3-moderate, 4-marked. These four scores were summed together and represented as an additional score, namely the 'RA total score'.

3.1.9 Micro-computed tomography (µCT) analysis of calcaneus (heel bone):

[00458] Bone degradation observed in RA occurs especially at the cortical bone and can be revealed by µCT analysis (Sims NA *et al.*, 2004; Oste L *et al.*, ECTC Montreal 2007). After scanning and 3D volume reconstruction of the calcaneus bone, bone degradation was measured as the number of discrete objects present per slide, isolated *in silico* perpendicular to the longitudinal axis of the bone. The more the bone that was

degraded, the more discrete objects that were measured. 1000 slices, evenly distributed along the calcaneus (spaced by about 10.8 μm), are analyzed.

3.1.10 Results

[00459] Selected compounds were tested in the mouse CIA study, Compound 33 was active at 30 mg/kg.

Example 3.2 Septic shock model

[00460] Injection of lipopolysaccharide (LPS) induces a rapid release of soluble tumour necrosis factor (TNF-alpha) into the periphery. This model is used to analyse prospective blockers of TNF release *in vivo*.

[00461] Six BALB/cJ female mice (20 g) per group were treated at the intended dosing once, po. Thirty minutes later, LPS (15 μg/kg; *E. Coli* serotype 0111:B4) was injected ip. Ninety minutes later, mice were euthanized and blood was collected. Circulating TNF alpha levels were determined using commercially available ELISA kits. Dexamethasone (5 μg/kg) was used as a reference anti-inflammatory compound. Selected compounds are tested at one or multiple doses, e.g. 3 and/or 10 and/or 30 mg/kg, po.

[00462] Selected compounds were tested in the septic shock model, Compounds 1, 33, and 72 were active at 30 mg/kg.

Example 3.3 MAB model

[00463] The MAB model allows a rapid assessment of the modulation of an RA-like inflammatory response by therapeutics (Kachigian LM. Nature Protocols (2006) 2512-2516: Collagen antibody-induced arthritis). DBA/J mice are injected i.v. with a cocktail of mAbs directed against collagen II. One day later, compound treatment is initiated (vehicle: 10% (v/v) HPβCD). Three days later, mice receive an i.p. LPS injection (50 μg/mouse), resulting in a fast onset of inflammation. Compound treatment is continued until 10 days after the mAb injection. Inflammation is read by measuring paw swelling and recording the clinical score of each paw. The cumulative clinical arthritis score of four limbs is presented to show the severity of inflammation. A scoring system is applied to each limb using a scale of 0–4, with 4 being the most severe inflammation.

0 Symptom free

1 Mild, but definite redness and swelling of one type of joint such as the ankle or wrist, or apparent redness and swelling limited to individual digits, regardless of the number of affected digits

2 Moderate redness and swelling of two or more types of joints

3 Severe redness and swelling of the entire paw including digits

4 Maximally inflamed limb with involvement of multiple joints

Example 3.4 Oncology models

[00464] *In vivo* models to validate efficacy of small molecules towards JAK2-driven myleoproliferative diseases are described by Wernig *et al.* Cancer Cell 13, 311, 2008 and Geron *et al.* Cancer Cell 13, 321, 2008.

Example 3.5 Mouse IBD model

[00465] *In vitro* and *in vivo* models to validate efficacy of small molecules towards IBD are described by Wirtz *et al.* 2007.

Example 3.6 Mouse Asthma model

[00466] *In vitro* and *in vivo* models to validate efficacy of small molecules towards asthma are described by Nials *et al.*, 2008; Ip *et al.* 2006; Pernis *et al.*, 2002; Kudlacz *et al.*, 2008.

Example 4: Toxicity, DMPK and Safety Models

Example 4.1 Thermodynamic solubility

[00467] A solution of 1 mg/mL of the test compound is prepared in a 0.2M phosphate buffer pH7.4 or a 0.1M citrate buffer pH3.0 at room temperature in a glass vial.

[00468] The samples are rotated in a Rotator drive STR 4 (Stuart Scientific, Bibby) at speed 3.0 at room temperature for 24 hours.

[00469] After 24 hours, 800µL of the sample is transferred to an eppendorf tube and centrifuged 5 min at 14000rpm. 200 µL of the supernatant of the sample is then transferred to a MultiscreenR Solubility Plate (Millipore, MSSLBPC50) and the supernatant is filtered (10-12" Hg) with the aid of a vacuum manifold into a clean Greiner polypropylene V-bottom 96well plate (Cat no.651201). 5 µL of the filtrate is diluted into 95 µL (F20) of the same buffer used to incubate in the plate containing the standard curve (Greiner,Cat no.651201).

[00470] The standard curve for the compound is prepared freshly in DMSO starting from a 10mM DMSO stock solution diluted factor 2 in DMSO (5000µM) and then further diluted in DMSO up to 19.5µM. 3µL of the dilution series as from 5000µM is then transferred to a 97µL acetonitrile-buffer mixture (50/50). The final concentration range is 2.5 to 150 µM.

[00471] The plate is sealed with sealing mats (MA96RD-04S, www.kinesis.co.uk) and samples are measured at room temperature on LCMS (ZQ 1525 from Waters) under optimized conditions using Quanoptimize to determine the appropriate mass of the molecule.

[00472] The samples are analyzed on LCMS with a flow rate of 1mL/min. Solvent A is 15mM ammonia and solvent B is acetonitrile. The sample is run under positive ion spray on an XBridge C18 3.5µM (2.1 x 30mm) column, from Waters. The solvent gradient has a total run time of 2 minutes and ranges from 5% B to 95% B.

[00473] Peak areas are analyzed with the aid of Masslynx software package and peak areas of the samples are plotted against the standard curve to obtain the solubility of the compound.

[00474] Solubility values are reported in µM or µg/mL.

Example 4.2 Aqueous Solubility

[00475] Starting from a 10mM stock in DMSO, a serial dilution of the compound is prepared in DMSO. The dilution series is transferred to a 96 NUNC Maxisorb plate F-bottom (Cat no. 442404) and 0.2M phosphate buffer pH7.4 or 0.1M citrate buffer pH3.0 at room temperature is added.

[00476] The final concentration ranged from 200µM to 2.5µM in 5 equal dilution steps. The final DMSO concentration did not exceed 2%. 200µM Pyrene is added to the corner points of each 96 well plate and serves as a reference point for calibration of Z-axis on the microscope.

[00477] The assay plates are sealed and incubated for 1 hour at 37°C while shaking at 230rpm. The plates are then scanned under a white light microscope, yielding individual pictures of the precipitate per concentration. The precipitate is analyzed and converted into a number which is plotted onto a graph. The first concentration at which the compound appears completely dissolved is the concentration reported, however the true concentration lies somewhere between this concentration and one dilution step higher.

[00478] Solubility values are reported in µg/mL

Example 4.3 Plasma Protein Binding (Equilibrium Dialysis)

[00479] A 10mM stock solution of the compound in DMSO is diluted with a factor 5 in DMSO. This solution is further diluted in freshly thawed human, rat, mouse or dog plasma (BioReclamation INC) with a final concentration of 10µM and final DMSO concentration of 0.5% (5.5µl in 1094.5µl plasma in a PP-Masterblock 96well (Greiner, Cat no. 780285))

[00480] A Pierce Red Device plate with inserts (ThermoScientific, Cat no. 89809) is prepared and filled with 750µL PBS in the buffer chamber and 500µL of the spiked plasma in the plasma chamber. The plate is incubated for 4 hours at 37°C while shaking at 230rpm. After incubation, 120µL of both chambers is transferred to 360µL acetonitrile in a 96-well round bottom, PP deep-well plates (Nunc, Cat no. 278743) and sealed with an aluminum foil lid. The samples are mixed and placed on ice for 30min. This plate is then centrifuged 30 min at 1200rcf at 4°C and the supernatant is transferred to a 96 v-bottom PP plate (Greiner, 651201) for analysis on LCMS.

[00481] The plate is sealed with sealing mats (MA96RD-04S) of www.kinesis.co.uk and samples are measured at room temperature on LCMS (ZQ 1525 from Waters) under optimized conditions using Quanoptimize to determine the appropriate mass of the molecule.

[00482] The samples are analyzed on LCMS with a flow rate of 1mL/min. Solvent A was 15mM ammonia and solvent B was acetonitrile. The sample was run under positive ion spray on an XBridge C18

3.5µM (2.1 x 30mm) column, from Waters. The solvent gradient has a total run time of 2 minutes and ranges from 5% B to 95% B.

[00483] Peak area from the compound in the buffer chamber and the plasma chamber are considered to be 100% compound. The percentage bound to plasma is derived from these results and was reported to the LIMS as percentage bound to plasma.

[00484] The solubility of the compound in the final test concentration in PBS is inspected by microscope to indicate whether precipitation is observed or not.

Example 4.4 Liability for QT prolongation

[00485] Potential for QT prolongation is assessed in the hERG patch clamp assay.

4.4.1 Conventional whole-cell patch-clamp

[00486] Whole-cell patch-clamp recordings are performed using an EPC10 amplifier controlled by Pulse v8.77 software (HEKA). Series resistance is typically less than 10 MΩ and compensated by greater than 60%, recordings are not leak subtracted. Electrodes are manufactured from GC150TF pipette glass (Harvard).

[00487] The external bathing solution contains: 135 mM NaCl, 5 mM KCl, 1.8 mM $CaCl_2$, 5 mM Glucose, 10 mM HEPES, pH 7.4.

[00488] The internal patch pipette solution contains: 100mM Kgluconate, 20 mM KCl, 1mM $CaCl_2$, 1 mM $MgCl_2$, 5mM Na_2ATP, 2mM Glutathione, 11 mM EGTA, 10 mM HEPES, pH 7.2.

[00489] Drugs are perfused using a Biologic MEV-9/EVH-9 rapid perfusion system.

[00490] All recordings are performed on HEK293 cells stably expressing hERG channels. Cells are cultured on 12 mm round coverslips (German glass, Bellco) anchored in the recording chamber using two platinum rods (Goodfellow). hERG currents are evoked using an activating pulse to +40 mV for 1000 ms followed by a tail current pulse to –50 mV for 2000 ms, holding potential was -80 mV. Pulses are applied every 20s and all experiments are performed at room temperature.

4.4.2 Data Analysis

[00491] IC_{50} and IC_{20} values are calculated for each compound tested. The fold difference between the IC_{20} and the unbound C_{max} concentrations of the test compound obtained at relevant therapeutic doses as determined by results obtained from the rat CIA model is calculated.

[00492] For the concentration response curves, peak tail current amplitude is measured during the voltage step to -50 mV. Curve-fitting of concentration-response data is performed using the equation:

$$y = a + [(b - a)/ (1+ 10^{\wedge} ((logc-x) d)]$$

[00493] where a is minimum response, b is maximum response and d is Hill slope, this equation can be used to calculate both IC_{50} (where y = 50 and c is the IC_{50} value) and IC_{20} (where y = 20 and c is the IC_{20} value). GraphPad® Prism® (Graphpad® Software Inc.) software was used for all curve fitting.
A difference of 100 fold or greater indicates a low potential for QT prolongation.

Example 4.5 Microsomal stability

[00494] A 10mM stock solution of compound in DMSO was diluted 1000 fold in a 182 mM phosphate buffer pH7.4 in a 96 deep well plate (Greiner, Cat no.780285) and pre-incubated at 37°C.

[00495] 40µL of deionised water was added to a well of a polypropylene Matrix 2D barcode labelled storage tube (Thermo Scientific) and pre-incubated at 37°C.

[00496] A Glucose-6-phophate-dehydrogenase (G6PDH) working stock solution was prepared in 182mM phosphate buffer pH7.4 and placed on ice before use. A co-factor containing $MgCl_2$, glucose-6-phosphate and NADP+ was prepared in deionised water and placed on ice before use.

[00497] A final working solution containing liver microsomes (Xenotech) of a species of interest (human, mouse, rat, dog), previously described G6PDH and co-factors was prepared and this mix was incubated for no longer than 20 minutes at room temperature.

[00498] 30µL of the pre-heated compound dilution was added to 40µL of pre-heated water in the Matrix tubes and 30µL of the microsomal mix was added. Final reaction concentrations were 3µM compound, 1mg microsomes, 0.4U/mL GDPDH, 3.3mM $MgCl_2$, 3.3mM glucose-6-phosphate and 1.3mM NADP+.

[00499] To measure percentage remaining of compound at time zero MeOH or ACN was added (1:1) to the well before adding the microsomal mix. The plates were sealed with Matrix Sepra sealsTM (Matrix, Cat. No.4464) and shaken for a few seconds ensure complete mixing of all components.

[00500] The samples which were not stopped are incubated at 37°C, 300rpm and after 1 hour of incubation the reaction was stopped with MeOH or ACN (1:1).

[00501] After stopping the reaction the samples were mixed and placed on ice for 30min to precipitate the proteins. The plates were then centrifuged 30 min at 1200rcf at 4°C and the supernatant was transferred to a 96 v-bottom PP plate (Greiner, 651201) for analysis on LCMS.

[00502] These plates were sealed with sealing mats (MA96RD-04S) of www.kinesis.co.uk and samples were measured at room temperature on LCMS (ZQ 1525 from Waters) under optimized conditions using Quanoptimize to determine the appropriate mass of the parent molecule.

[00503] The samples were analyzed on LCMS with a flow rate of 1mL/min. Solvent A was 15mM ammonia and solvent B was methanol or acetonitrile, depending on the stop solution used. The samples were run under positive ion spray on an XBridge C18 3.5µM (2.1 x 30mm) column, from Waters. The solvent gradient had a total run time of 2 minutes and ranges from 5% B to 95% B.

[00504] Peak area from the parent compound at time 0 was considered to be 100% remaining. The percentage remaining after 1 hour incubation was calculated from time 0 and was calculated as the percentage remaining.The solubility of the compound in the final test concentration in buffer is inspected by microscope and results are reported.

[00505] The data on microsomal stability are expressed as a percentage of the total amount of compound remaining after 60 minutes.

* 0-25

** 26-50

*** 51-75

**** 76-100

N/A – not available

TABLE IX – Microsomal stability

Cpd #	Human (%)	Rat (%)
1	*	*
3	*	*
4	*	*
9	*	*
10	***	*
11	*	*
12	**	*
17	****	****
19	***	****
20	N/A	*
23	N/A	N/A
25	*	****
26	***	**
27	***	N/A
30	*	*
32	****	****
33	****	***
34	**	*
35	*	*
36	*	*

Cpd #	Human (%)	Rat (%)
37	**	**
39	**	**
41	*	*
42	***	*
44	*	*
46	*	*
47	**	**
49	**	*
50	****	**
51	***	*
52	***	*
53	**	**
54	***	**
58	*	*
60	**	****
61	*	****
63	**	****
65	**	**
66	*	****
68	*	**
69	****	**
70	*	*
71	*	**
72	**	*
73	****	*
74	***	****
75	*	*
77	*	*
78	*	*
79	*	**
80	*	*
81	***	****
82	*	****

Cpd #	Human (%)	Rat (%)
83	*	*
84	****	**
87	****	****
88	***	****
89	****	*
90	**	*
91	**	****
95	****	****
96	****	****
98	****	****
99	***	***
100	**	*
101	*	*
102	*	*
105	**	**
107	*	*
118	*	*
121	***	****
122	***	***
123	****	****
127	*	*
130	*	*
141	****	N/A
142	****	*
145	*	*
147	**	*
148	***	*
151	N/A	***
152	N/A	*
153	N/A	*
154	*	***

Example 4.6 Caco2 Permeability

[00506] Bi-directional Caco-2 assays were performed as described below. Caco-2 cells were obtained from European Collection of Cell Cultures (ECACC, cat 86010202) and used after a 21 day cell culture in 24-well Transwell plates (Fisher TKT-545-020B).

[00507] $2x10^5$ cells/well were seeded in plating medium consisting of DMEM + GlutaMAXI + 1% NEAA + 10% FBS (FetalClone II) + 1% Pen/Strep. The medium was changed every 2 – 3 days.

[00508] Test and reference compounds (propranolol and rhodamine123 or vinblastine, all purchased from Sigma) were prepared in Hanks' Balanced Salt Solution containing 25 mM HEPES (pH7.4) and added to either the apical (125µL) or basolateral (600µL) chambers of the Transwell plate assembly at a concentration of 10 µM with a final DMSO concentration of 0.25%.

[00509] 50µM Lucifer Yellow (Sigma) was added to the donor buffer in all wells to assess integrity of the cell layers by monitoring Lucifer Yellow permeation. As Lucifer Yellow (LY) cannot freely permeate lipophilic barriers, a high degree of LY transport indicates poor integrity of the cell layer.

[00510] After a 1 hour incubation at 37°C while shaking at an orbital shaker at 150rpm, 70µL aliquots were taken from both apical (A) and basal (B) chambers and added to 100µLl 50:50 acetonitrile:water solution containing analytical internal standard (0.5µM carbamazepine) in a 96 well plate.

[00511] Lucifer yellow was measured with a Spectramax Gemini XS (Ex 426nm and Em 538nm) in a clean 96 well plate containing 150µL of liquid from basolateral and apical side.

[00512] Concentrations of compound in the samples were measured by high performance liquid-chromatography/mass spectroscopy (LC-MS/MS).

[00513] Apparent permeability (P_{app}) values were calculated from the relationship:

$$P_{app} = [compound]_{acceptor\ final} \times V_{acceptor} / ([compound]_{donor\ initial} \times V_{donor}) / T_{inc} \times V_{donor} / \text{surface area} \times 60 \times 10^{-6}\ cm/s$$

V = chamber volume

T_{inc} = incubation time.

Surface area = $0.33cm^2$

[00514] The Efflux ratios, as an indication of active efflux from the apical cell surface, were calculated using the ratio of P_{app} B>A/ P_{app} A>B.

[00515] The following assay acceptance criteria were used:

Propranolol: P_{app} (A>B) value $\geq 20(\times 10^{-6}$ cm/s)

Rhodamine 123 or Vinblastine: P_{app} (A>B) value < 5 ($\times 10^{-6}$ cm/s) with Efflux ratio ≥ 5.

Lucifer yellow permeability: ≤ 100 nm/s

Table X – Caco2 Efflux rate

Cpd #	Papp (A2B) cmx10-6sec-1	Efflux ratio
1	19.6	0.78
17	27.5	0.85
23	0.35	1
25	0.4	15.5
27	1.05	7
32	17.4	1.61
33	10.24	0.66
37	1.7	1
39	7.03	1.33
42	6.05	7.7
46	1.64	1.08
47	25.05	0.6
50	0.4	1
51	6.8	6.85
54	2.8	10
61	6.75	1
70	13.35	1

Cpd #	Papp (A2B) cmx10-6sec-1	Efflux ratio
71	18.3	1.5
72	26	0.7
74	10.15	4.1
77	12.75	1
79	9.4	4.5
82	1.32	43.73
83	29.63	0.84
84	4.1	8.7
87	N/A	N/A
88	0.7	69.7
90	5.7	4
95	0.45	117
98	0.15	190
102	11.8	3
122	12.3	1
154	0.7	75

Example 4.7 Pharmacokinetic study in rodents

4.7.1 Pharmacokinetic study

[00516] Compounds are formulated in PEG200/physiological saline or PEG400/DMSO/physiological saline mixtures for the intravenous route and in 0.5% methylcellulose or 10-30% hydroxylpropyl-β-cyclodextrine pH3 or pH7.4 for the oral route. Test compounds are orally dosed as a single esophageal gavage at 5-10 mg/kg and intravenously dosed as a bolus via the caudal vein at 1 mg/kg. Each group consists of 3 rats. Blood samples are collected either via the jugular vein using cannulated rats or at the retro-orbital sinus with lithium heparin as anti-coagulant at the time points in the following range: 0.05 to 8 hours (intravenous route), and 0.25 to 6 or 24 hours (oral route). Whole blood samples are centrifuged at 5000 rpm for 10 min and the resulting plasma samples are stored at -20°C pending analysis.

4.7.2 Quantification of compound levels in plasma

[00517] Plasma concentrations of each test compound are determined by an LC-MS/MS method in which the mass spectrometer is operated in positive electrospray mode.

4.7.3 Determination of pharmacokinetic parameters

[00518] Pharmacokinetic parameters are calculated using Winnonlin® (Pharsight®, United

Example 4.8 7-Day rat toxicity study

[00519] A 7-day oral toxicity study with test compounds was performed in Sprague-Dawley male rats to assess their toxic potential and toxicokinetics, at daily doses of 100, 300 and 500 mg/kg/day, by gavage, at the constant dosage-volume of 5 mL/kg/day.

[00520] The test compounds were formulated in 30% (v/v) HPβCD in purified water. Each group included 5 principal male rats as well as 3 satellite animals for toxicokinetics. A fourth group was given 30% (v/v) HPβCD in water only, at the same frequency, dosage volume and by the same route of administration, and acted as the vehicle control group.

[00521] The goal of the study was to determine the lowest dose that resulted in no adverse events being identified (no observable adverse effect level - NOAEL). Compounds 37 and 176 were tested in this protocol.

[00522] It will be appreciated by those skilled in the art that the foregoing descriptions are exemplary and explanatory in nature, an as indiced intended to illustrate the invention and its preferred embodiments. Through routine experimentation, an artisan will recognise apparent modifications and variations that may be made without departing from the spirit of the invention. Thus, the invention is intended to be defined not by the above description, but by the following claims and their equivalents.

[00523] REFERENCES

Choy EH, Panayi GS. (2001). N Engl J Med. 344: 907-16.

Chubinskaya S and Kuettner KE (2003). Regulation of osteogenic proteins by chondrocytes. The international journal of biochemistry & cell biology 35(9)1323-1340.

Clegg DO et al. (2006) N Engl J Med. 2006 354:795-808. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis.

Firestein GS. (2003). Nature. 423:356-61.

Kachigian LM. (2006) Collagen antibody-induced arthritis, Nature Protocols 2512-2516:

Lee DM, Weinblatt ME (2001). Lancet. 358: 903-11.

Legendre F, Dudhia J, Pujol J-P, Bogdanowicz P. (2003) JAK/STAT but not ERK1/ERK2 pathway mediates interleuking (IL)-6/soluble IL-6R down-regulation of type II collagen, aggrecan core, and link protein transcription in articular chondrocytes. J Biol Chem. 278(5)2903-2912.

Li WQ, Dehnade F, Zafarullah M. (2001) Oncostatin M-induced matrix metalloproteinase and tissue inhibitor of metalloproteinase-3 genes expression in chondrocytes requires janus kinase/STAT signaling pathway. (2001) J Immunol 166:3491-3498.

O'Dell JR. (2004) Therapeutic strategies for rheumatoid arthritis. N Engl J Med. 350(25):2591-602.

Osaki M, Tan L, Choy BK, Yoshida Y, Cheah KSE, Auron PE, Goldring MB. (2003) The TATA-conatining core promoter of the type II collagen gene (COL2A1) is the target of interferon-gamma-mediated inhibition in human chondrocytes: requirement for STAT1alpha, JAK1 and JAK2. Biochem J 369:103-115.

Oste L *et al.*, ECTC Montreal 2007: A high throughput method of measuring bone architectural disturbance in a murine CIA model by micro-CT morphometry

Otero M, Lago R, Lago F, Gomez Reino JJ, Gualillo O. (2005) Signalling pathway involved in nitric oxide synthase type II activation in chondrocytes: synergistic effect of leptin with interleukin-1. Arthritis Research & Therapy 7:R581-R591.

Rodig SJ, Meraz MA, White JM, Lampe PA, Riley JK, Arthur CD, King KL, Sheehan KCF, Yin L, Pennica D, Johnson EM, Schreiber RD. (1998) Disruption of the Jak1 gene demonstrates obligatory and nonredundant roles of the jaks in cytokine-induced biologic responses Cell 93: 373-383.

Sims NA *et al.*, (2004) Targeting osteoclasts with zoledronic acid prevents bone destruction in collagen-induced arthritis, Arthritis Rheum. 50 2338-2346:

Smolen JS, Steiner G. (2003). Nat Rev Drug Discov. 2: 473-88.

Wernig *et al.* (2008) Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera, Cancer Cell 13(4), 311-320

Geron *et al.* (2008) Selective inhibition of JAK2-driven erythroid differentiation of polycythemia vera progenitors Cancer Cell 13 (4), 321-30

Wieland HA, Michaelis M, Kirschbaum BJ, Rudolphi KA. (2005). Nat Rev Drug Discov. 4:331-44. Osteoarthritis - an untreatable disease?

Wirtz *et al.* (2007) Mouse Models of Inflammatory Bowel Disease, Advanced Drug Delivery Reviews, 2007, 1073-1083:

Tam, L., McGlynn, L.M., Traynor, P., Mukherjee, R., Bartlett, J.M.S., Edwards, J. (2007) British Journal of Cancer, 97, 378-383

Constantinescu et al., 2007, Trends in Biochemical Sciences 33(3): 122-131

Tetsuji Naka, Norihiro Nishimoto and Tadamitsu Kishimoto, Arthritis Res 2002, 4 (suppl 3):S233-S242

O'Shea, J.J., Pesu, M., Borie, D.C., Changelian, P.S., Nature Reviews, 2004, 555-564

Nials *et al.* (2008) Mouse Models of Allergic Asthma: Acute and Chronic Allergen Challenge, Disease Models & Mechanisms, 213-220.

Ip *et al.* (2006) Interleukin (IL)-4 and IL-13 up-regulate monocyte chemoattractant protein-1 expression in human bronchial epithelial cells: involvement of p38 mitogen-activated protein kinase, extracellular signal-

regulated kinase 1/2 and Janus kinase-2 but not c-Jun NH2-terminal kinase 1/ 2 signalling pathways, Clin. Exp. Immun, 162-172.

Pernis et al. (2002) JAK-STAT signaling in asthma J. Clin. Invest. 1279.

Kudlacz et al. (2008) The JAK-3 inhibitor CP-690550 is a potent anti-inflammatory agent in a murine model of pulmonary eosinophilia, Eur J Pharmaco 154-161.

Mullighan CG, Zhang J, Harvey RC, Collins-Underwood JR, Schulman BA, Phillips LA, Tasian SK, Loh ML, Su X, Liu W, Devidas M, Atlas SR, Chen I-M, Clifford RJ, Gerhard DS, Carroll WL, Reaman GH, Smith M, Downing JR, Hunger SP Willmane CL; (2009) JAK mutations in high-risk childhood acute lymphoblastic leukemia, PNAS May 22. [Epub ahead of print]

Argiles JM, Lopez-Soriano FJ. (1998)Catabolic proinflammatory cytokines. Curr Opin Clin Nutr Metab Care. 1:245-51.

Bush KA, Farmer KM, Walker JS, Kirkham BW. (2002) Reduction of joint inflammation and bone erosion in rat adjuvant arthritis by treatment with interleukin-17 receptor IgG1 Fc fusion protein. Arthritis Rheum. 46: 802-5.

Jou IM, Shiau AL, Chen SY, Wang CR, Shieh DB, Tsai CS, Wu CL. (2005) Thrombospondin 1 as an effective gene therapeutic strategy in collagen-induced arthritis. Arthritis Rheum. 52:339-44.

Nishida K, Komiyama T, Miyazawa S, Shen ZN, Furumatsu T, Doi H, Yoshida A, Yamana J, Yamamura M, Ninomiya Y, Inoue H, Asahara H. (2004) Histone deacetylase inhibitor suppression of autoantibody-mediated arthritis in mice via regulation of p16INK4a and p21(WAF1/Cip1) expression. Arthritis Rheum. 10: 3365-76.

Rall LC, Roubenoff R.(2004) Rheumatoid cachexia: metabolic abnormalities, mechanisms and interventions. Rheumatology; 10:1219-23.

Salvemini D, Mazzon E, Dugo L, Serraino I, De Sarro A, Caputi AP, Cuzzocrea S. (2001) Amelioration of joint disease in a rat model of collagen-induced arthritis by M40403, a superoxide dismutase mimetic. Arthritis Rheum. 44:2909-21.

Shelton DL, Zeller J, Ho WH, Pons J, Rosenthal A. (2005) Nerve growth factor mediates hyperalgesia and cachexia in auto-immune arthritis. Pain. 116:8-16.

Sims NA, Green JR, Glatt M, Schlict S, Martin TJ, Gillespie MT, Romas E. (2004) Targeting osteoclasts with zoledronic acid prevents bone destruction in collagen-induced arthritis. Arthritis Rheum., 50: 2338-46.

Walsmith J, Abad L, Kehayias J, Roubenoff R. (2004) Tumor necrosis factor-alpha production is associated with less body cell mass in women with rheumatoid arthritis. J Rheumatol.; 31:23-9.

Khachigian, L. M. Collagen antibody-induced arthritis. (2006) Nature Protocols 1, 2512-6.

Lin HS, Hu CY, Chan HY, Liew YY, Huang HP, Lepescheux L, Bastianelli E, Baron R, Rawadi G, Clément-Lacroix P. (2007) Anti-rheumatic activities of histone deacetylase (HDAC) inhibitors in vivo in collagen-induced arthritis in rodents. Br J Pharmacol. Apr;150 (7):829-31.

[00524] All publications, including but not limited to patents and patent applications, cited in this specification are herein incorporated by reference as if each individual publication were specifically and individually indicated to be incorporated by reference herein as though fully set forth.

[00525] From the foregoing description, various modifications and changes in the compositions and methods of this invention will occur to those skilled in the art. All such modifications coming within the scope of the appended claims are intended to be included therein.

[00526] It should be understood that factors such as the differential cell penetration capacity of the various compounds can contribute to discrepancies between the activity of the compounds in the *in vitro* biochemical and cellular assays.

[00527] At least some of the chemical names of compounds of the invention as given and set forth in this application, may have been generated on an automated basis by use of a commercially available chemical naming software program, and have not been independently verified. Representative programs performing this function include the Lexichem naming tool sold by Open Eye Software, Inc. and the Autonom Software tool sold by MDL, Inc. In the instance where the indicated chemical name and the depicted structure differ, the depicted structure will control.

[00528] Chemical structures shown herein were prepared using either ChemDraw® or ISIS® /DRAW. Any open valency appearing on a carbon, oxygen or nitrogen atom in the structures herein indicates the presence of a hydrogen atom. Where a chiral center exists in a structure but no specific stereochemistry is shown for the chiral center, both enantiomers associated with the chiral structure are encompassed by the structure.

WHAT IS CLAIMED IS:

1. A compound according to Formula I:



I

wherein

each Cy1 and Cy2 is independently selected from aryl and heteroaryl;

L1 is selected from a single bond, -O-, -C(O)-, -$S(O)_2$-, -$N(R^{4a})$-, -$CON(R^{4a})$-, -$SO_2N(R^{4a})$-, -$N(R^{4a})CO$-, -$N(R^{4a})SO_2$- or –C(=N-OR^4);

each R^1 is independently selected from C_1-C_6 alkyl, substituted C_1-C_6 alkyl, acyl, substituted acyl, substituted or unsubstituted acylamino, substituted or unsubstituted amido, substituted or unsubstituted C_1-C_6 alkoxy, substituted or unsubstituted amino, substituted or unsubstituted amino, substituted sulfinyl, substituted sulfonyl, substituted or unsubstituted aminosulfonyl, sulfonic acid, sulfonic acid ester, carboxy, cyano, substituted or unsubstituted C_3-C_7 cycloalkyl, substituted or unsubstituted 4-7 membered heterocycloalkyl, halo, and hydroxyl;

each R^{3a} is independently selected from C_1-C_6 alkyl, substituted C_1-C_6 alkyl, acyl, substituted acyl, substituted or unsubstituted acylamino, substituted or unsubstituted amido, substituted or unsubstituted C_1-C_6 alkoxy, alkoxycarbonyl, substituted alkoxycarbonyl, arylalkyloxy, substituted arylalkyloxy, substituted or unsubstituted amino, aryl, substituted aryl, arylalkyl, substituted sulfanyl, substituted sulfinyl, substituted sulfonyl, substituted or unsubstituted aminosulfonyl, substituted or unsubstituted arylsulfonyl, sulfonic acid, sulfonic acid ester, azido, carboxy, cyano, substituted or unsubstituted C_3-C_7 cycloalkyl, substituted or unsubstituted C_4-C_7 heterocycloalkyl, halo, -O-heteroaryl, substituted or unsubstituted heteroaryl, hydroxy, nitro, and thiol;

each R^{2b}, R^{2c}, and R^{2d} is independently selected from H, C_1-C_6 alkyl, substituted C_1-C_6 alkyl, acyl, substituted acyl, substituted or unsubstituted acylamino, substituted or unsubstituted C_1-C_6 alkoxy, substituted or unsubstituted –O-aryl, alkoxycarbonyl, substituted alkoxycarbonyl, arylalkyloxy, substituted arylalkyloxy, substituted or unsubstituted amino, aryl, substituted aryl, arylalkyl, substituted sulfanyl, substituted sulfinyl, substituted sulfonyl, substituted or unsubstituted aminosulfonyl, substituted or unsubstituted arylsulfonyl, sulfonic acid, sulfonic acid ester, azido,

carboxy, substituted or unsubstituted amido, cyano, substituted or unsubstituted C_3-C_7 cycloalkyl, substituted or unsubstituted 4-7 membered heterocycloalkyl, halo, -O-heteroaryl, substituted or unsubstituted heteroaryl, hydroxy, nitro, and thiol;

each R^{2a} and R^{4a} is independently selected from H, C_1-C_6 alkyl, substituted C_1-C_6 alkyl, C_3-C_7 cycloalkyl, or substituted C_3-C_7cycloalkyl;

m1 is 0, 1, or 2; m2 is 0, 1, 2, 3 or 4; and n1 is 0, 1, 2, 3, or 4;

provided that

when L1 is -N(R^{4a})-, -CON(R^{4a})-, or -SO_2N(R^{4a})-, and R^{2c} is other than H, alkyl, cycloalkyl, aryl or heteroaryl, then n1 is 1, 2, 3, or 4;

or a pharmaceutically acceptable salts thereof, for use in the treatment and./or prevention of diseases involving cartilage degradation, bone and/or joint degradation, for example osteoarthritis; and/or conditions involving inflammation or immune responses, such as Crohn's disease, rheumatoid arthritis, psoriasis, allergic airways disease (e.g. asthma, rhinitis), juvenile idiopathic arthritis, colitis, inflammatory bowel diseases, endotoxin-driven disease states (e.g. complications after bypass surgery or chronic endotoxin states contributing to e.g. chronic cardiac failure), diseases involving impairment of cartilage turnover (e.g. diseases involving the anabolic stimulation of chondrocytes), congenital cartilage malformations, diseases associated with hypersecretion of IL6 and transplantation rejection (e.g. organ transplant rejection) or proliferative diseases.

2. The compound according to claim 1, wherein

each Cy1 and Cy2 is independently selected from aryl and heteroaryl;

L1 is selected from a single bond, -O-, -C(O)-, -$S(O)_2$-, -N(R^{4a})-, -CON(R^{4a})-, -SO_2N(R^{4a})-, -N(R^{4a})CO-, -N(R^{4a})SO_2- or –C(=N-OR^4);

each R^1 is independently selected from unsubstituted C_1-C_6 alkyl, unsubstituted acyl, unsubstituted acylamino, unsubstituted amido, unsubstituted C_1-C_6 alkoxy, unsubstituted amino, unsubstituted amino, unsubstituted aminosulfonyl, sulfonic acid, sulfonic acid ester, carboxy, cyano, unsubstituted C_3-C_7 cycloalkyl, unsubstituted 4-7 membered heterocycloalkyl, halo, and hydroxyl;

each R^{3a} is independently selected from C_1-C_6 alkyl (optionnally substituted with halo, cyano, hydroxy, unsubstituted C_1-C_6 alkoxy, amino (optionally substituted with –C_1-C_4 alkyl substituted with hydroxy)), unsubstituted acyl, unsubstituted acylamino, amido (optionnally substituted with unsubstituted C_1-C_4 alkyl), C_1-C_6 alkoxy (optionnally substituted with halo, cyano), unsubstituted C_1-C_4 alkoxycarbonyl, unsubstituted arylalkyloxy, amino (optionnally substituted with C_1-C_4 alkyl), unsubstituted aryl, unsubstituted arylalkyl, unsubstituted sulfonyl, aminosulfonyl (optionnally substituted with C_1-C_4 alkyl), unsubstituted arylsulfonyl, sulfonic acid, sulfonic acid ester, azido, carboxy, cyano, unsubstituted C_3-C_7 cycloalkyl, unsubstituted C_4-C_7 heterocycloalkyl, halo, unsubstituted -O-heteroaryl, unsubstituted heteroaryl, hydroxy, nitro, and thiol;

each R^{2b}, R^{2c}, and R^{2d} is independently selected from H, C_1-C_6 alkyl (optionnlly substituted with hydroxy, unsubstituted C_1-C_6 alkoxy, unsubstituted aminoacyl, amino (optionally substituted with C_{1-4} alkyl), unsubstituted amido, 4-7-membered heterocycloalkyl (optionally substituted with C_{1-4} alkyl), unsubstituted aryl, heteroaryl (optionally substituted with C_{1-4} alkyl)), unsubstituted acyl, unsubstituted acylamino, unsubstituted C_1-C_6 alkoxy, unsubstituted –O-aryl, unsubstituted C_1-C_6 alkoxycarbonyl, unsubstituted arylalkyloxy, amino (optionnally substituted with unsubstituted C_1-C_6 alkyl), aryl (optionnally substituted with amido (optionally substituted with unsubstituted C_1-C_6 alkyl), C_1-C_6 alkyl (optionally substituted with hydroxy, 5-7 membered heterocycloalkyl), 5-7 membered heterocycloalkyl, amino (optionally substituted with unsubstituted acyl, sulfonyl),), unsubstituted arylalkyl, unsubstituted aminosulfonyl, unsubstituted arylsulfonyl, sulfonic acid, sulfonic acid ester, azido, carboxy, cyano, halo, hydroxy, nitro, thiol, amido (optionnally substituted with unsubstituted C_1-C_6 alkyl), unsubstituted C_3-C_7 cycloalkyl, 4-7 membered heterocycloalkyl (optionnally substituted with C_1-C_6 alkyl (optionnally substituted with acyl, hydroxy), unsubstituted acyl, aryl (optionally substituted with halo)), unsubstituted -O-heteroaryl, heteroaryl (optionnally substituted with unsubstituted C_1-C_6 alkyl, unsubstituted C_1-C_6 alkoxy, unsubstituted C_3-C_7 cycloalkyl, aryl (optionally substituted with amido, 5-7 membered heterocycle (optionally substituted with unsubstituted C_1-C_6 alkyl), C_1-C_6 alkyl (optionally substituted with hydroxy, unsubstituted 5-7 membered heterocycle), amino (optionally substituted with unsubstituted acyl, sulfonyl), heteroaryl (optionally substituted with 5-7 membered heterocycloalkyl (optionally substituted C_1-C_6 alkyl)));

each R^{2a} and R^{4a} is independently selected from H, unsubstituted C_1-C_6 alkyl, unsubstituted C_3-C_7 cycloalkyl;

m1 is 0, 1, or 2; m2 is 0, 1, 2, 3 or 4; and n1 is 0, 1, 2, 3, or 4;

provided that

when L1 is $-N(R^{4a})-$, $-CON(R^{4a})-$, or $-SO_2N(R^{4a})-$, and R^{2c} is other than H, alkyl, cycloalkyl, aryl or heteroaryl, then n1 is 1, 2, 3, or 4;

or a pharmaceutically acceptable salts thereof.

3. The compound or pharmaceutically acceptable salt according to claim 1 or 2 wherein each R^1 is independently selected from C_1-C_6 alkyl, substituted C_1-C_6 alkyl, and halo.

4. The compound or pharmaceutically acceptable salt according to claim 3 wherein each R^1 is independently selected from Me, CF_3, Cl and F.

5. The compound or pharmaceutically acceptable salt according to claim 1 or 2 wherein R^{2a} is independently selected from H, C_1-C_6 alkyl, and substituted C_1-C_6 alkyl.

6. The compound or pharmaceutically acceptable salt according to claim 1 or 2 wherein R^{2a} is H.

7. The compound or pharmaceutically acceptable salt according to claim 1 or 2 wherein the compound is according to Formula II or III:



II



III

wherein Cy2, L1, R^{2b}, R^{2c}, R^{2d}, R^{3a}, m2 and n1 are as in claim 1 or 2.

8. The compound or pharmaceutically acceptable salt according to claim 7 wherein each of R^{2b}, and R^{2d} is independently H, C_1-C_6alkyl, substituted C_1-C_6 alkyl, or halo.

9. The compound or pharmaceutically acceptable salt according to claim 8 wherein each of R^{2b}, and R^{2d} is independently H, Me, F or Cl.

10. The compound or pharmaceutically acceptable salt according to any one of claims 1-9 wherein L1 is a single bond, n1 is 0, and R^{2c} is H, Cl, F, Me, Et, OMe, OEt, O-i-Pr, CF_3, $CONH_2$, $CONMe_2$, CONHMe, CN, NHCOMe, COOH, OH or COOEt.

11. The compound or pharmaceutically acceptable salt according to any one of claims 1-9 wherein L1 is a single bond, n1 is 0, and R^{2c} is NHCOMe, or COOH.

12. The compound or pharmaceutically acceptable salt according to any one of claims 1-9, wherein L1 is CONH; n1 is 2 or 3; and R^{2c} is NMe_2, OMe, or NHCOMe.

13. The compound or pharmaceutically acceptable salt according to any one of claims 1-9 wherein L1 is selected from a single bond, -C(O)-, and -CON(R^{4a})-; n1 is 0, 1, 2, 3, or 4; and R^{2c} is substituted or unsubstituted C_1-C_6 alkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted C_3-C_7 cycloalkyl, or substituted or unsubstituted 4-7 membered heterocycloalkyl.

14. The compound or pharmaceutically acceptable salt according to claim 13 wherein R^{2c} is C_1-C_6 alkyl.

15. The compound or pharmaceutically acceptable salt according to claim 13 wherein R^{2c} is Me, Et, i-Pr, 1,3-dihydroxyprop-2-yl.

16. The compound or pharmaceutically acceptable salt according to claim 13 wherein and R^{2c} is substituted or unsubstituted C_3-C_7 cycloalkyl.

17. The compound or pharmaceutically acceptable salt according to claim 16 wherein R^{2c} is substituted or unsubstituted cyclopropyl, substituted or unsubstituted cyclobutyl, substituted or unsubstituted cyclohexyl, or substituted or unsubstituted cyclopentyl.

18. The compound or pharmaceutically acceptable salt according to claim 13 wherein R^{2c} is substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl.

19. The compound or pharmaceutically acceptable salt according to claim 18 wherein R^{2c} is substituted or unsubstituted Ph, substituted or unsubstituted pyridyl, substituted or unsubstituted pyrrolyl, substituted or unsubstituted pyrazolyl, substituted or unsubstituted imidazolyl, substituted or unsubstituted triazolyl, substituted or unsubstituted oxazolyl, substituted or unsubstituted thiazolyl, substituted or unsubstituted indolyl, substituted or unsubstituted indazolyl, substituted or unsubstituted benzimidazolyl, substituted or unsubstituted benzofuranyl, substituted or unsubstituted benzodioxanyl, substituted or unsubstituted benzoxazolyl, substituted or unsubstituted quinolinyl, or substituted or unsubstituted isoquinolinyl.

20. The compound or pharmaceutically acceptable salt according to claim 13 wherein R^{2c} is substituted or unsubstituted 4-7 membered heterocycloalkyl.

21. The compound or pharmaceutically acceptable salt according claim 20 wherein R^{2c} is piperidinyl, morpholinyl, piperazinyl, or pyrrolidinyl, each of which may be unsubstituted or substituted with C_1-C_6 alkyl, acyl, phenyl, or OH.

22. The compound or pharmaceutically acceptable salt according to any one of claims 1-9, or 13-21, wherein R^{4a} is H.

23. The compound or pharmaceutically acceptable salt according to claim 22, wherein n1 is 0, 1, 2 or 3.

24. The compound or pharmaceutically acceptable salt according to claim 23 wherein n1 is 0, or 1.

25. The compound or pharmaceutically acceptable salt according to any one of claims 1-9 or 13-21, wherein L1 is CO; and n1 is 0, 1, 2 or 3.

26. The compound or pharmaceutically acceptable salt according to claim 25, wherein n1 is 0, or 1.

27. The compound or pharmaceutically acceptable salt according to any one of claims 1-9, wherein the –Cy1-L1-$(CH_2)_{n1}$-R^{2c} group is selected from:



and wherein n1 and R^{2c} are as in claim 1.

28. The compound or pharmaceutically acceptable salt according to any one of claims 1-9, wherein the –Cy1-L1-$(CH_2)_{n1}$-R^{2c} group is selected from:



and wherein n1 and R^{2c} are as in claim 1.

29. The compound or pharmaceutically acceptable salt according to any one of claims 1-9, wherein the –Cy1-L1-$(CH_2)_{n1}$-R^{2c} group is selected from:



and wherein n1 and R^{2c} are as in claim 1.

30. The compound or pharmaceutically acceptable salt according to any one of claims 27-29, wherein R^{2c} is a N-containing 4-7 membered heterocycloalkyl group or a heteroaryl group.

31. The compound or pharmaceutically acceptable salt according to claim 30, wherein R^{2c} is:



or .

32. The compound or pharmaceutically acceptable salt according to claim 30, wherein R^{2c} is pyrazolyl, pyrrolyl, imidazolyl, or triazolyl.

33. The compound or pharmaceutically acceptable salt according to any one of claims 27-32, wherein n1 is 0, 1 or 2.

34. The compound or pharmaceutically acceptable salt according to any one of claims 1-9, wherein the –Cy1-L1-$(CH_2)_{n1}$-R^{2c} group is selected from:



or .

35. The compound or pharmaceutically acceptable salt according to any one of claims 1-34, wherein Cy2 is Ph; and m2 is 0.

36. The compound or pharmaceutically acceptable salt according to any one of claims 1-34, wherein Cy2 is Ph; m3 is 1, 2 or 3; and each R^{3a} is independently C_1-C_6alkyl, haloC_1-C_6alkyl, alkoxy, or halo.

37. The compound or pharmaceutically acceptable salt according to any one of claims 1-34, wherein Cy2 is Ph; m3 is 1, 2 or 3; and each R^{3a} is independently Cl, F, Me, Et, OMe, OEt, O-i-Pr, CF_3, OCF_3, CONH2, CONMe2, CONHMe, SO_2NH_2, SO_2NMe_2, CN, NHCOMe, COOH, OH or COOEt.

38. The compound or pharmaceutically acceptable salt according to claim 1 or 2 wherein the compound is according to Formula IVa, IVb, IVc, or IVd:



IVa , IVb ,



or

IVc IVd .

and wherein n1 is 1, 2, or 3; R^{3a} is Cl, F, Me, Et, OMe, OEt, O-i-Pr, CF_3, OCF_3, OCH_2CN, $CONH_2$, $CONMe_2$, CONHMe, SO_2NH_2, SO_2NMe_2, CN, NHCOMe, COOH, OH or COOEt; and R^{2c} is substituted or unsubstituted 4-7 membered heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.

39. The compound or pharmaceutically acceptable salt according to claim 38 wherein R^{2c} is substituted or unsubstituted pyrrolidinyl, substituted or unsubstituted piperidinyl, substituted or unsubstituted piperazinyl, or substituted or unsubstituted morpholinyl.

40. The compound or pharmaceutically acceptable salt according to claim 38 wherein R^{2c} is



or .

41. The compound or pharmaceutically acceptable salt according to claim 38 wherein R^{2c} is substituted or unsubstituted pyrazolyl, substituted or unsubstituted pyrrolyl, substituted or unsubstituted imidazolyl, substituted or unsubstituted triazolyl, substituted or unsubstituted oxazolyl, substituted or unsubstituted benzimidazolyl, substituted or unsubstituted indolyl, or substituted or unsubstituted indazolyl.

42. The compound or pharmaceutically acceptable salt according to any one of claims 38-41, wherein R^{3a} is Cl, F, Me, Et, OMe, OEt, O-i-Pr, CF_3, OCF_3, SO_2NH_2, SO_2NMe_2, or CN.

43. The compound or pharmaceutically acceptable salt according to any one of claims 38-41, wherein R^{3a} is Cl, F, Me, or OMe.

44. The compound according to claim 1 or 2 wherein the compound is selected from compounds listed in Table 1.

45. The compound according to any one of claims 1 to 44 wherein the disease involves inflammation.

46. The compound according to claim 45, wherein the disease is selected from rheumatoid arthritis, osteoarthritis, allergic airway disease (e.g. asthma) and inflammatory bowel diseases.

47. The compound according to any one of claims 1 to 44, wherein the disease is a condition involving an immune response or an autoimmune disease.

48. The compound according to claim 47, wherein the autoimmune disease is selected from COPD, asthma, systemic lupus erythematosis, type I diabetes mellitus and inflammatory bowel disease

49. The compound according to any one of claims 1 to 44, wherein the disease involves an impairment of cartilage turnover.

AMENDED CLAIMS
received by the International Bureau on 20th November 2009 (20.11.2009)

WHAT IS CLAIMED IS:

1. A compound according to Formula I:



I

wherein

each Cy1 and Cy2 is independently selected from aryl and heteroaryl;

L1 is selected from a single bond, -O-, -C(O)-, -$S(O)_2$-, -$N(R^{4a})$-, -$CON(R^{4a})$-, -$SO_2N(R^{4a})$-, -$N(R^{4a})CO$-, -$N(R^{4a})SO_2$- or –C(=N-OR^4);

each R^1 is independently selected from C_1-C_6 alkyl, substituted C_1-C_6 alkyl, acyl, substituted acyl, substituted or unsubstituted acylamino, substituted or unsubstituted amido, substituted or unsubstituted C_1-C_6 alkoxy, , substituted or unsubstituted amino, substituted sulfinyl, substituted sulfonyl, substituted or unsubstituted aminosulfonyl, sulfonic acid, sulfonic acid ester, carboxy, cyano, substituted or unsubstituted C_3-C_7 cycloalkyl, substituted or unsubstituted 4-7 membered heterocycloalkyl, halo, and hydroxyl;

each R^{3a} is independently selected from C_1-C_6 alkyl, substituted C_1-C_6 alkyl, acyl, substituted acyl, substituted or unsubstituted acylamino, substituted or unsubstituted amido, substituted or unsubstituted C_1-C_6 alkoxy, alkoxycarbonyl, substituted alkoxycarbonyl, arylalkyloxy, substituted arylalkyloxy, substituted or unsubstituted amino, aryl, substituted aryl, arylalkyl, substituted sulfanyl, substituted sulfinyl, substituted sulfonyl, substituted or unsubstituted aminosulfonyl, substituted or unsubstituted arylsulfonyl, sulfonic acid, sulfonic acid ester, azido, carboxy, cyano, substituted or unsubstituted C_3-C_7 cycloalkyl, substituted or unsubstituted C_4-C_7 heterocycloalkyl, halo, -O-heteroaryl, substituted or unsubstituted heteroaryl, hydroxy, nitro, and thiol;

each R^{2b}, R^{2c}, and R^{2d} is independently selected from H, C_1-C_6 alkyl, substituted C_1-C_6 alkyl, acyl, substituted acyl, substituted or unsubstituted acylamino, substituted or unsubstituted C_1-C_6 alkoxy, substituted or unsubstituted –O-aryl, alkoxycarbonyl, substituted alkoxycarbonyl, arylalkyloxy, substituted arylalkyloxy, substituted or unsubstituted amino, aryl, substituted

aryl, arylalkyl, substituted sulfanyl, substituted sulfinyl, substituted sulfonyl, substituted or unsubstituted aminosulfonyl, substituted or unsubstituted arylsulfonyl, sulfonic acid, sulfonic acid ester, azido, carboxy, substituted or unsubstituted amido, cyano, substituted or unsubstituted C_3-C_7 cycloalkyl, substituted or unsubstituted 4-7 membered heterocycloalkyl, halo, -O-heteroaryl, substituted or unsubstituted heteroaryl, hydroxy, nitro, and thiol;

each R^{2a} and R^{4a} is independently selected from H, C_1-C_6 alkyl, substituted C_1-C_6 alkyl, C_3-C_7 cycloalkyl, or substituted C_3-C_7cycloalkyl;

m1 is 0, 1, or 2; m2 is 0, 1, 2, 3 or 4; and n1 is 0, 1, 2, 3, or 4;

provided that

when L1 is -$N(R^{4a})$-, -$CON(R^{4a})$-, or -$SO_2N(R^{4a})$-, and R^{2c} is other than H, alkyl, cycloalkyl, aryl or heteroaryl, then n1 is 1, 2, 3, or 4;

or a pharmaceutically acceptable salts thereof, for use in the treatment and./or prevention of diseases involving cartilage degradation, bone and/or joint degradation, for example osteoarthritis; and/or conditions involving inflammation or immune responses, such as Crohn's disease, rheumatoid arthritis, psoriasis, allergic airways disease (e.g. asthma, rhinitis), juvenile idiopathic arthritis, colitis, inflammatory bowel diseases, endotoxin-driven disease states (e.g. complications after bypass surgery or chronic endotoxin states contributing to e.g. chronic cardiac failure), diseases involving impairment of cartilage turnover (e.g. diseases involving the anabolic stimulation of chondrocytes), congenital cartilage malformations, diseases associated with hypersecretion of IL6 and transplantation rejection (e.g. organ transplant rejection) or proliferative diseases.

2. The compound or pharmaceutically acceptable salt according to claim 1, wherein L1 is selected from a single bond, -O-, -C(O)-, -$S(O)_2$-, -$N(R^{4a})$-, -$CON(R^{4a})$-, -$SO_2N(R^{4a})$-, - $N(R^{4a})CO$-, - $N(R^{4a})SO_2$-.

3. The compound or pharmaceutically acceptable salt according to claim 1 or 2 wherein each R^1 is independently selected from C_1-C_6 alkyl, substituted C_1-C_6 alkyl, and halo.

4. The compound or pharmaceutically acceptable salt according to claim 3 wherein each R^1 is independently selected from Me, CF_3, Cl and F.

5. The compound or pharmaceutically acceptable salt according to claim 1 or 2 wherein R^{2a} is independently selected from H, C_1-C_6 alkyl, and substituted C_1-C_6 alkyl.

6. The compound or pharmaceutically acceptable salt according to claim 1 or 2 wherein R^{2a} is H.

7. The compound or pharmaceutically acceptable salt according to claim 1 or 2 wherein the compound is according to Formula II or III:



II



III

wherein Cy2, L1, R^{2b}, R^{2c}, R^{2d}, R^{3a}, m2 and n1 are as in claim 1 or 2.

8. The compound or pharmaceutically acceptable salt according to claim 7 wherein each of R^{2b}, and R^{2d} is independently H, C_1-C_6 alkyl, substituted C_1-C_6 alkyl, or halo.

9. The compound or pharmaceutically acceptable salt according to claim8 wherein each of R^{2b}, and R^{2d} is independently H, Me, F or Cl.

10. The compound or pharmaceutically acceptable salt according to any one of claims 1-9 wherein L1 is a single bond, n1 is 0, and R^{2c} is H, Cl, F, Me, Et, OMe, OEt, O-i-Pr, CF_3, $CONH_2$, $CONMe_2$, CONHMe, CN, NHCOMe, COOH, OH or COOEt.

11. The compound or pharmaceutically acceptable salt according to any one of claims 1-9 wherein L1 is a single bond, n1 is 0, and R^{2c} is NHCOMe, or COOH.

12. The compound or pharmaceutically acceptable salt according to any one of claims 1-9, wherein L1 is CONH; n1 is 2 or 3; and R^{2c} is NMe_2, OMe, or NHCOMe.

13. The compound or pharmaceutically acceptable salt according to any one of claims 1-9 wherein L1 is selected from a single bond, -C(O)-, and -CON(R^{4a})-; n1 is 0, 1, 2, 3, or 4; and R^{2c} is substituted or unsubstituted C_1-C_6 alkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted C_3-C_7 cycloalkyl, or substituted or unsubstituted 4-7 membered heterocycloalkyl.

14. The compound or pharmaceutically acceptable salt according to claim 13 wherein R^{2c} is C_1-C_6 alkyl.

15. The compound or pharmaceutically acceptable salt according to claim 13 wherein R^{2c} is Me, Et, i-Pr, 1,3-dihydroxyprop-2-yl.
16. The compound or pharmaceutically acceptable salt according to claim 13 wherein and R^{2c} is substituted or unsubstituted C_3-C_7 cycloalkyl.
17. The compound or pharmaceutically acceptable salt according to claim 16 wherein R^{2c} is substituted or unsubstituted cyclopropyl, substituted or unsubstituted cyclobutyl, substituted or unsubstituted cyclohexyl, or substituted or unsubstituted cyclopentyl.
18. The compound or pharmaceutically acceptable salt according to claim 13 wherein R^{2c} is substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl.
19. The compound or pharmaceutically acceptable salt according to claim 18 wherein R^{2c} is substituted or unsubstituted Ph, substituted or unsubstituted pyridyl, substituted or unsubstituted pyrrolyl, substituted or unsubstituted pyrazolyl, substituted or unsubstituted imidazolyl, substituted or unsubstituted triazolyl, substituted or unsubstituted oxazolyl, substituted or unsubstituted thiazolyl, substituted or unsubstituted indolyl, substituted or unsubstituted indazolyl, substituted or unsubstituted benzimidazolyl, substituted or unsubstituted benzofuranyl, substituted or unsubstituted benzodioxanyl, substituted or unsubstituted benzoxazolyl, substituted or unsubstituted quinolinyl, or substituted or unsubstituted isoquinolinyl.
20. The compound or pharmaceutically acceptable salt according to claim 13 wherein R^{2c} is substituted or unsubstituted 4-7 membered heterocycloalkyl.
21. The compound or pharmaceutically acceptable salt according claim 20 wherein R^{2c} is piperidinyl, morpholinyl, piperazinyl, or pyrrolidinyl, each of which may be unsubstituted or substituted with C_1-C_6 alkyl, acyl, phenyl, or OH.
22. The compound or pharmaceutically acceptable salt according to any one of claims 1-9, or 13-21, wherein R^{4a} is H.
23. The compound or pharmaceutically acceptable salt according to claim 22, wherein n1 is 0, 1, 2 or 3.
24. The compound or pharmaceutically acceptable salt according to claim 23 wherein n1 is 0, or 1.
25. The compound or pharmaceutically acceptable salt according to any one of claims 1-9 or 13-21, wherein L1 is CO; and n1 is 0, 1, 2 or 3.
26. The compound or pharmaceutically acceptable salt according to claim 25, wherein n1 is 0, or 1.
27. The compound or pharmaceutically acceptable salt according to any one of claims 1-9, wherein the $-Cy1-L1-(CH_2)_{n1}-R^{2c}$ group is selected from:



and wherein n1 and R^{2c} are as in claim 1.

28. The compound or pharmaceutically acceptable salt according to any one of claims 1-9, wherein the –Cy1-L1-$(CH_2)_{n1}$-R^{2c} group is selected from:



and wherein n1 and R^{2c} are as in claim 1.

29. The compound or pharmaceutically acceptable salt according to any one of claims 1-9, wherein the –Cy1-L1-$(CH_2)_{n1}$-R^{2c} group is selected from:



and wherein n1 and R^{2c} are as in claim 1.

30. The compound or pharmaceutically acceptable salt according to any one of claims 27-29, wherein R^{2c} is a N-containing 4-7 membered heterocycloalkyl group or a heteroaryl group.

31. The compound or pharmaceutically acceptable salt according to claim 30, wherein R^{2c} is:

32. The compound or pharmaceutically acceptable salt according to claim 30, wherein R^{2c} is pyrazolyl, pyrrolyl, imidazolyl, or triazolyl.

33. The compound or pharmaceutically acceptable salt according to any one of claims 27-32, wherein n1 is 0, 1 or 2.

34. The compound or pharmaceutically acceptable salt according to any one of claims 1-9, wherein the $-Cy1-L1-(CH_2)_{n1}-R^{2c}$ group is selected from:



35. The compound or pharmaceutically acceptable salt according to any one of claims 1-34, wherein Cy2 is Ph; and m2 is 0.

36. The compound or pharmaceutically acceptable salt according to any one of claims 1-34, wherein Cy2 is Ph; m3 is 1, 2 or 3; and each R^{3a} is independently C_1-C_6alkyl, haloC_1-C_6 alkyl, C_1-C_6 alkoxy, or halo.

37. The compound or pharmaceutically acceptable salt according to any one of claims 1-34, wherein Cy2 is Ph; m3 is 1, 2 or 3; and each R^{3a} is independently Cl, F, Me, Et, OMe, OEt, O-i-Pr, CF_3, OCF_3, CONH2, CONMe2, CONHMe, SO_2NH_2, SO_2NMe_2, CN, NHCOMe, COOH, OH or COOEt.

38. The compound or pharmaceutically acceptable salt according to claim 1 or 2 wherein the compound is according to Formula IVa, IVb, IVc, or IVd:



IVa ,



IVb ,



or



IVc IVd ,

and wherein n1 is 1, 2, or 3; R^{3a} is Cl, F, Me, Et, OMe, OEt, O-i-Pr, CF_3, OCF_3, OCH_2CN, $CONH_2$, $CONMe_2$, CONHMe, SO_2NH_2, SO_2NMe_2, CN, NHCOMe, COOH, OH or COOEt; and R^{2c} is substituted or unsubstituted 4-7 membered heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.

39. The compound or pharmaceutically acceptable salt according to claim 38 wherein R^{2c} is substituted or unsubstituted pyrrolidinyl, substituted or unsubstituted piperidinyl, substituted or unsubstituted piperazinyl, or substituted or unsubstituted morpholinyl.

40. The compound or pharmaceutically acceptable salt according to claim 38 wherein R^{2c} is



or .

41. The compound or pharmaceutically acceptable salt according to claim 38 wherein R^{2c} is substituted or unsubstituted pyrazolyl, substituted or unsubstituted pyrrolyl, substituted or unsubstituted imidazolyl, substituted or unsubstituted triazolyl, substituted or unsubstituted oxazolyl, substituted or unsubstituted benzimidazolyl, substituted or unsubstituted indolyl, or substituted or unsubstituted indazolyl.

42. The compound or pharmaceutically acceptable salt according to any one of claims 38-41, wherein R^{3a} is Cl, F, Me, Et, OMe, OEt, O-i-Pr, CF_3, OCF_3, SO_2NH_2, SO_2NMe_2, or CN.

43. The compound or pharmaceutically acceptable salt according to any one of claims 38-41, wherein R^{3a} is Cl, F, Me, or OMe.

44. The compound according to claim 1 or 2 wherein the compound is selected from:

N-{4-[5-(4-Methoxy-phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino]-phenyl}-acetamide

[5-(4-Methoxy-phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl]-pyridin-3-yl-amine

[5-(4-Methoxy-phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl]-pyridin-4-yl-amine

[5-(4-Methoxy-phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl]-phenyl-amine

[5-(4-Methoxy-phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl]-p-tolyl-amine

[5-(4-Methoxy-phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl]-(4-pyrazol-1-yl-phenyl)-amine

(4-Ethyl-phenyl)-[5-(4-methoxy-phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl]-amine

[5-(4-Methoxy-phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl]-(4-1,2,4-triazol-1-yl-phenyl)-amine

[5-(4-Methoxy-phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl]-(6-morpholin-4-yl-pyridin-3-yl)-amine

[5-(4-Methoxy-phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl]-(4-morpholin-4-yl-phenyl)-amine

{4-[5-(4-Methoxy-phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino]-phenyl}-morpholin-4-yl-methanone

[5-(4-Methoxy-phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl]-[6-(4-methyl-piperazin-1-yl)-pyridin-3-yl]-amine

[5-(4-Methoxy-phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl]-(4-pyridin-3-yl-phenyl)-amine

[5-(4-Methoxy-phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl]-(6-methoxy-pyridin-3-yl)-amine

Methyl 4-(2-(phenylamino)-[1,2,4]triazolo[1,5-a]pyridin-5-yl)benzoate

4-(2-(phenylamino)-[1,2,4]triazolo[1,5-a]pyridin-5-yl)benzoic acid

4-(5-(4-isopropoxyphenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)benzoic acid

5-(4-methoxyphenyl)-N-(pyridin-2-yl)-[1,2,4]triazolo[1,5-a]pyridin-2-amine

4-(5-(4-(trifluoromethoxy)phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)benzoic acid

4-(5-(4-(trifluoromethoxy)phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)benzamide

5-(6-fluoropyridin-2-yl)-N-phenyl-[1,2,4]triazolo[1,5-a]pyridin-2-amine

Methyl 4-(5-(4-(cyanomethoxy)phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)benzoate

Methyl 2-(5-(4-methoxyphenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)-4-methylthiazole-5-carboxylate

4-(5-(4-hydroxyphenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)benzamide

4-(5-(4-isopropoxyphenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)benzamide

4-(5-(4-(cyanomethoxy)phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)benzamide

Methyl 4-(5-(4-methoxyphenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)benzate

N-(2,4-difluoro-3-methoxyphenyl)-5-(4-methoxyphenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-amine

N-(5-(4-methoxyphenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl)benzo[d]oxazol-6-amine

N-(4-(4-(4-fluorophenyl)piperazin-1-yl)phenyl)-5-(4-methoxyphenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-amine

4-(5-(4-methoxyphenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)benzoic acid

N-(4-(4-isopropylpiperazin-1-yl)phenyl)-5-(4-methoxyphenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-amine

N-(4-((1H-pyrazol-1-yl)methyl)phenyl)-5-(4-methoxyphenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-amine

N-(4-((1H-imidazol-1-yl)methyl)phenyl)-5-(4-methoxyphenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-amine

N-(4-((1H-1,2,4-triazol-1-yl)methyl)phenyl)-5-(4-methoxyphenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-amine

N-(3-(5-(4-methoxyphenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)phenyl)acetamide

5-(4-methoxyphenyl)-N-(4-(oxazol-5-yl)phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-amine

(4-(5-(4-methoxyphenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)phenyl)(4-methylpiperazin-1-yl)methanone

(4-(5-(4-methoxyphenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)phenyl)(4-methylpiperidin-1-yl)methanone

(4-(5-(4-methoxyphenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)phenyl)(piperidin-1-yl)methanone

N-(3-(dimethylamino)propyl)-4-(5-(4-methoxyphenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)benzamide

N-cyclohexyl-4-(5-(4-methoxyphenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)benzamide

4-(5-(4-methoxyphenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)-N-(3-methoxypropyl)benzamide

4-(5-(4-methoxyphenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)-N-(pyridin-3-yl)benzamide

4-(5-(4-methoxyphenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)-N-(pyridin-3-ylmethyl)benzamide

4-(5-(4-methoxyphenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)-N-(pyridin-2-ylmethyl)benzamide

N-isopropyl-4-(5-(4-methoxyphenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)benzamide

4-(5-(4-methoxyphenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)-N-(2-(pyrrolidin-1-yl)ethyl)benzamide

N-(3,5-dimethylisoxazol-4-yl)-4-(5-(4-methoxyphenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)benzamide

(4-hydroxypiperidin-1-yl)(4-(5-(4-methoxyphenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)phenyl)methanone

4-(5-(4-methoxyphenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)-N-(1-methylpiperidin-4-yl)benzamide

Isoindolin-2-yl(4-(5-(4-methoxyphenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)phenyl)methanone

N-(4-(5-(2-(dimethylamino)pyrimidin-5-yl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)phenyl)acetamide

3-(2-(4-acetamidophenylamino)-[1,2,4]triazolo[1,5-a]pyridin-5-yl)-N,N-dimethylbenzamide

N-(4-(5-(4-fluorophenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)phenyl)acetamide

N-(4-(5-(3-chloro-4-fluorophenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)phenyl)acetamide

N-(4-(5-(3-(trifluoromethyl)phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)phenyl)acetamide

N-(4-(5-(4-ethoxy-3-fluorophenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)phenyl)acetamide

N-(4-(5-(3,4-dimethoxyphenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)phenyl)acetamide

N-(4-(5-(4-cyanophenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)phenyl)acetamide

N-(4-(5-(3-cyanophenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)phenyl)acetamide

N-(4-(5-(4-(trifluoromethyl)phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)phenyl)acetamide

N-(4-(5-(3,4-difluorophenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)phenyl)acetamide

N-(4-(5-(3-(trifluoromethoxy)phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)phenyl)acetamide

N-(4-(5-(3,5-difluorophenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)phenyl)acetamide

N-(4-(5-(3-chlorophenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)phenyl)acetamide

N-(4-(5-(3-fluorophenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)phenyl)acetamide

N-(4-(5-(4-chlorophenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)phenyl)acetamide

N-(4-(5-(4-isopropoxyphenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)phenyl)acetamide

N-(4-(5-(3,4,5-trifluorophenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)phenyl)acetamide

N-(2-(dimethylamino)ethyl)-4-(5-(4-methoxyphenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)benzamide

4-(5-(4-methoxyphenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)-N-methyl-N-(2-(pyridin-2-yl)ethyl)benzamide

4-(5-(4-methoxyphenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)-N-(6-methoxypyridin-3-yl)benzamide

N-((1,5-dimethyl-1H-pyrazol-3-yl)methyl)-4-(5-(4-methoxyphenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)benzamide

4-(5-(4-methoxyphenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)-N-((1,3,5-trimethyl-1H-pyrazol-4-yl)methyl)benzamide

4-(5-(4-methoxyphenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)-N-methyl-N-((1-methyl-1H-imidazol-5-yl)methyl)benzamide

N-((1,5-dimethyl-1H-pyrazol-3-yl)methyl)-4-(5-(4-methoxyphenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)-N-methylbenzamide

N-(1,3-dihydroxypropan-2-yl)-4-(5-(4-methoxyphenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)benzamide

N-(2-acetamidoethyl)-4-(5-(4-methoxyphenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)benzamide

N-((1,3-dimethyl-1H-pyrazol-5-yl)methyl)-4-(5-(4-methoxyphenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)benzamide

N-((1-ethylpiperidin-4-yl)methyl)-4-(5-(4-methoxyphenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)benzamide

Ethyl 3-(5-(4-methoxyphenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)benzoate

N-(4-(8-(naphthalen-2-yl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)phenyl)acetamide

1-(4-(4-(5-(4-methoxyphenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)benzoyl)piperazin-1-yl)ethanone

N-(2-amino-2-oxoethyl)-4-(5-(4-methoxyphenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)benzamide

N-(6-acetamidopyridin-3-yl)-4-(5-(4-methoxyphenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)benzamide

4-(5-(4-methoxyphenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)-N-(2-(piperidin-1-yl)ethyl)benzamide

4-(5-(4-methoxyphenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)-N-(1-methyl-1H-pyrazol-3-yl)benzamide

4-(5-(4-methoxyphenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)-N-(2-methoxypyridin-3-yl)benzamide

N-(3-cyclopropyl-1-methyl-1H-pyrazol-5-yl)-4-(5-(4-methoxyphenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)benzamide

3-(5-(4-methoxyphenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)benzoic acid

4-(5-(4-(methylsulfonamido)phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)benzoic acid

4-(5-(3-(hydroxymethyl)phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)benzic acid

4-(5-(2,4-dimethoxyphenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)benzic acid

4-(5-(4-sulfamoylphenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)benzic acid

4-(5-(3-(methoxymethyl)phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)benzic acid

4-[5-(3-Methoxymethyl-phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino]-benzoic acid

N-(2-Ethyl-5-methyl-2H-pyrazol-3-yl)-4-[5-(4-methoxy-phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino]-benzamide

{3-[5-(4-Methoxy-phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino]-phenyl}-(4-methyl-piperazin-1-yl)-methanone

{3-[5-(4-Methoxy-phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino]-phenyl}-piperidin-1-yl-methanone

N-(3,5-Dimethyl-isoxazol-4-yl)-3-[5-(4-methoxy-phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino]-benzamide

3-[5-(4-Methoxy-phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino]-N-(2-pyrrolidin-1-yl-ethyl)-benzamide

N-(3-Dimethylamino-propyl)-3-[5-(4-methoxy-phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino]-benzamide

1-(4-{3-[5-(4-Methoxy-phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino]-benzoyl}-piperazin-1-yl)-ethanone

N-(2-Acetylamino-ethyl)-3-[5-(4-methoxy-phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino]-benzamide

3-[5-(4-Methoxy-phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino]-N-pyridin-2-ylmethyl-benzamide

3-[5-(4-Methoxy-phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino]-N-(1-methyl-piperidin-4-yl)-benzamide

3-[5-(4-Methoxy-phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino]-N-pyridin-3-ylmethyl-benzamide

N-Benzyl-3-[5-(4-methoxy-phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino]-benzamide

N-(4-(8-(1H-indol-5-yl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)phenyl)acetamide

4-(5-(1H-pyrazol-5-yl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)benzoic acid

4-[5-(2H-Pyrazol-3-yl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino]-benzoic acid

4-(5-(3-(N,N-dimethylsulfamoyl)phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)benzic acid

4-(5-(4-(methoxymethyl)phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)benzic acid

4-(5-(4-methoxyphenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)benzamide

3-(5-(4-methoxyphenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)benzamide

5-(4-methoxyphenyl)-N-(pyridin-3-yl)-[1,2,4]triazolo[1,5-a]pyridin-2-amine

[5-(4-Methoxy-phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl]-[6-(1H-pyrazol-4-yl)-pyridin-3-yl]-amine

N-(4-{5-[5-(4-Methoxy-phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino]-pyridin-2-yl}-phenyl)-acetamide

5-(4-methoxyphenyl)-N-(6'-(4-methylpiperazin-1-yl)-2,3'-bipyridin-5-yl)-[1,2,4]triazolo[1,5-a]pyridin-2-amine

5-(4-methoxyphenyl)-N-(6-(4-morpholinophenyl)pyridin-3-yl)-[1,2,4]triazolo[1,5-a]pyridin-2-amine

(4-(5-(5-(4-methoxyphenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)pyridin-2-yl)phenyl)methanol

5-(4-methoxyphenyl)-N-(6'-morpholino-2,3'-bipyridin-5-yl)-[1,2,4]triazolo[1,5-a]pyridin-2-amine

N-(3-(5-(5-(4-methoxyphenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)pyridin-2-yl)phenyl)methanesulfonamide

3-(5-(5-(4-methoxyphenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)pyridin-2-yl)-N-methylbenzamide

4-(5-(5-(4-methoxyphenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)pyridin-2-yl)benzamide

5-(4-methoxyphenyl)-N-(6-(4-(morpholinomethyl)phenyl)pyridin-3-yl)-[1,2,4]triazolo[1,5-a]pyridin-2-amine

45. The compound according to claim 1 or 2 wherein the compound is selected from :

(4-Fluoro-phenyl)-[5-(4-methoxy-phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl]-amine

2-[5-(4-Methoxy-phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino]-thiazol-4-one

2-[5-(4-Methoxy-phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino]-5-methyl-thiazol-4-one

4-[5-(4-Methoxy-phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino]-N,N-dimethyl-benzamide

4-[5-(4-Methoxy-phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino]-N-methyl-benzamide

(3-Fluoro-phenyl)-[5-(4-methoxy-phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl]-amine

[5-(4-Methoxy-phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl]-thiazol-2-yl-amine

1-{4-[5-(4-Methoxy-phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino]-phenyl}-ethanone

2-[5-(4-Methoxy-phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino]-4-methyl-thiazole-5-carboxylic acid dimethylamide

[5-(4-Methoxy-phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl]-(3,4,5-trimethoxy-phenyl)-amine

2-{4-[5-(4-Methoxy-phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino]-phenyl}-propan-2-ol

1-{4-[5-(4-Methoxy-phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino]-phenyl}-ethanone O-methyl-oxime

5-[5-(4-Methoxy-phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino]-pyridine-2-carbonitrile

1-{4-[5-(4-Methoxy-phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino]-phenyl}-ethanone oxime

1-{4-[5-(4-Methoxy-phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino]-phenyl}-ethanol

5-[5-(4-Methoxy-phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino]-pyridine-2-carboxylic acid amide

[5-(4-Methoxy-phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl]-[6-(1H-tetrazol-5-yl)-pyridin-3-yl]-amine

N-Cyclopropyl-4-(5-{4-[(2-hydroxy-ethylamino)-methyl]-phenyl}-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)-benzamide

46. The compound according to any one of claims 1 to 45 wherein the disease involves inflammation.

47. The compound according to claim 46, wherein the disease is selected from rheumatoid arthritis, osteoarthritis, allergic airway disease (e.g. asthma) and inflammatory bowel diseases.

48. The compound according to any one of claims 1 to 45, wherein the disease is a condition involving an immune response or an autoimmune disease.

49. The compound according to claim 48, wherein the autoimmune disease is selected from COPD, asthma, systemic lupus erythematosis, type I diabetes mellitus and inflammatory bowel disease

50. The compound according to any one of claims 1 to 45, wherein the disease involves an impairment of cartilage turnover.

INTERNATIONAL SEARCH REPORT

International application No
PCT/EP2009/059600

A. CLASSIFICATION OF SUBJECT MATTER
INV. C07D471/04 A61K31/437 A61P19/02

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
C07D A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)
EPO-Internal, BEILSTEIN Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 2008/025821 A (CELLZOME UK LTD [GB]; WILSON FRANCIS [GB]; RAMSDEN NIGEL [GB]; BELL KA) 6 March 2008 (2008-03-06) The Examples page 1 - page 3 claim 1 ----- -/--	1-49

[X] Further documents are listed in the continuation of Box C.

[X] See patent family annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
14 September 2009	30/09/2009

Name and mailing address of the ISA/	Authorized officer
European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Fax: (+31-70) 340-3016	Sarakinos, Georgios

Form PCT/ISA/210 (second sheet) (April 2005)

INTERNATIONAL SEARCH REPORT

International application No
PCT/EP2009/059600

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	NETTEKOVEN MATTHIAS ET AL: "Synthetic access to 2-amido-5-aryl-8-methoxy-triazolopyridine and 2-amido-5-morpholino-8-methoxy-triazolopyridine derivatives as potential inhibitors of the adenosine receptor subtypes" SYNTHESIS, GEORG THIEME VERLAG, STUTTGART, DE, no. 11, 1 January 2003 (2003-01-01), pages 1649-1652, XP002416826 ISSN: 0039-7881 compounds 1A-1L	1-49
A	WO 03/010167 A (HOFFMANN LA ROCHE [CH]) 6 February 2003 (2003-02-06) Examples	1-49
A	WO 2007/009773 A (NOVARTIS AG [CH]; NOVARTIS PHARMA GMBH [AT]; IMBACH PATRICIA [CH]; FUR) 25 January 2007 (2007-01-25) the whole document	1-49
A	US 2005/222171 A1 (BOLD GUIDO [CH] ET AL) 6 October 2005 (2005-10-06) the whole document	1-49
P,A	WO 2009/047514 A (CANCER REC TECH LTD [GB]; PAVE GREGOIRE ALEXANDRE [GB]; FIRTH JAMES DO) 16 April 2009 (2009-04-16) Examples claim 1 the whole document	1-49
P,A	WO 2009/010530 A (NOVARTIS AG [CH]; LEGRAND DARREN MARK [GB]; BRUCE IAN [GB]; DALE JAMES) 22 January 2009 (2009-01-22) the whole document	1-49
P,A	WO 2009/017954 A (PHENOMIX CORP [US]; CAMPBELL DAVID ALAN [US]; HEPPERLE MICHAEL E [US]) 5 February 2009 (2009-02-05) claim 1 the whole document	1-49
P,A	WO 2009/027283 A (SERONO LAB [CH]; SWINNEN DOMINIQUE [FR]; JORAND-LEBRUN CATHERINE [FR];) 5 March 2009 (2009-03-05) the whole document	1-49

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No
PCT/EP2009/059600

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 2008025821 A	06-03-2008	AU 2007291190 A1	06-03-2008
		CA 2662074 A1	06-03-2008
		EP 2057158 A1	13-05-2009
WO 03010167 A	06-02-2003	BR 0211206 A	13-07-2004
		CA 2453919 A1	06-02-2003
		CN 1541216 A	27-10-2004
		JP 4105089 B2	18-06-2008
		JP 2005511492 T	28-04-2005
		MX PA04000532 A	04-05-2004
		RU 2297416 C2	20-04-2007
		US 6514989 B1	04-02-2003
WO 2007009773 A	25-01-2007	AU 2006271924 A1	25-01-2007
		CA 2615433 A1	25-01-2007
		CN 101228167 A	23-07-2008
		EP 1910368 A1	16-04-2008
		JP 2009501748 T	22-01-2009
		KR 20080036997 A	29-04-2008
		US 2008234284 A1	25-09-2008
US 2005222171 A1	06-10-2005	US 2009099167 A1	16-04-2009
WO 2009047514 A	16-04-2009	NONE	
WO 2009010530 A	22-01-2009	PE 04922009 A1	27-05-2009
WO 2009017954 A	05-02-2009	NONE	
WO 2009027283 A	05-03-2009	NONE	